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ABSTRACI' 
Histocompatibility molecules, encoded by genes of the major 
histocompatibility complex (MHC), play a pivotal role in shaping the T-cell 
repertoire by trapping peptides via their peptide-binding sites and presenting these 
MHC-peptide complexes for T-cell recognition. Among these molecules, one 
serologically-defined set called HLA-DR4 comprises several DRBl variants or T-cell 
defined subtypes, in which the 13 chains differ from each other by only a few residues. 
The crossreactivity of some alloreactive T-cell clones and alloantibodies with certain 
DR4 and non-DR4 molecules that carry a homologous 13 chain sequence (residues 
67-86) suggest that similar sequences generate similar structures. Such an element or 
"sh.ared epitope" has been predicted to be implicated in the development and 
pathogenesis of rheumatoid arthritis (RA). 
The present study was based on the prediction that T-cell defined 
determinants on HLA-DR4 subtypes and the "shared epitope" could be 
distinguished by antibodies and that such antibodies would be useful for structural 
analysis of these epitopes. Thus, the principal objectives were to develop such 
monoclonal antibodies (mAbs), to analyze differences in the "shared epitopes" on 
DR molecules that are associated with RA and to investigate the composition of 
these epitopes. 
Approximately seventy anti-DR4 mAbs were selected from thirty fusions 
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CHAPTER 1 
HLA-DR: GENETICS AND EXPRESSION 
1.0 INTRODUcriON 
Histocompatibility molecules, called HLA antigens in humans, were discovered 
independently by Dausset, van Rood and Payne about thirty-five years ago. They 
found that sera from multiparous and multi-transfused patients could agglutinate 
white blood cells from certain individuals. Shortly thereafter, through the use of 
rather primitive serology and skin grafting techniques, it was discovered that the 
degree of identity for these "human leucocyte antigens" correlated with skin graft 
survival or rejection in related and unrelated individuals. Thus, it was established that 
InA antigens are major transplantation antigens and that they are codominately 
expressed (Amos. 1967). The story of these fascinating discoveries and the scientists 
who contributed immensely to this field has been chronicled in •History of HI.A:Ten 
Recollections", edited by Terasa.ki (1990). 
The importance of HIA molecules as major transplantation antigens is, 
however, secondaiy to their primary function, which is to bind and display antigenic 
peptides to self-restricted T cells (Zingernagel and Doherty, 1974). Two types of 
lll.A molecules, class I and class II, evolved as structurally-related molecules, but 
with somewhat divergent functions. Essentially, class I molecules present 
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endogenously-derived peptides to cytotoxic T cells that express CD8 molecules, while 
class II molecules present both endogenously and exogenously-derived peptides to the 
helper /inducer T cells that express CD4 molecules (Rammensee et al., 1993). 
Virtually all nucleated cells constitutively express class I molecules on the cell 
surface, but the expression of Class IT molecules is normally restricted to the 
membranes of antigen-presenting cells such as B cells, dendritic cells and 
macrophages. 
Alllll.A molecules have a similar superficial groove, which contains most of 
the polymorphic amino acid residues that differentiate one specificity from another. 
This groove acts as a receptor for binding a wide variety of peptides (Bjorkman et 
aL, 1987; Sette and Grey, 1992; Brown et al., 1993). Insertion of peptide into the 
class I groove occurs during assembly in the endoplasmic reticulum (ER) and this 
step appears necessary for correct folding, transport and surface expression (reviewed 
by Monaco et al. 1990). Class IT molecules, on the other hand, associate with another 
ch~ called the invariant (Inv) ch~ which prevents peptide binding to the dass n 
groove during assembly in the ER and during transport to the endosomal vesicles. 
At this latter stage the lnv chain dissociates which allows the class n groove to bind 
peptide (reviewed by Cresswell, 1992). 
T cells that interact with MHC-peptide complexes are selected during 
ontogeny in the thymus to be self-MHC restricted. Thus, the majority of mature T 
cells express T cell receptors (TCR) that are self-tolerant and that recognize foreign 
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peptides in the context of self-MHC (von Boehmer et al., 1989). A consequence of 
MHC-restriction is that allo-MHC molecules are also recognized as foreign, which 
has serious implications for organ transplantation. The most unfavourable outcome 
of bone marrow transplantation is graft versus host disease (GVHD), which can 
ocarr even when there are minuscule differences between the lllA specificities. 
Intriguingly, this disease is reminiscent of autoimmune diseases, many of which are 
associated with subsets of particular lll.A specificities. 
The main focus of this review will be HLA-DR, including the complexities of 
its gene organization, its numerous polymorphisms and details of the expressed 
proteins. Emphasis will be placed on the structural features that determine the 
specificity and function of DR molecules. In the second part of this review (Chapter 
2), the focus will be on the association of certain lllA-DR molecules, notably, DR4, 
DRl, DR14, and DRlO with Rheumatoid Arthritis. 
1.1 OVERVIEW OF THE MAJOR HISTOCOMPATIBILriY COMPLEX 
HLA molecules are encoded by multiple genes in the major histocompatibility 
complex (MHC) which is located on the short arm of chromosome 6. The MHC 
extends over four million base pairs (4Mb) and contains approximately 100 genes, of 
which many code for non-lll.A molerules (Campbell and Trowsdale, 1993). 
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Conventionally, the MHC has been divided into three main regions: class ll at the 
centromeric end, followed by class m, and class I at the telomeric end (Figure 1.1 ). 
The class ll region occupies about 1 Mb of DNA and is usually divided into 
subregions: lll.A-DP, -DO and -DR, but there are several other related and 
unrelated genes present. The organization of genes in this region, and the products 
that they encode, are detailed in section 1.2. 
The class m region occupies about 1Mb of DNA and contains roughly forty 
non-lllA genes. Several genes code for proteins that have immunologically-related 
functions, such as the complement genes ( C4, C2 and BF), heat shock proteins (HSP 
70) and tumour necrosis factors (1NFA and 1NFB). However, there are numerous 
other genes interspersed throughout this region and which are not depicted in Figure 
1.1. The function of these genes is mostly unknown (Campbell and Trowsdale, 
1993). 
The largest segment is the class I region, which comprises the final 2 Mb. It 
contains between thirty and forty genes, including those coding for the heavy chain 
(a) of class I molecules (lllA-A, C and B). These genes are highly polymorphic and 
together with the beta-2-microglobulin {P2M) gene encode more than 100 serological 
specificities. Forty-one lllA-A, 18 HLA-C, and 61 lllA-B alleles have been 
identified at the DNA level (Bodmer et al., 1992). The gene for p2M is non-
polymorphic and is encoded on chromosome 17. Other functional HLA genes in this 
region, are lll.A-E, -F, and -G (reviewed by Geraghty, 1992). 
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Figure 1.1. Schematic representation of the major histocompatibility complex, adapted 
from Campbell and Trowsdale, (1993). The centromere Is indicated at the left. HLA·Ciass 1: 
open symbols Indicate polymorphic genes; dotted symbols, non-polymorphic genes; gray 
symbols Indicate pseudogenes. Class II genes are depleted In Figure 1.2 
HLA-E is poorly expressed on many different cells including T cells and eosinophils, 
while lll.A-F and HI.A-G are expressed during different stages of fetal development. 
Numerous HI.A pseudogenes have also been mapped to this region. 
ORGANIZATION OF HLA CLASS II GENES 
The number of HI.A genes and the order of the subregions (HI.A-DP, -DQ 
and -DR) were originally mapped using a combination of eDNA and genomic cloning 
(reviewed by Korman et al., 1985; Trowsdale et al., 1985). linking of these 
subregions and further identification of several new genes were accomplished by 
employment of new techniques and discoveries. These include the combination of 
rarely cutting restriction enzymes that cut unmethylated CpG-rich DNA sequences, 
which are associated with the 5 • ends of genes (lindsay & Bird, 1987; Bird, 1990), 
and pulse field gel electrophoresis (PFGE), (Hardy et aL, 1986; Hanson et al., 1991). 
The use of the yeast artificial chromosome (Y AC) cloning techniques also permitted 
the cloning of very large fragments of DNA (Ragoussis et al., 1991); this technique 
combined with PFGE was successfully used to determine the number of genes and 
the interlocus distances in different HLA-DR haplotypes (Ragoussis et al., 1992). A 
schematic diagram (Figure 1.2) of the class ll region was adapted from the map 
published by Campbell and Trowsdale (1993). 
6 
0 
HLA CLASS II REGION 
I I 
II 
II 
v 
DP1 • DP8 
600 
I I 
I I 
II 
\I 
II 
001.009 
I 
I I 
I \ I 11000 
I \ I I 
I ~ I 
I I \ 
I 
I I DR1 • DR16 
I I 
!; 
DRB3:DR52 
DRB4:0Rl53 
DRB5:DR51 
Figure 1.2 Organization of genes In the class II region, adapted from 
Campbell and Trowadale, (1993). Open symbols Indicate functional genes 
coding for class II specificities, DP1·6, DQ1·9,DR1·16, DR51, DR52, DR 53; 
dotted symbols Indicate poorly expressed HLA genes or non-HLA genes; 
black symbols Indicate pseudogenes. 
t.2.1A Non-HLA genes 
Two large gene clusters containing several non-Hl.A genes have recently been 
mapped to this region. One cluster that maps between the DQ and DP subregions 
contains the TAP and LMP genes, which code for proteins that are involved in 
peptide loading of class I molecules (Monaco et al., 1990; Trowsdale et al., 1990; 
Deverson et al., 1990; Beck et al., 1992; Monaco, 1992; Powis et al. , 1993). 
The TAP1 and TAP 2 genes belong to the ATP-binding cassette (ABC) 
superfamily, which code for a transporter molecule that ferries peptides from the 
cytoplasm to the lumen side of the endoplasmic reticulum {Trowsdale et al. , 1990). 
Binding of peptides to newly synthesized class I heavy chains precedes the 
association of /32 microglobulin with the heavy chains and may be essential for the 
stable expression of class I molecules on the cell surface (Townsend et al., 1989; 
Spies et al., 1990). The LMP (low molecular weight polypeptide) genes are related 
to a structure with multiple proteolytic activities called multicatalytic proteinase 
complex or proteosome that is involved in the production of peptides for class I 
molecules (Brown et al., 1991; Glynne et al., 1991; Kelly et al., 1991). 
Several other genes are clustered centromeric to DP. The functions of these 
genes, for example the RING/ KE genes, are mostly unknown. Other genes such as 
the gene for collagen (type 11A2) are not immunologically relevant. 
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l~lB Classical HLA genes 
The lll.A-DR, -DQ and -DP genes extend over approximately 700 kilobases 
(Kb) of DNA in the class II region. aosely related genes (DN~ DMA, DMB, 
OOB), which lie between DPA1 and DQB2, are transcribed but poorly expressed on 
the cell membrane; their functions are essentially unknown. There are also several 
HIA-class II pseudogenes (DP A2, DPB2, DQB2, DQA2, DQB3, DRB2, DRB6, 
DRB7, DRB8 and DRB9), and the number of DRB pseudogenes depends on the 
haplotype of the individual (see section 1.2.2). The remaining 1-ILA-DP, -DQ and -
DR loci contain at least one A gene and one B gene that encode the ap dimer of 
a class II molecule or specificity. Many of these genes have several different allelic 
forms. 
Following the 11th International Histocompatibility Workshop (IHW), the 
WHO nomenclature committee for factors of the lll.A system completed and 
published a list of loci, genes, alleles and specificities (Bodmer et al., 1992). The list, 
at that time, included 8 DPA1 alleles and 36 DPB1 alleles, but only six different 
specificities (DP1 to DP6) were designated, as defined by primed lymphocyte testing. 
Similarly, although lll.A-DQ genes are highly polymorphic with 14 DQA1 alleles and 
19 DQB1 alleles described at the DNA level, only nine serological DQ specificities 
(001 to 009) have been designated. Since the 11th lliW report, many new alleles, 
particularly for DPB 1, have been descnl>ed, but they will not be included here. Since 
the emphasis of this review is HlA-DR, the number of genes, alleles and specificities 
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for Hl.A-DR are considered in more detail in the following sections. 
1.2.2 Genomic Organization of the HLA-DR Region 
It was discovered several years ago, using Southern blotting and cosmid 
cloning techniques, that the number of functional DRB genes and DR pseudogenes 
differed according to the serologically-defined haplotype (Sorrentino et al., 1985; 
Rollini et al., 1985; Spies et al., 1985; Andersson et al., 1987). Confirmation of this 
has come from studies in which Y AC cloning techniques and PFGE were used to 
map this region in several different haplotypes (Ragouissis et al. 1991; Ragouissis et 
al., 1992; Kendall et al., 1992). For example, the DR53 positive-haplotypes (DR4, 
DR7 and DR9) were found to contain 110 Kb of DNA more than the DR52 
haplotypes (DR3, DRS and DR6), (Kendall et al., 1992). 
Five different groups of haplotypes (DR1, DR51, DR52, DR8 and DR53) 
were described by the HLA nomenclature committee (Bodmer et al., 1992). 
Grouping is based partly on sequence similarity in the 3 ' untranslated regions of the 
DRB genes and partly on linkage disequih"brium with other DR genes (Rollini et al., 
1985; Spies et aL, 1985; Mach et al., 1986; Gorski, 1989; Young et al., 1987; Erh"ch 
and Gyllensten, 1991). Recently, the members in these groups were also shown to 
have similar polymorphic regulatory sequences in the promoter regions ofDRB genes 
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(Louis et al., 1993 ). 
The number of DRB functional and pseudogenes are shown in Figure 1.3. The 
ORB1 gene is expressed in all haplotypes and together with DRA encodes the 
common serologically-defined specificities, OR1 to OR16, (Bodmer et al, 1992). No 
other known functional ORB genes are expressed in the haplotype groups ORl 
(DRl, DR103 and DRlO) or DR8 (Louis et aL, 1993); however, the DRl group 
contains the DRB6 and DRB9 pseudogenes. 1be OR51 group haplotypes {DR15 
and OR16) also carry a ORBS gene (DR51) and two pseudogenes DRB6 and DRB9; 
the DR52 group (DR3, DR11, DR12, DR13, and DR14) carries a ORB3 (OR52) and 
one pseudogene DRB2; the DR53 group haplotypes (DR4, DR7, and OR9) carry 
DRB4 (DR53) and three pseudogenes, (DRB7, DRB8 and DRB9). 
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Figure 1.3 Schematic representation of the genomic organization of DR genes in the 
different haplotypes, adapted from Campbell and Trowsdale, 1993. Open boxes show the 
genes that code for the DR specificities; the gray goxes show the pseudogenes that are 
contained within each haplotype. 
1.3 THE MOLECULAR STRUCTURE OF HLA-DR MOLECULES 
1.3.1 Primary Structure 
The primary structures of the alpha (a) and beta (/3) chains of DR were partly 
determined by amino acid sequencing and more completely from nucleotide 
sequences derived from cloned eDNA and genomic DNA (reviewed in Shackleford 
et al., 1982). The arrangement of exons in ORA and ORB genes roughly corresponds 
to the number of domains identified in the polypeptide chains (Figure 1.4 ). The first 
exon codes for the signal sequences and the first two amino acids of the first domain. 
Expression of class II molecules is co-ordinately regulated by several promoter-like 
elements that are located 5' of the coding regions (Glimcher and Kara, 1993; Louis 
et al., 1993). 
Both the a and /3 chains of DR as well as other class II molecules are Type 
1 glycoproteins, which have the carboxyl termini located on the cytoplasmic side of 
the membrane, the hydrophobic segments spanning the membrane and the amino 
termini located on the external side of the membrane (Figure 1.4). The DR a chain 
is composed of 229 amino acids (15 internally, 23 transmembrane, and 191 
externally) whereas the DR/3 chain contains '137 residues (16 intemally, 22 
transmembrane and 199 externally), (Kaufman and Strominger,1979; Kratzin et al. 
1981; Yang et al. 1982). 
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Figure 1.4 Schematic representation of the arrangement of exons that enmde the 
domains of the DR alpha and beta chains. UT, untranslated; SS, signal sequence; 
TM, transmembrane; CYT, cytoplasmic. al, a2 and /31, {32, external domains of the 
alpha and beta chains respectively. (adapted from Stites et al., 1984) 
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The DRp chain has one asparagine-linked oligosaccharide at position 19 while the 
DRa chain has two asparagine-linked oligosaccharides at positions 78 and 116 
(Strominger 1980; Shackleford et al., 1982). Biochemical studies using tunicamycin 
to inhibit the formation of asparagine-linked sugars or endoglycosidases to remove 
sugars have shown that the carbohydrates contribute very little to the heterogeneity 
(Shackleford et al., 1983). 
1.3.2 Secondary Structure 
Both the alpha and beta chains have external domain-like structures (Figure 
1.4). The a chain contains two domains a 1 (1-84) and a 2 (85-178), and is 
immunoglobulin-like due to a cysteine-linked disulphide bond. There are two 
immunoglobulin-like intrachain disulphide bonds in the fJ chain1 (1-91) and P2 (92-
192). The a 1 and fJ 1 domains are distal and N-terminal while the a 2 and 112 domains 
are proximal to the membrane (Kaufman and Strominger 1979; Kaufman et ~ 1982; 
Korman et al.,1982). 
Nucleotide sequencing of lll.A-DR genes showed that the DR a chain is non-
polymorphic and that the majority of the polymorphic residues are located in the first 
domain of the p chain (Long et al., 1983; Gustafsson et al_, 1982; Cairns et ~ 1985; 
Bell et al., 1985). It was apparent from Kabat and Wu-type variability plots that 
nearly all the polymorphic residues are clustered in three regions, called allelic hyper-
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variable regions: HVR-1, codons 9-14; HVR-11, codons 25-38; HVR-111, codons 67-76 
(Bell et al., 1987). These hypervariable regions are analogous to those that had 
earlier been described for murine 1-A and I-E molecules (reviewed by Mengle-Gaw 
& McDevitt, 1985). These HVRs determine the individual serological and T-cell 
defined DR specificities. However, it was also apparent that there is extensive 
sharing of one or more of these HVR among different alleles. These shared regions 
or "patchwork patterns of allelic diversity" were predicted to have arisen by gene 
conversion events (Mengle-Gaw et al., 1984; Gorski and Mach, 1986; Erlich and 
Gyllensten, 1991). 
1.3.3 Three-dimensional Structure 
Resolution of the X-ray crystallographic structure of a class I (HLA-A2) 
molecule by Bjorkman et al., (1987) was a major step in clarifying the primary 
function of Hl.A molecules in immune recognition. Its most revealing feature was a 
shallow groove or cleft that was formed by the pairing of the a 1 and a 2 domains. This 
groove consisted of eight antiparallel beta-strands with an alpha-helical structure on 
each side. Nearly all of the known polymorphic amino acid residues in the HLA-A2 
molecule were located on the floor or sides of the groove; remarkably, the groove 
contained bound peptide. From these observations, it was predicted that the side 
chains of residues, which point up from the floor or inwards from the alpha helix, 
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would bind peptide and that the side chains of those residues that point upwards and 
outwards from the alpha helix would bind the T cell receptor. 
By aligning the homologous regions of class II molecules with those of class 
I molecules, Brown et al. (1988) constructed a hypothetical model with a peptide 
binding site that was similar to that of the HIA-A2 molecule. Recently, the same 
group published the three-dimensional (3-D) structure of a DR1 crystal, which is 
comparable to the class I structures and the Brown model (Brown et al., 1993). For 
example, the {3 2 and a 2 domains of the class II molecules correspond to the a 3 
domain and {3 2M, respectively of class I. The class II {3 1 and a 1 domains, like the a 2 
and a 1 domains of class I, interact to form a similar peptide binding groove. 
There are some dissimilarities between the 3-D structures of class I and class 
II molecules, particularly with respect to the peptide binding site. First, the grooves 
of human and mouse class I are closed at both ends and accommodate peptides of 
8-10 residues with longer ones bulging in the middle (Jardetsky et al., 1991; Madden 
et al., 1991; Zhang et al., 1992). The class II groove is open at both ends and binds 
peptides that are considerably longer (15-24AA) and protrude from both ends 
(Rudensky et al., 1991; Chicz et al., 1992; Brown et al., 1993). While specific 
peptide-binding pockets in the class I groove have been readily identified from 
sequences of eluted peptides (Rotzschke et al., 1991; Falk et al., 1991; Hunt et al., 
1992), only one clearly identifiable pocket has been discerned in the class II groove. 
This is a hydrophobic pocket located at one opening of the groove and includes the 
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duster (p86, 89,90; a31,52). Other pocken are suggested by the clustering of 
particular polymorphic amino acids in the groove such as (P13,26,28,71,74,78), 
~9,11,30; a66), (P37,38,58). Another map difference is that in all three DRl 
aystals, two dimers were associated with eadl other ( dimer~) whereas none of the 
class I crystals were in this state. 
1.4 BIOSYNTHESIS AND EXPRESSIOS OF HLA-DR MOLECULES 
L4.1 Assembly 
Transcription of the class ll genes is co-ordinately regulated by promoter 
sequences found 5 ' of the coding regions ( reviewed by Glimcher and Kara, 1992). 
Synthesis of the a and p polypeptides oa:urs on the polysomes of the rough 
endoplasmic reticulum, after which they are normally assembled as isotypic DRap, 
DQap, or DPap molecules. Mismatched pairing of the isotypic chains can potentially 
occur. This was clearly demonstrated by DNA-mediated transfer experiments in mice 
in which cloned genes from 1-A/ and I-E:'• were expressed as mixed molecules on 
the cell surface of transfected class ll negative L cells (Germain and Quill, 1986). 
The experiments also showed that this pairing was determined by polymorphic 
sequences in the amino terminus of the 1-A/l chain. Recent studies have shown that 
such aberrant molecules are functional in that they are capable of antigen 
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presentation (Ruberti et al., 1992) 
Trans-associated or hybrid DQ molecules have been detected in 
immunoprecipitates (Charron et al., 1984; Nepom et al., 1987). This phenomenon 
was also experimentally demonstrated by transfection and expression of haplotype 
mismatched DQA and B genes (Kwok et aL, 1988); it was later shown by the same 
group that not all DQ JJ chains could associate with all DQa chains (Kwok et al., 
1993). Again drawing on studies done earlier in the murine system, it appears that 
allelic and interallelic pairing and expression depend on the correct combination of 
polymorphic residues in the amino terminus of the chains (reviewed by Germain and 
Malissen, 1986; Braunstein et al., 1987). 
1.4.2 Role of the Invariant Chain 
Several years ago it was shown, by electrophoretic analysis of 
immunoprecipitates from biosynthetically labelled class II molecules, that the class 
II heterodimer is associated with another molecule, which is called the gamma or 
Invariant (Inv) chain (Jones et al., 1979). The initial experiments suggested that the 
Inv chain assisted in transporting the ajj dimer from the ER through the various sub-
cellular compartments and inserting it into the cell membrane (Kvist et al., 1982). 
This theory was challenged when it was clearly shown that transfected class ll genes 
could be expressed in Inv negative fibroblasts that do not constitutively express class 
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II (Miller and Germ~ 19~ Sekaly et al., 1986). Transfected class II molecules 
expressed on the Inv negative fibroblasts were found to have altered antibody-binding 
epitopes and/ or peptide presentation capabilities (Petersen & Miller, 1990; Roche 
et al., 1990), thereby renewir:g interest in the function of the Inv chain. 
The structure of 1m- differs significantly from that of the afJ subunits 
(reviewed by Cresswell, 1992). It is a type II glycoprotein, which has the amino 
terminal on the cytoplasmic side, a hydrophobic transmembrane piece and a lumenal 
carboxyl terminaL It is also heavily glycosylated and has several alternate forms, with 
the majority being 31-33Kd. ~ewly synthesized Inv forms a trimer and each member 
of the trimer can bind a class II heterodimer through a signal piece in its carboxyl 
lumenal region (Roche et al, 1991). This piece remains associated with class II 
during transport of the nonameric complex from the ER through the Golgi and trans-
Golgi reticulum (Teyton et al., 1990). Here, the complexes are sorted to the 
endocytic route by the same wgeting signal in the cytoplasmic tail of the lnv chain. 
In the acidic environment of the endosomes, processing of exogenous antigens occurs 
(Neefjies et al., 1990). Arrival of the complex into these compartments results in 
degradation of the Inv chain and binding of processed peptide to the class n groove. 
The peptide-loaded class II molecules are then transported to the cell surface by 
some unknown mechanism. As a further note to the chaperon-like role of Inv, 
Anderson and Miller (1992) recently showed that transportation and expression of 
class II molecules in Inv negative cells is considerably less efficient than in Inv 
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positive cells, and that such molecules are abnormally glycosylated and 
conformationally unstable. 
1.4.3 Peptide Involvement in the Conformation of Class II Molecules 
Several studies have established the importance of peptide binding to the 
groove in sustaining the overall structural features of the molecule (Sadegh-Nasseri 
and Germain 1991; Germain and Hendr~ 1991). Using chain-specific monoclonal 
antibodies to purify molecules from the different subcellular compartments, it was 
found that newly synthesized and assembled dimers were unstable and easily 
denatured, whereas molecules that had matured in the post Golgi reticulum and 
endosomal compartments were more stable and resistant to denaturation. 
Furthermore, class II molecules expressed in cells that have large deletions in the 
MHC region and that are known to be defective in antigen processing, were also 
conformationally unstable; such molecules bad modified peptide-presentation 
capabilities (Mellins et al. 1990a; Riberty and Cresswell, 1992; Sette et al. 1992). The 
majority of class II molecules that were purified from antigen-processing cells 
contained a large piece of the lnv chain that had not dissociated, presumably, 
because there was a deficiency of processed peptide in the endosomal compartments 
(Sette et al., 1992). DeNagel and Pierce (1992) have further suggested that after 
dissociation of the Inv chain, other proteins belonging to the HSP70 family may be 
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required in order to facilitate peptide binding to the groove. They speculate that the 
HSP may do this by directly transporting the peptide to the groove or by transporting 
peptides from a different compartment to one containing the class ll molecules. 
1.4.3A Characteristics of peptides isolated from class II grooves 
Most of the peptides, which have been eluted from murine and human class 
ll molecules, are derived from membrane and secretory proteins (Rudensky et al., 
1991, Chicz et al., 1992). For example, Chicz et al. (1993) found that about 85% of 
the peptides eluted from HLA-DR molecules were derived from endogenous 
proteins. This was unexpected since Class ll molecules were predicted to bind 
primarily exogenously-derived peptides. Neefjies and Ploegh (1992) have suggested 
that these endogenously-synthesized proteins may gain access to the endosomal 
compartments by autophagy and/ or translocation from the cytosol to lysosomes. Like 
exogenous antigens, they may then be processed into peptides that can bind to class 
n molecules. 
Peptides isolated from class ll molecules are, also, longer and more variable 
(12-25 mer) than peptides that have been eluted fram class I molecules. They are 
also characterized by so-called "ragged ends" (Rudensky et al., 1991; Hunt et al., 
1992; Chiez et al., 1993). This feature is due to the class n binding site being open 
at both ends (Brown et al., 1993}, so that a typical 15-17mer peptide, depending on 
its chemical mmposition and the composition of the groove, might bind in different 
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forms. Only a core of 8-10 residues actually binds while the other residues overhang 
both ends of the groove. 
Peptide-binding motifs were not readily apparent from comparison of the 
sequences of eluted peptides that were isolated from a variety of DR molecules; 
furthermore, most 15-17 mer peptides bound to all or most class II molecules 
(Rudensky et al. 1991; Chicz et al. 1992; Chicz et al., 1993). This supported the 
findings of previous studies, in which a high level of degenerate peptide binding by 
class II molecules was found; (Rothbard and Gefter, 1991; 0 'Sullivan et al. 1991). 
Recently, a large M 13 peptide display library was generated to screen isolated DR 
molecules for peptide motifs that are associated with binding to DR (Hammer et al., 
1992; Hammer et al., 1993). Peptide motifs, which include a broad range of binding 
with respect to a variety of DR molecules, were found. These had so-called 
promiscuous anchor residues at positions 1 and 4 and allele-specific residues at 
position 6. The amino and carboxyl termini of the peptides are known to be oriented 
with the amino and carboxyl termini of the peptide binding site (Brown et al., 1993). 
Therefore, Hammer et al., (1993) predicted that promiscuous anchor residues 
(anchor positions in the amino end of the peptide) bind to the non-polymorphic DR 
a positions (amino end of the groove), while allele-specific anchor residues, which 
are in the carboxyl end of the peptide, bind to a pocket created by the polymorphic 
residues in the {3 strands (carboxyl end of the groove). Similar peptide motifs for 
binding to HI.A-DR4 molecules have also been described by Sette et al (1993). 
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1.5 HLA-DR SPECIFICffiES 
The discovery of the mixed lymphocyte culture reaction (MLC) by Bain et al., 
(1964) and Bach et al., (1964) led to the identification of lll.A-D and later to 
recognition of lll.A-Dw determinants (Yunis and Amos, 1971). Similar specificities 
that were identified on B lymphocytes by alloantisera (van-Leeuwen et al., 1973; van 
Rood et al., 1975; van Rood et al., 1976) were named lll.A-DR after the 7th 
IHW,1977 because they were "related• to the cellular-defined ID.A-Dw 
determinants (see review by Winchester and Kunkel, 1979). The fact that Dw and 
DR are different determinants on the same molecule, was obscured for many years 
because several Dw subtypes can associate with a single serological specificity. For 
example, the HLA-DR4 specificity was shown to contain at least five different T -cell 
Dw subtypes (Groner et al., 1983; Reinsmoen et al, 1982). The relationship of DR-
Dw was clarified by eDNA cloning and nucleotide sequencing (Cairns et al., 1985; 
Bell et al., 1985; Gregersen et al., 1986) Subsequently, DNA typing methods have 
been used to identify several new variants for most DR specificities (Kimura et al., 
1992; Bodmer et al., 1992; Stastny and Kimura, 1992). 
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1.5.1 HLA-DR Nomenclature 
The lll.A nomenclature for serological specificities, splits and subtypes, was 
revised after the 1987 IHW in an effort to consolidate all the information obtained 
from serological, T -cell and DNA typing and sequencing (Dupont, 1989); the most 
recent update followed the 11th lliW (Bodmer et al., 1992). A partial list of ORB 
alleles, for which serologically-defined and/or cellular-defined specificities have been 
identified, is shown in Table 1.1; it should be noted, however, that several other 
functional alleles have been identified at the gene, but not at the product level. The 
following is an interpretation of the new nomenclature. 
A serological specificity refers to a group of molecules that carries 
determinants common to all molecules within that specificity; it may be encoded by 
one (for example DR10) or several related alleles (for example DR4). Each of the 
listed alleles have been DNA-typed and sequenced before assigning the locus, allele 
and number. In the example DRB1*0102, DRB1* indicates that it is a functional 
allele encoded by DRBl; the first two numerals (01) indicate the specificity (DRl) 
and the second two numerals (02) indicate that it is the second allele in the DRl 
specificity. Thus, the serologically-defined DR1 specificity consists of a DRp1 chain, 
(encoded by either DRB1*0101, B1*0102 or B1*0103), which is associated with the 
invariant DRa chain. Within each DR group, there are T -cell defined specificities 
that are referred to as Dw subtypes. Each subtype is encoded by distinct DRB alleles; 
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Table 1.1 Common HLA-DR serological and T -cell defined specificities and the ORB genes 
that encode them . 
Serological 
Specificities 
DR1 
DR1 
DR103 
DR10 
DR15 (2) 
DR15 (2) 
DR16 (2) 
DR16 (2) 
DR17 (3) 
DR17 (3) 
DR11 (5) 
DR11 (5) 
DRII (5) 
DR12 (5) 
DR13 (6) 
DR13 (6) 
DR13 (6) 
DR14 (6) 
DR14 (6) 
DRS 
DR8 
DRS 
T -cell-
Defined 
Specificities 
Dw1 
Dw20 
Dw'BON' 
Dw2 
Dw12 
Dw21 
Dw22 
Dw3 
Dw'RSH' 
Dw5 
Dw'NM' 
Dw'FS' 
Dw"DB6" 
Dw18 
Dw19 
Dw'HAG' 
Dw9 
Dw16 
Dw8.1 
DwS.2 
DwS.3 
DRBI* 
0101 
0102 
0103 
1501 
1502 
1601 
1602 
0301 
0302 
11011/11012 
1102 
ll03 
1201 
1301 
1302 
1303 
1401 
1402 
0801 
08021/0S022 
OS031/08032 
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DRB5 DRB3 DRB4 
DR5 I 0101 
DR51 0102 
DR51 0201 
DR51 0202 
DR52 
DR52 
DR52 
DR52 0101 
DR52 0201 
DR52 0202 
DR52 0301 
DR 52 
DR52 
DR52 
DR 52 
Table 1.1 Continued 
T -cell-
Serological Defined DRBI* DRB5 DRB3 DRB4 
Specificities Specificities 
DR4 Dw4 0401 DR53 0 ](1 
DR4 DwlO 0402 DR53 OH•l 
DR4 Dwl3.1 0403 DR53 0 101 
DR4 Dw14. l 0404 DR 53 0101 
DR4 Dw15 0405 DR53 01 01 
DR4 Dw'KT2' 0406 DR 53 01 01 
DR4 Dwl3 .2 0407 DR53 01 {11 
DR4 Dwl4.2 0408 DR 53 01 01 
DR7 Dw17 0701 DR53 0101 
DR7 Dw'DB1' 0702 DR 53 0101 
DR9 Dw23 09011/09012 DR 53 01 01 
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for example Dwl is encoded by DRB1*0101. Since serological and T-cell typing 
methods were in use long before DNA sequencing and typing methods were 
available, the nomenclature for the Dw specificities does not necessarily match 
numerically with the DRBl* alleles. 
1.5.2 Serological Determinants: Location and Composition 
Elucidation of the primary and secondary structure of DR molecules revealed 
that the /3 1 domain contained almost al1 of the polymorphic residues. Variability plots 
indicated that these polymorphic residues clustered in three regions of the first 
domain: HVR I, 9-13; HVR TI, 25-38; HVR III, 67-74 (see Section 1.3.2). When these 
residues are localized to the 3-D structure of the DRl molecule, it can be seen that 
HVR I and HVR n are on the /3-pleated sheets while HVR-ill is located on the a 
helix. From analysis of the sequence data for the many different specificities that 
have been either serologically or T-cell defined, it is clear that many DR specificities 
do not have allele-specific amino acid residues (Figure 1.5). No antisera have been 
described which strictly correlate with a Dw specificity, but by using a combination 
of allosera with "short specificities" patterns were obtained that correlated with the 
product of a single DRBl allele (Juji et al., 1992). 
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SPECIFICITY 
DRI Dwl 
DRI Dw20 
DRI03 
DwBON 
DR4 Dw4 
DR4 DwlO 
DR4 Dwl3 
DR4 Dwl4 
DR4 DwlS 
DR4 DwKT 
DR3 Dw3 
DRll DwS 
DRll DwNM 
DR12 DwDB6 
DRI3 Dw18 
DR13 Dwl9 
DR13 DwHAG 
DR14 Dw9 
DR14 Dwl6 
DR8 Dw8.1 
DR8 Dw8.2 
DR8 Dw8.3 
DR7 Dw7 
DR7 DwDBl 
DR9 Dw23 
DR15 Dw2 
DRlS Dw12 
DRI6 Dw21 
DRl6 Dw22 
DRIS Dw2 
DRIS Dwl2 
DR16 Dw21 
DR16 Dw22 
ALLELE 
B1*0101 
BI•OJ02 
Bt•0103 
Bt•0402 
BJ•o4o3n 
Bt•0404/8 
Bt•0405 
BI•0406 
Bt•OJOI 
BI•llOI 
BI*l102 
B1*1201 
Bl*l 301 
Bl*l302 
Bt•t303 
Bl*l401 
Bl* 1402 
Bl*0801 
BJ•0802 
Bl*0803 
Bl*0701 
Bl*0702 
Bl*0901 
BI•t501 
Bl*l502 
Bl*l60l 
Bl*l602 
B5*0101 
B5*0102 
B5*0201 
BS*0202 
wa 1 
5-16 
WQL~VECH 
WQLUECH 
WQLUECH 
EQ\""jJ{ECH 
EQ\"UIECH 
EQ\!JIECH 
EQ\~CH 
EQ\hl!ECH 
EQ\ -,;}{ECH 
EYSTSECH 
EYST'SECH 
EYSTSECH 
EYSTGECY 
EYSTIECH 
EYSTSECH 
EYST'SECH 
EYSTSECH 
EYSTSECH 
EYSTGECY 
EYSTGECY 
EYSTGECY 
EYGTYKCH 
EYGTYKCH 
KQ~CH 
WQPDECH 
WQPDECH 
WQPKRECH 
WQPKRECH 
~YECH 
~CH 
QQI>t.:l'ECH 
~H 
AMP.\0 ACID RES IDl"ES 
HVR II 
26-33 
LLERCIYN 
LLERCIYN 
LLERCIYN 
FLDRYFYH 
FLDRYFYH 
FLDRYFYH 
FLDRYFYH 
FLDRYFYH 
FLDRYFYH 
YLDRYfl-1]'1; 
FLDRYFYN 
FLDRYFYN 
LLERHFH]'I; 
FLDRYFHN 
FLDRYFHN 
FLDRYFYN 
FLDRYFHN 
FLERYFHN 
FLDRYFYN 
FLDRYFYN 
FLDRYFYN 
FLERLFYN 
FLERLFYN 
YLHRGIYN 
FLDRYFYN 
FLDRYFYN 
FLDRYFYN 
FLDRYFYN 
FLHRDIYN 
FLHRGIYN 
FLHRGIYN 
FLHRGIYN 
{3 Sheet 
yy 
NV 
y 
y 
y 
y 
y 
y 
y 
y 
y 
F 
F 
F 
F 
F 
F 
y 
y 
y 
y 
y 
y 
y 
y 
y 
F 
F 
y 
y 
y 
y 
y 
y 
57-60 
DAEY 
DAEY 
DAEY 
DAEY 
DAEY 
DAEY 
DAEY 
SAEY 
D.-\EY 
D.-\EY 
DEEY 
DEEY 
VAES 
DAEY 
D.-\EY 
S.-\EY 
AAEH 
DAEY 
SAEY 
D.-\EY 
SAEY 
VAES 
VAES 
VAES 
DAEY 
DAEY 
DAEY 
DAEY 
DAEY 
DAEY 
DAEY 
DAEY 
H\"R ill 
67-78 
LLEQRRA_-\ \ ""DTY 
LLEQRRAA \ ""DTY 
ILEDERA.-\ \-on· 
LLEQKRAA \ "DTY 
ILEDER.-\..-\ \ ""Dn" 
LL-EQRR.U:\""DTY 
LLEQRRAA \ ""DTY 
LLEQRR-\A \ ""DTY 
LLEQRR.U:\ ""DTY 
LLEQKRGR\""0~1 
FLEDRRA-\ \ -un· 
lLEDER.-\..-\ \-""DlY 
ILEDRR.-\..-\ \ ""DTY 
ILEDERAA \""DTY 
!LEDER.-\.-\\ ""DTY 
ILEDKRAA \""Dn-
LLERRRAE\ ""DTY 
LLEQRRAA \ ""DTY 
FLEDRRAL \ ""DTY 
FLEDRRAL \ ""DTY 
ILEDRRAL \ ""DTY 
ILEDRRGQVIJfV 
ILEDRRGQ\ liTV 
FLERRRAE\liTV 
ILEQARAA \'DTY 
ILEQARAA \'DTY 
FLEDRRAA VDTY 
ILEDRRAA VDTY 
FLEDRRAA VDTY 
FLEDRRAAVDTY 
n..EQARAA \-""DTY 
ILEQARAA VDTY 
a Sheet 
85-86 
VG 
YV 
\'"\-IG 
\'VtG 
VG 
\ 'Y 
vv 
\'G 
vv 
AV 
YV 
VG 
YG 
'\[\l 
VG 
VG 
VG 
VG 
VG 
VG 
VG 
vv 
VG 
VG 
VG 
VG 
VG 
AV 
AV 
Figure l..S Polymorphic amino acid sequences of the /J1 domain of DR {J chains which 
are associated with T -cell defined specificities. 
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t.5.2A Hypothetical mapping by analysis or sequence data 
The location and composition of certain serological epitopes on HIA 
molecules can be predicted by comparing the antibody-binding patterns, which are 
obtained with homozygous HLA cell lines, to the available amino acid sequence data. 
Mouse cell transfectants expressing wild-type HlA genes have proven extremely 
valuable for localizing the antibody-binding epitope to the gene product (Klohe et 
al., 1988; Madrigal et al., 1989; Heyes et al., 1992; CHAPTER 6). By comparing 
antibody binding data from several sources to class II sequence data, epitopes for 
several well known mAbs have been predicted (Marsh and Bodmer, 1989; Marsh et 
al., 1992). For example, they have predicted that DR7-specific mAbs bind to either 
DRB1:11-14:GKY~ 25:0, 30:L· or 71-74:RRGG. Similarly, Gorski et al., (1990) 
putatively mapped a monoclonal antibody-binding epitope to a shared sequence 
(DRB1:13G, 16Y), which is only found on DR8 and DR12 molecules. 
Extensive analyses were carried out during the 11th IHW using computer 
software to compare reaction patterns that had been obtained using several thousand 
HLA antisera against well-characterized B cell lines with the class II amino acid 
sequences (Clarke et al., 1992; Barbetti et al., 1992). They found that several DR 
specificities correlated with the presence of a single allele-specific residues on DR 
f3 chains, for example, DR1, DR3, DR4, DR7, DR9, DR10, DR11, DR12, and DR51. 
In addition, so-called "multi-specific" antisera or "broadly-reactive" mAbs could be 
mapped to a single residue or a short sequence found on several different DR {3 
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chains. It is of interest that many of these single residues, which have been suggested 
as antibody-binding epitopes, are located on the floor of the peptide-binding site at 
positions that are involved in peptide binding (Brown et al., 1993). H this is correct, 
it seems unlikely that antibodies could interact directly with these residues as their 
side chains would be obscured by peptide and, thus, unavailable for antibody binding. 
1.5.28 The analytical approach 
One would predict that serological epitopes on DR molecules are similar to 
most other antibody-binding epitopes on native proteins. That is, they are formed by 
the combination of several amino acids that are linearly distant in the primary 
structure, but spatially-associated in the 3-D structure (Laver et al., 1990). X-Ray 
crystallographic analyses of different Fab-Ag complexes have revealed that the 
epitopes on lysozyme and neuraminidase occupy a large area comprising 15-17 amino 
acid that occur on different strands (Amit et al, 1986; Tulip et al., 1992). Such 
complexes have a high degree of topographic and chemical complementarity at their 
interacting surfaces (Maruzza and Poljak, 1993). Although a subset of the residues 
in the epitope contribute most of the binding energy, they are not usually arranged 
in a linear way. Thus, it seems unlikely that an epitope for an anti-HI.A-DR antibody 
will be mapped to a single amino acid; it is likely, however, that an "allele-specific• 
residue may be critical for the overall structural integrity of an epitope. 
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Unequivocal mapping of an alloepitope would require the co-aystamzation 
of a Fab fragment and its cognate antige~ but since this is not feasible, alternate 
methods have been employed These involve the use of cells that express altered 
class ll genes, such as mutants that have been immunoselected for loss of antibody-
binding epitopes. Such mutants were first used for mapping epitopes on murine class 
ll molecules (Glimcher et al., 1983; Becket al 1984; Becket al. 1991). Sequencing 
of the relevant genes from these cells identified the mutations that generated a 
structural alteration in the MHC molecule with subsequent loss of the binding 
epitope. For example, Becket al, (1991) mapped several polymorphic epitopes to 
residues 61-70 on l-AP chains. In a similar manner, it was shown that several diverse 
residues on DR P1*03 chains were involved in the integrity of an epitope common 
to all DR3 molecules (Mellins et al., 1990a). 
Other commonly used methods for epitope mapping include DNA-mediated 
transfection and expression of wild-type genes, or genes that have been deliberately 
altered, by hemi-exon or exon shuffling or site-directed mutagenesis, into class ll 
negative cells (Germain et al., 1985; Cohn et ai_, 1986; Brown et al., 1986; Braunstein 
and Germain, 1987; Ronchese et al., 1987). It was found that most murine 1-A and 
1-E alloepitopes mapped predominately to the carboxyl region of the P1 domain; 
however, some serological epitopes on DR molecules were found to map to other 
regions on DR fJl chains (Alber et al., 1989; Gorski et ai_, 1990; Fu et al., 1992a,b). 
These regions included the carboxyl-terminaJ and amino-terminal of the p1 domain, 
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and an unidentified region on the P2 domain. 
Although the second domain of DRp chains is highly conserved, (Bell et al. 
1987; Gorski, 1989), there are sporadic polymorphic differences that have been 
predicted to determine some of the common serological epitopes (Gorski, 1989). For 
example, a DR4-specific mAb, which was mapped to the carboxyl-terminal region of 
DR4 p chains in a study by Alber et al., (1989) was more precisely mapped using 
site-directed mutagenesis to DRB1*96:E (Maurer and Gorski, 1991). This position 
is located at the amino end of the P2 domain, thus strengthening the idea that the 
second domain controls some of the common serological specificities. It further 
indicated that certain predicted allele-specific residues may be critical in determining 
epitopes on DR molecules. 
1.5.3 T -cell Defined Determinants 
Most serological DR specificities include several Ow subtypes, each encoded 
by a distinct ORB allele. These subtypes are conventionally identified by T cell typing 
methods and alloreactive T -cell clones (Dupont e a1, 1973; Bach et al., 1983; Groner 
et al., 1983; Singal et al., 1985; Flomenberg et al, 1989; Obata et al., 1992). Analysis 
of DRB1 sequences for Dw subtypes, clearly show that all subtypes within a generic 
specificity, have identical sequences with the exception of a few critical residues on 
the p1 alpha helix (see Figure 15). Paradoxically, the same residues that differentiate 
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these subtypes from each another are usually homologous to that of a subtype 
belonging to another generic DR specificity. Again, there are few, if any allele-
specific residues for T -cell defined subtypes; the uniqueness is provided by the entire 
sequence which may involve 20-30 residues. 
This phenomenon is illustrated using some of the DR4 and DR1 subtypes 
(Figure 1.6). The DR4 subtypes differ from each other by one to four amino acid 
residues. For example, Dw14.2 (Bl*0408) differs from Dw14.1 (0404) by a single 
conserved substitutio~ glycine for valine at position 86, and it differs from Dw4 
(0401) by a conserved substitutio~ arginine for lysine at position 71. Although the 
differences are conservative, each of these three subtypes can be differentiated by 
alloreactive T cell clones (Pile et al., 1992a). In contrast Dw10 (0402) differs from 
the other DR4 subtypes by three to four residues. Two of these involve major non-
conservative substitutions at positions 70 (negatively charged aspartic acid for an 
uncharged glutamine) and 71 (negatively charged glutamic acid for positively charged 
lysine or arginine) and the other two involve non-conservative substitutions at 
positions 67 (isoleucine for leucine) and 86 (valine for glycine). 
The DR4 and DR1 molecules have major differences in their first two 
hypervariable regions. However, the HVR m sequences on the alpha helix of the 
different fJ chains reveal some interesting simi1arities as well as differences. For 
example, residues on the alpha helix that differentiate the DR1 subtypes Dw1 and 
Dw • BON, • from each other are strikingly similar to the analogous sequences in 
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Dw14.2 and DwlO, respectively (Figuret.6). In fact, Dw4, Dw14.1, Dw14.2 and Owl 
are so homologous that alloreactive T -cell clones and antibodies have been identified 
that react with determinants on all these molecules and any others such as Dw16, 
that are carry these sequences (Duquesnoy et aL, 1984; Flomenberg et aL, 1989; 
Weyand and Goronzy, 1989; Hiraiwa et al., 1990; Obato et al, 1992). This suggests 
that homologous sequences in these regions generate similar structures, such as the 
putative "shared epitope• that has been predicted to confer suscepnl>ility to the 
development of Rheumatoid Arthritis (see CHAPTER 2). 
Amino Acids in DR B1 Domain 
HLA-DR Beta Sheet Alpha Helix 
Allele Subtype 1 56 57 67 70 71 72 73 74 
B1•0401 Dw4 D L Q K R A A 
Bt•0404 Dw14 D L Q R R A A 
Bl•0405 Dw15 s L Q R R A A 
Bt•01ot Dwl 1\XXXXXXXXXXXX) D L Q R R A A 
Bt•OI03 DwBON kxxxxxxxxxxxx >l D I DERAA 
B1*0402 DwlO D I DERAA 
Figure 1.6 Amino acid differences and similarities between related and 
unrelated DR alleles. DR4 alleles {open boxes) differ from DR1 alleles 
(hatched boxes) at amino acids 1-56, but share sequences at positions 
57-86. 
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1.5.4 Alloreactivity 
Several studies using class II mutants and inbred mouse strains have mapped 
the key allodeterminants to positions 67, 70 and 71 on the alpha helix of 1-A f3 chains 
(reviewed by Mengle-Gaw and McDevitt, 1985). However, due to extensive 
interallelic homology in this region, it seems unlikely that alloreactive T cells 
recognize these amino acids directly. If there are no allele-specific residues for each 
subtype, what then is the nature of the aBo-determinant that defines a single Dw 
specificity? It has been suggested that the polymorphic differences on the /3-pleated 
sheet, which forms the floor of the groove, must also contribute to the structure of 
the T cell determinant (Lechler and Lombardi, 1991; Obato et al., 1992). For 
example, two DR4 subtypes Dw13 and DwKT2 differ by only a single residue 
(tyrosine for serine at position 37), which lies on the floor of the groove. Since the 
side chains of position 37 are presumably involved in peptide binding, and since the 
groove contains peptide, it is likely that such (and perhaps all) alloreactive T cells 
recognize MHC-peptide complexes. For example the recognition of some alloreactive 
T cell clones has been shown to depend on the cell in which the molecule is 
presented, which suggests the recognition of a cell-specific peptide plus MHC 
(Kappler and Marrak, 1988). Further evidence for peptide being involved in the 
formation of an allodet~rminant has come from reports of alloreactive T cells that 
react also with self-MHC plus a particular antigenic peptide, that is in an antigen-
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specific manner (De Koster et al., 1989; Panina-Bordignon et al., 1991; Lechler et al., 
1992). Thus, the general consensus is that most alloreactive T cell clones bind 
conformational determinants that are dependent on critical residues (notably those 
at positions 67, 70, 71, 74 and 86) on the alpha helix, on certain residues on the floor 
of the groove and on bound peptide (Lechler et al., 1992; Coppin et al., 1993; 
Demotz et al., 1993; Sherman and Chattopadhyay, 1993). One of the most interesting 
findings, which may have implications for transplantation, is that some alloreactive 
T cells are directed to allo-peptides that are derived from processed non-self MHC 
molecules and presented in the context of self-DR (Liu et al., 1992). 
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CHAPTER2 
HLA-DR MOLECULES AND RHEUMATOID ARTHRITIS 
2.0 INTRODUCTION 
An association between histocompatibility molecules and disease was first 
demonstrated in mice in which it was shown that certain inbred strains were 
susceptible to virally-induced murine leukaemia (Lilly et al., 1964 ). Although the first 
InA-associated diseases to be identified were leukaemias and Hodgkin • s disease 
(Amiel et al., 1967; Forbes and Morris, 1970), the majority were subsequently found 
to have an autoimmune component. InA-associated diseases are generally 
characterized by unknown aetiology, a tendency to be inherited, but not by simple 
Mendelian genetics, and weak penetrance. With few exceptions, they are more closely 
associated with HIA-class ll than with class I molecules. 
The magnitude of these associations is quantitated by calculating the relative 
risk (RR), which is the probability of developing the disease if the particular HlA 
antigen is present. Thus, disease studies are done using a large sample of well-
defined patients and healthy controls that are matched for gender, age and ethnic 
background. The formula that is used to calculate the relative risk is: (P+C)/(p-c+), 
where p+ represents patients that are positive for the test antigen; C, controls, 
negative for the antigen; P-, patients, negative for the antigen, c+ ,controls positive 
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for the antigen. Thus, a RR of 1 indicates that the test antigen does not confer any 
higher risk than any other antigen. A RR that is less than 1 suggests that the test 
antigen confers protection, while a RR that is greater than 1 suggests that the test 
antigen confers susceptibility to the development of the disease. A notable exception 
to the class ll association is ankylosing spondylitis (AS) and HIA-B27, which 
epitomizes many of the features of liLA-associated autoimmune diseases mentioned 
above (Schlosstein et al., 1973; Brewerton et al.., 1973). For example, although B27 
is found in more than 90% of the patients with this disease, most people with B27 
do not get AS. Presumably, another factor (or factors) that has not yet been defined 
is required to initiate and maintain the disease state. It is perplexing and frustrating 
that after more than twenty years since this association was made, and despite great 
strides in molecular immunology including the cloning of B27 genes and the 
production of B27 transgenic animal models, we still have very little idea of what 
triggers this disease or how to arre it. 
From a historical perspective it is interesting to see how the study of m.A-
disease associations has evolved Such studies have been a major component of 
nearly all the international HLA workshops. As improvements in liLA-typing 
methods were made and as the complexities of HIA-genetics and linkage 
disequilibrium were deciphereds weak associations with class I gave way to stronger 
ones with class ll molecules. For example, the originaJ association of type I diabetes 
with lllA-A1,-B8 was later found to be more significant for DR3 and 002, which 
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are in linkage disequilibrium with A1 and B8. An even higher degree of relative risk 
was conferred by HLA-DR3 and DR4 heterozygosity (Svejgaard and Ryder, 1989). 
Tbe molecular basis of the HLA association was further elucidated by nucleotide 
sequencing of certain lilA genes that were implicated in either susceptibility or 
protection to type I diabetes both in humans and in murine models (Acha-Orbea and 
McDevitt, 1986; Todd et al., 1987). Subsequently, it was shown that the absence 
of aspartic acid at position 57 on certain DQp (DQ2 and DQ8) and the equivalent 
1-~ chains of 1-Anod mice conferred susceptibility, while the presence of aspartic 
acid at the same position conferred resistance to the disease. 
It is beyond the scope of this review to describe the many different InA-
associated autoimmune diseases. The lll.A-DR4 associated diseases, particularly 
Rheumatoid Arthritis are most relevant to the work that will be described in this 
thesis. Thus, various aspects pertaining to Rheumatoid Arthritis and the associated 
HL\ molecules will be reviewed. 
l.l RHEUMATOID ARTHRITIS: AN OVERVIEW 
Rheumatoid arthritis (RA) is a self-perpetuating autoaggressive disease of 
unknown etiology that afflicts approximately 1% of the population, with prevalence 
rates ranging from 0.1% in certain parts of Africa to to 1.6% in Finland (Spector, 
1990). like many autoimmune diseases it affects more females than males, which 
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suggests a role for sex hormones (Khan et al., 1988). It has a tendency to occur in 
families with a concordance rate of approximately 30% for monozygotic twins and 
7% for dizygotic twins (reviewed by Wordsworth and Bell, 1992). However, a recent 
study disputes this figure and suggests that the concordance rate for monozygotic 
twins is only 15% (Silman et al., 1993a). It has been suggested that the concordance 
rates are higher when the studies are done through a rheumatology clinic than when 
done at the community level (Walport et ~ 1992) 
One of the difficulties in establishing the size of the genetic contribution is 
disease heterogeneity. The criteria on which rurrent diagnosis is based were 
established by the American Rheumatism Association in 1987 (Arnett et al., 1988) 
These criteria and the various stages of disease progression have been reviewed by 
Harris (1990). Typically, the disease is marked by inflammation and gradual erosion 
of the joints with most of the immune-mediated attack focused on the synovial tissue. 
However, RA is not confined to the joints and it frequently affects other tissues, 
particularly the skin and lungs. Consequently, RA patients range from those with 
mild polyarthritis to those with severe symptoms, including loss of mobility and extra-
articular involvement Thus, within this generic classification of RA, there may be 
disease subsets in which genetics plays a further role (Deighton, 1993). 
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2.1.1 Immunopathogenesis of the Rheumatoid Synovium 
In progressive RA the structure of the synovium closely resembles lymphoid 
tissue. The membrane becomes hyperplastic and is enriched in phagocytic and 
fibroblastic cells. Typically there is a lymphocyte-rich zone that is similar to the 
paracortical areas of a lymph node with CD4 positive T cells and endothelial cells 
predominating. Transitional areas resemble the follicular and medullary regions of 
a lymph node with an enrichment of B-lymphocytes and plasma cells. Uninfiltrated 
interstitial areas contain histiocytes, many of which are positive for class II and 
macrophage markers. The synovial fluid is particularly enriched in 
polymorphonuclear cells as well as in a variety of lymphocytes. 
The predominant cells in the synovium are activated CD4 positive T cells, 
which express markers that are characteristic of memory cells; these include 
CD45RO, IL-2 receptors, class II molecules and adhesion molecules, such as LF A-1 
asialyl-Lewis X and VlA-4 (Panayi, 1993; Gaston, 1993). These adhesion molecules 
promote binding to their respective ligands (I-CAM, EI.AM-1 and VCAM-1) on 
endothelial cells. Furthermore, the secretion of lymphokines (IL-2 and IFN-y) by T 
cells upregulates the expression of adhesion molecules, thus, exacerbating T cell 
infiltration into the synovium. The main effector cells are macrophages and 
synoviocytes which, together with the activated T cells, release a huge array of 
cytokines including IL-l, TNF-a, IL-6, numerous growth factors, and the 
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IL-2 and IFN-y (reviewed by Panayi, 1993; Firestein and Zvaifler, 1993). In concert, 
these factors promote the destruction of the joints and surrounding tissue. 
Approximately 70% of patients with RA are seropositive, that is, they have 
increased levels of anti-immunoglobulin, commonly called rheumatoid factor (RF) 
both in the synovium and in the circulation. RF positivity is generally associated with 
a poorer prognosis (Olsen et al., 1988; van Zeben et al., 1991), but there are patients 
who have severe RA and who are not RF positive (Calin et al., 1989). The 
production of RF is not restricted to RA but is found in several diseases, particularly 
lymphoproliferative diseases; it is also produced from activated B lymphocytes in 
culture. However, the variable region genes from this type of RF (usually IgM) shows 
restricted usage of variable region genes (Vaughan et al., 1993). In contrast the 
variable region genes from RF (IgM, lgG or IgA) have undergone somatic 
hypermutation. This suggests an ongoing antigen-driven response but, despite 
intensive research in this area, no antigens derived either from self-components or 
microbial organisms have been shown to be uniquely associated with RA. 
Susceptibility to RA and expression of the disease may be coded for by several 
genes, particularly genes in the MHC. It has been determined that most of the 
genetic component is contributed by HlA, and that HlA is more important in severe 
progressive RA than in mild disease (reviewed in Oilier and Thompson, 1992). For 
example, although the vast majority of hospital-based patients with RA are HIA-
DR4, this may not be the case at the community level (see section 2.5). Other non-
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HLA genes that may confer susceptibility include immunoglobulin genes, notably 
polymorphisms that are associated with the kappa constant region (Moxley et al., 
1989) and T -cell receptor genes.. In the latter case, there have not been any 
consistent findings of particular V -region genes despite intensive research in this area 
(Wordsworth, 1992). 
THE HLA-DR ASSOCIATION WITH RHEUMATOID ARTIIRITIS 
2.2.1 Historical Perspectives 
The first indication of an HLA-D association with RA came from an early 
study by Astorga and Williams (1969), in which they clearly showed decreased or 
negative mixed lymphocyte reactivity (MLR) in 64% of RA when mixed lymphocyte 
cultures were done between patients. However, since none of the then-known HLA 
antigens could be correlated with altered MLR, these findings remained inexplicable. 
Following this discovery, HLA-D determinants were more clearly defined and it was 
shown that reduced MLR in RA patients correlated with an increased frequency of 
HLA-Dw4 in these patients (Stastny, 1976; McMichael et al., 1977). This association 
was confirmed by several serological studies in which HI.A-DR4, which included the 
HLA-Dw4 specificity, was increased in the majority of RA patients (Stastny, 1978; 
Stastny, 1980; Christiansen et al. 1984; Zoschke et al. 1986). 
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The complexity of the DR4 specificity and its subtypes was first elucidated by 
a modified MLC using homozygous typing cells as stimulator (HTC-typing) and later 
by 2-dimensional gel analysis of immunoprecipitated molecules. Five different DR4 
subtypes (Dw4; Dw10; Dw13, formerly DB3; Dw14, formerly, LD40; Dw15, formerly 
DYI) were identified by HTC-typing (Reinsmoen & Bach, 1982; Bach et al. 1983; 
Thompsen et al., 1983; Jarquemada et al., 1984) and immunochemica.l analysis of 
immunoprecipitated molecules (Groner et al., 1983; Nepom et al. 1983). 
Analysis of the lll.A-DR and Ow frequencies in RA patients of different 
ethnic backgrounds revealed several intriguing facts. The DR4 subtypes (Dw4 and 
Dw14) were most commonly associated with RA in Caucasoids living in North 
America and Northern Europe (Stastny, 1980 ); Dw4 was also found to be associated 
with RAin several other ethnic groups including North American blacks, Mexicans, 
and certain American Indian tribes (Stastny, 1980). In the Japanese population RA 
was associated with the DR4 subtype Dw15 (Ohta et al.,1982). In contrast the HIA-
DR4 association was not found in certain populations such as Greeks and Israeli 
Jews; although these populations carry DR4, it is mostly the DwlO subtype (Stastny, 
1980; Amar et al., 1982; Schiff et al., 1982). In these patients from the Mediterranean 
region and patients of Asian Indian origin (Woodrow et al., 1981), the predominant 
HLA-DR antigen was found to be DRl. Furthermore, several investigators had found 
that DR1 was increased, secondary to DR4, in some of the Caucasian patient 
populations (Stastny, 1980; Christiansen et al., 1984). Thus, by the early 1980's the 
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HLA-association was still incomplete and obscure. 
2.2.2 The Evolution of the Shared Epitope Hypothesis 
Several important discoveries in the mid-eighties contributed to deciphering 
the HLA-association with RA As outlined above, serology and HTC-typing had 
clearly shown that three DR4 subtypes (Dw4, Dw14 and Dw15) and DR1 were 
associated with RA in different ethnic groups, while the DR4 subtype Dw10 and 
possibly Dw13 seemed to be protective. Furthermore, Duquesnoy et al (1984) 
reported that an antigen called MC1 correlated with DR1 and most DR4 specificities, 
and that it was found in 93% of the patients with RA compared to 47% in normal 
controls. This suggested that MC1 was a better indicator of susceptibility to RA than 
either DR4 or DRl. 
The advent of recombinant DNA technology facilitated cloning and 
sequencing of class n genes, which revealed regions of hypervariability that were 
shared among different alleles (See CHAPTER 1.). Gregersen et al., (1987) noted 
from examination of sequences from cloned DR1 and DR4 genes (Bell et al. 1986; 
Cairns et al, 1986; Gregersen et al., 1986), that the third hypervariable region of the 
DRl f3 chain was almost identical to those of the DR4 f3 chains of Dw4 (0401), Dw14 
(0404), and Dw15 (0405). However, the DR4 subtypes DwlO (0402) and Dw13 
(0403), which were not associated with RA, differed from the susceptible DR4 
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subtypes by conservative and non-conservative substitutions in this region (Figure 
2.1). Moreover, the substitutions at which the "protective" Dw10 subtype differed 
from the "susceptible" subtypes were located at positions 67, 70, and 71. In the H-2b 
and H-2bml2 murine models these positions had been previously shown to be critical 
in determining alloreactivity, antigen presentation, and susceptibility to 
experimentally-induced myasthenia gravis (Mengle-Gaw et aL, 1984; Hochman, 1984 ). 
2.2.2A HLA-DRBl * susceptibility sequence 
On the basis of the discoveries and observations outlined above, a unifying 
hypothesis, that became known as the shared epitope hypothesis, was advanced by 
Gregersen et al., 1987. It predicted that the homologous sequences 67-
74:ll..EQKRAA/LLEQRRAA on the implicated DR p chains, generated a shared 
epitope that is important in conferring susceptibility to the development of RA The 
same group also reported that a serologically-defined epitope (109d6) was highly 
associated with RA; this epitope was also present on DR10, later shown to be 
associated with RA in some populations (Merryman et al., 1988). Since DRlO 
molecules were also found to carry a similar sequence (67-74:lLERRRAA) to that 
of the putative shared epitope, Winchester and Gregersen (1988) suggested that the 
"epitope" resulting from the substitution of arginine for glutamine in the shared 
sequence was also positively charged and was "conformationally-equivalent" to the 
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epitope generated from 67-74:LI.EQK/RRAA in RA. It was later shown that this 
109d6 serological epitope is present on other molecules such as DR53, DR9 and 
DR14Dw9. Since these molemles, with the possible exception of DR9 (Massardo et 
al., 1990), are not associated with ~ this epitope is unlikely to be a marker of 
susceptibility to RA. The shared epitope hypothesis was further strengthened by the 
discovery that a rare DR6 allele (DRB1*1402), which encodes the same shared 
sequence, is highly associated with RA in two North American Indian populations 
(Willkins et al., 1991 and Nekon et al., 1991). 
The DR subtypes that carry 67-74:lLEQKRAAjLLEQRRAA/UERRRAA 
and their amino acid differences are shown in Figure 2.1. All DRp chains have either 
valine (V) or glycine (G) at position 86 and several newly-identified alleles vary only 
by G or V at position 86 (for example, DRB1*0404 and 0408 or 0101 and 0102). 
Several investigators have questioned the importance of position 86 to the formation 
of the shared epitope and whether it is relevant in conferring RA susceptibility (Gao 
et al. 1991a; Nelson et al, 1991). While some studies suggested that the shared 
epitope plus 86G (for example, DRB1*0401,0405,0408, 0101,1001) contnbuted 
greater susceptibility~ others could not confirm this (Wordsworth et al., 1992). 
Recently, the DR1 associatioo with RAin Israeli Jews was shown to be greater for 
the variant DRB1*0102 (86V), (de Vries et al., 1993). This suggests that the 
contribution of position 86 to the shared epitope is minor in conferring susceptibility 
toRA 
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HLA-DR SUBTYPES AND RHEUMATOID ARTHRITIS 
HLA-DR Beta Sheet 
SUBTYPES 
1 56 57 
BI*0401 DR4Dw4 D 
Bl*0404 DR4Dwl4.1 D 
Bl*0408 DR4Dwl4.2 D 
Bl*0405 DR4Dwl5 s 
B1*0403 DR4Dwl3.1 s D 
B1"'0407 DR4Dw13.2 s D 
Bl *0406 DR4DwKT s D 
Bl *0402 DR4Dw10 D 
Bl*OlOl DRlDwl E;·; ~~2 ;~~~:gg~2S:g~;~ '~~L' >\~ D 
Bl*l402 DRI4Dwl6 ' . . ' . . . . ' . . . ' . . . . :1 D 
Bl*lOOI DRlO I I I I I I I I I I I I I I I I ll D 
Alpha Helix 
67 
L 
L 
L 
L 
L 
L 
L 
I 
L 
L 
1 
70 71 72 73 74 
Q K R A A 
Q R R A A 
Q R R A A 
Q R R A 
..!L 
Q R R A E 
Q R R A E 
Q R R A E 
86 
G 
v 
G 
G 
v 
G 
v 
DERAA V 
QRRAA G 
QRRAA G 
RRRAA G 
Figure 2.1 HLA-DR subtypes and association with rheumatoid arthritis 
(RA). The DR4 subtypes (open bars) have nearly identical amino acid 
sequences on the beta sheets, but differ on the alpha helix. The DR subtypes 
associated with RA are shown in italics and have homologous sequences 
(boxed) on the alpha helix; non-DR4 subtypes associated with RA differ in 
sequence on the beta sheets (different patterns). 
2.3 HLA-DR FREQUENCIES AND TilE PREVALENCE OF RHEUMATOID 
AR'IHRITIS IN DIFFERENT POPULATIONS 
DNA-based typing of class n genes using the polymerase chain reaction for 
gene amplification followed by the use of allele-specific oligonucleotide probes has 
facilitated the precise identification of the DR alleles that are associated with RA in 
different ethnic groups. Thus, a considerable amount of new data regarding HLA 
associations, allele frequencies, and the prevalence of RA in diverse populations has 
accumulated from disease and anthropological studies. The findings of some of these 
studies are summarized in Table 2.1. Wherever possible, the frequencies of the 
implicated DR specificities are given for the control population in the disease study 
and for the general population in each ethnic group. 
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Table 2.1 Distribution of rheumatoid arthritis, HLA-DR association and frequencies in different populations. 
Frequency of DR Specificities in the Normal 
Associated DR Specificities and Relative Population 
Risk (RR) 
DR4 B 1*04 Alleles DR1 DRIO References Ethnic Group 
DR4; 35 .1 20.2 1.2 Larsen et al., 1989 
Canadian Whites 
DR4 (RR,3.4) ; DR! (RR,2 .9) 14.3 22.9 NA Singal et al., 1991 
18.2 01 >04/08>03 12 0.7 Imanishi et al., 1992 
DRl; DR4 (RR,3.7); 040l(RR,6.1); NA NA NA Nepom et al., 1989 
0404/8 (RR,3 .7); 
DR1 (RR, 1.7) DR4 (RR,3.5): 0401(RR,5.3); 33.3 19.2 NA Gao et al., 1991 
USA Whites 0404/8 RR, (0.9) 
12.4 01>04/0~>03 10.1 1.7 lmanish1 et al., 1992 
Table 2.1 continued. 
Ut 
N 
Ethnic Group 
UK Whites 
London 
Norwich 
Norwegian 
Finnish 
Swedish 
Yugoslavian 
Italian 
Spanish 
Associated DR Specificities and Relative 
Risk (RR) 
DR1 (RR, 1.2) DR4 (RR,l0.5); 
0401(RR, 11); 0404 (RR,14.3) 
No significant increase 
DR4 (RR,7.9): 0401 & 0404 
DR4 
DR4: 0401 & 0404; DRl 
DRI (RR,2.84) DR4 (RR1.9) 
DR4(6.9): 0401 & 0404 
DR10 (RR,5.3); DR4 (1 .8); DRl (1.2) 
DRlO (RR,3.8); DR4 (RR,2.4): 0405 & 0401 
Frequency of DR Specificities in the normul 
population 
DR4 B 1*04 Alleles DRl DRJO References 
17 01>04>03 33 NA Wordsworth et al , l989 
37 20 NA Thompson et al, I 993 
13.9 10.7 1.7 Imanishi et al., 1992 
34 01>04>03 14 2 Ronningen et al, 1990 
29.5 38.6 NA Paimela et al , 1993 
21 01>04>03>02 10 NA Wallin et ul , 199 I 
34 45 NA Jajic et al. 1992 
10.3 9.3 1.5 Imanishi et al., 1992 
10 01>04>02 15.3 4.5 Angellini et al, 1991 
7.1 0 I >03/07>02 8.5 1.5 Imanishi et al., 1992 
26.5 20.5 4.5 Sanchez et al, I 990 
22.7 03/07>04/08>0 1 23.3 3.7 Ye1amos et al, 1993 
16 0 I >04/08>02>03 10.9 0.9 Jmunishi et ul., 1992 
Table 2.1 continued. 
Ut 
w 
Ethnic Group 
Orook 
Israeli Jews 
Indian (Asian) 
Indian (UK) 
S. Chinese 
Han Chinese 
Thai Chinese 
Japanese 
Associated DR Specificities and Relative 
Risk (RR) 
DRl;DRlO 
DRI 
DR4: 0405 (RR,9.2) 
DR4 
DRlO (RR 3.8); DRl (3.4) 
DR4 (RR, 3.4): 0404>0405 
DR4 (RR,4.6): 
DR4 (RR,2.S); DR 1 (RR,6.8) 
DR4 (RR,2.2) 
DR4:0405 (RR,3.3) 
Frequency of DR Specificities in the normal 
population 
DR4 B 1*04 Alleles DRI DRlO References 
!loki ot nl. 1«)1)2 
14 02>01>03>04 7 5.M Curlhy cl ul , I «J!J:l 
Gaoetal, 1991 
32.8 02>03>04>05 Gao et al, 1991 
26.1 14.1 2.2 Taneja et al, 1993 
11.9 6 8.9 Oilier et al, 1991 
10.6 04>03>02/0 1 5.6 5.6 Imanishi et al., 1992 
17.8 05>04 () 4.4 Scglins ct ul, 1992 
14 05>06>04>02 0 5 Molkentin et al. 1993 
15 1 1.5 lmunishi ct ol . 1992 
16.4 0 2.1 lmunishi et al ., 1992 
Tsuchiya et al., 1992 
22.8 05>06>03/07 5.5 0.6 lmanishi et al., 1992 
Table 2.1 continued. 
Frequency of DR Specificities in the normal 
Associated DR Specificities and Relative population 
Risk (RR) 
DR4 B 1•04 Alleles DRI DR10 References Ethnic Group 
N.Zealand Polynesians 
DR4: 0405 & 0404 (RR,ll) 26 03>01>04/05 NA NA Tan et al, 1993 
S.Africa Negroids 2.8 01>04>05 2.8 1.7 Imanishi et al. , 1992 
Cape Town 
DR4 (RR,3. 9) 13 NA NA Martell et a1 , 1989 
I o tl 4 7 :u. lnua11 11alai nl nl . I111J7 
Zimbawean DR4 8 14 6 Martell et a1, 1990 
1.9 9.2 3.8 lmanishi et al. , 1992 
Sotha DR4 (RR,12.9) 9.3 NA NA Pile et al , 1991 
Zula DR4 (RR,59) 7.1 NA NA Pile et al , 1991 
Kuwait DR3 (RR,23.56) NA NA NA Suttur et nl. I 990 
Chile DR9 (RR,9.3) 29 16 NA Gonzales et a1, 1992 
Yakima Indians DRB1*1402 (RR,3.3) NA NA NA Willkins et al , 1991 
Tlingit Indians DRB1*1402 (RR,2.4) 21 2 2 Nelson et al , 1992 
2.3.1 Correlation or RA Prevalence with lllcreased HLA-DRB1*0401 Frequency 
An intriguing observation (Winchester, 1992) which is clear from the studies 
summarized in Table 2.1, is a North to South trend for both the frequency of 
DRB 1*0401 and the prevalence of RA For example, Caucasoids living in North 
America and Northern Europe have a high DRB1*0401 frequency and an increased 
prevalence of RA, while Caucasoids living in certain Mediterranean countries have 
a low DRB 1 *0401 frequency and a reduced RA prevalence. In Spaniards, Greeks and 
Israeli Jews, RA is more frequently associated with DR10 and/or DRl. Recent 
studies have also implicated DRB1*0405, which was unexpected since the frequency 
of DRB1*0405 in those populations is lower than for other DR4 alleles. As 
previously noted the frequency of "protective" alleles, Dw10 (0402) and Dw13 
(0403 /0407), is significantly higher in these countries than in Northern Europe. 
The controversy regarding the lll.A-association with RAin India has not been 
completely clarified from these studies. For example, Oilier et al., (1991) and others 
have found that RAin Indians living in the UK is associated primarily with DRlO 
and DRl. However, Taneja et al (1993) and the 11th lliW studies (summarized by 
Nelson et al, 1991) found a positive association with DR4, specifically DRB1*0404. 
These differences are likely to reflect the size and racial diversity of the population 
of India. For example, in the 11th lliW anthropology study the frequencies of DR4 
were 4.3% for Punjabis in New Delhi; 18.6%, for the Iyers in South India; and 
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11.7% for Bhargavas in North India; mixed Indians living in Canada, the United 
Kingdom and USA had a frequency of 10.8 percent (Singal et al, 1992). 
The prevalence of RA and the frequency of DR4 and DRB1*0401 in Africa 
are quite variable (Modyetal, 1989; McGill, 1993), but again they more or less 
parallel each other. For example, both DR4 and RA are virtually non-existent in 
Nigeria (Silman et al., 1993b ); in South African Negroids the prevalence rate ranges 
from 02% to 0.9%, with the highest RA prevalence and DRB1*0401 frequency being 
found together in urban regions such as Soweto. It would be of interest to know the 
RA prevalence rate in one of the Negroid tribes (San Bushman), which has a 
DRB 1*0401 frequency of 44.8%. It has been pointed out, that the prevalence rates 
given for RAin Africa may be diluted by a larger population of younger people than 
that which is seen in Europe (McGill, 1993; Pile et aL, 1992b). 
Japan has a moderate prevalence of RA (0.6%) despite having a high 
frequency of the "susceptible" DRB1*0405; it is noteworthy that the DRB1*0401 
frequency is less than 1 percent. Similar or reduced prevalence and an increased 
DRB1*0405 frequency have also been reported for southern China and the Thai 
Chinese (Silman et al; 1992). Furthermore, in New Zealand Polynesians in which the 
high frequency of DR4 is due to the allele B 1*0403, the prevalence of RA is 
reported to be low and it is associated with DRB1*0404 and 0405 (Tan et al., 1993). 
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.2.3.1A Frequency of the shared epitope in ethnic groups 
Since susceptibility to RA is closely associated with the putative shared 
epitope (DRB1*67-74:ILEQKRAAjllEQRRAA/LIERRRAA), several of the 
studies summarized in Table 2.1 reported the frequency of the "susceptibility 
sequence" in RA patients and controls. As might be predicted the highest frequency 
of this sequence was found in Northern Caucasoid RA patients (80% to 93% 
compared to about 40% in the control populations). Frequencies in Southern 
Caucasoids patients were generally lower, with the lowest being reported in a study 
of Greek patients in which 435% of RA patients had the sequence compared to 
155% of the controls (Boki et al., 1992). However in another study involving Greek 
patients, the sequence was present in 605% of the patients, compared to 22.1 % of 
the controls (Carthy et al~1993). This finding is a little lower than that found in 
Italians (64.5% for patients versus 29.3% for controls) and Spaniards (68.6% versus 
37%), (Angellini et al. 1991; Yelamos et al. 1993). In Jewish and Indian patients, the 
frequency of the susceptibility sequence accounted for about 56% of the patients 
(Gao et al. 1991; Ollier et al, 1991). The frequency of the susceptibility sequence in 
one study of South African Blacks (78% for patients compared to 24% for controls) 
closely parallels that found in northern Caucasoids (Pile et al., 1991), while the 
frequency in Orientals is significantly lower (roughly 40% versus 15%), Seglias et al., 
1992; Molkentin et al., 1993). As has been previously pointed out, the Yakima 
Indians and 11inglit Indians have an exceptionally high frequency of DRB1*1402 
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(61% in control populations) and have a high prevalence of RA (greater than 85% 
of the patients having DRB1*1402). Cerna et al, (1993) have recently shown that in 
native South American Indians in which HlA polymorphism is restricted, the 
frequency of DR14 *1402 and 1406 is also high. 
2.4 ASSOCIATION OF HLA CLASS II MOLECULES THAT DO NOT CARRY 
TilE SUSCEPTIBILITY SEQUENCE WITH RHEUMATOID ARTHRITIS 
Aside from DR molecules carrying a version of the susceptibility sequence, 
very few DR molecules have been consistently associated with RA susceptibility. 
However, a significant association with DR3 in an Arabic population was recently 
reported (Sattar et al, 1990). It has also been shown that DR3 is associated with 
gold-induced cytotoxicity in RA patients (Panayi et aL, 1978; McCusker et al., 1991). 
DRp1*0301 shares glutamine and lysine at positions 70 and 71 with DRp1*0401, but 
differs from the susceptibility sequence at positions 73, 74, and 77. It is generally 
considered to be neutral in conferring RA susceptibility, but based on these reports 
it may be associated with some subsets of RA It is interesting that Larsen et al. 
(1989) found that DR3 in combination with DR4 was significantly increased in 
females with RA, whereas DR3 in combination with DR7 was "protective". 
HLA-DR53 is also associated with RA, but it has been suggested that this is 
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due to Jinkage disequilibrium with DR4. The evidence for it not being associated 
with RA is based on the fact that DR53 is also in linkage disequilibrium with DR7 
and DR9. DR7 appears to be negatively associated with RA (Ronningen, 1990; 
Nelson et ~ 1992), but DR9 has recently been shown to be significantly increased 
in RA patients in a Chilean population (Gonzales et aL, 1992). This raises the issue 
of whether DR9 and DR53 have "conformationally equivalent epitopes" as was 
proposed by Winchester and Gregerson (1988). This idea was partly formulated on 
the presence of a serological epitope for the monoclonal antibody (109.d6) on DR53 
and DR10 molecules, which together with DR9 and DR14 (JH *1401) molecules carry 
part of the "shared susceptibility sequence". It is also of interest that an Italian study 
also found an increase in DR14 in RA patients, although this increase was not 
significant. The main difference between the susceptibility sequence on fJ chains for 
DR10 and those for DR9, Dw9, and DR53 is a glutamic acid substitution for alanine 
at position 74, which has been predicted in the DR4 subtypes (Dw13 and DwKT2) 
to confer protection. Winchester et al. (1992) have recently suggested that, if the 
association of DR9 (which also has a phenylaline substitution at position 67) with RA 
is confirmed, then positions 67 and 74 might not be that critical for susceptibility, 
thus limiting the consensus sequence to 70-73:(QKRA/ORRAfRRRA). Perhaps 
then, the earlier suggestion by Winchester & Gregerson (1988), that DR53 in 
association with a susceptible DR4 (or DR9) molecule increases RA susceptibility, 
has some merit. 
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The association of RA with 003 (007 and 008), which is in linkage 
disequilibrium with DR4, is still somewhat controversial. It has been suggested that 
007 molecules are also implicated in the development of RA (Singal et al., 1987; 
McCusker & Singal 1988; Lanchbury et ~ 1989). In contrast, others found that 007 
and 008 are equally distributed in RA patients (Wallin et al., 1988; Wordworth et 
al, 1989; Nepom et al., 1989; Gao et al, 1990, Angellini et al., 1991). In fact, Taneja 
et al. (1993) found that DQ8 was significantly associated with RA patients of Asian 
Indian origin, while DQ7 was not. Although some studies support the idea that 007 
is implicated in severe RA (Stephens et al., 1989; Singal et al., 1992b), it is possible 
that this finding merely reflects the fact that DRB1*0401, which is in linkage 
disequilibrium with DQ7 and DQ8, is associated with disease severity. For example, 
virtually all patients with Felty • s syndrome, which is a subset of severe RA carry 
DRB1•0401 and usually 007 (Lanchbury et al,1991; Wallin et al., 1991). 
2.4.1 Susceptible and Protective Haplotypes 
Much of this review has focused on the association of class n molecules with 
susceptibility to the development of RA However, as previously mentioned the DR4 
molecules, Dw10 and Dw13 molecules are associated with decreased risk for RAIn 
addition other class n molecules have been shown to be negatively associated with 
RA, but this •protectiveness • is not consistent for all the ethnic groups. For example, 
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DR2 (DR15 and DR16) has been found to confer protection in Northern Caucasoids 
(Young et al., 1984; Jaraquemada et al~ 1986; Stastny et al., 1988; Ronningen et al., 
1991), while the same phenomenon was not found in studies of Greek patients 
(Carthy et al., 1992). Two recent studies on InA associations with mild and extra-
articular forms of RA revealed that DR2 is significantly more common in mild forms 
than in severe forms (Singal et al., 1992b; McMahon et al. 1993). 
Other lll.A-DR molecules that are associated with protection include DR11 
(11th. lliW); DR7 (Stastny et al., 1988; Ronningen et al., 1990); DRB1*0803 (11th 
IHW); DR6 (Stastny et al., 1988; Ronningen et al., 1990, 11th lliW). Certain 
phenotypes containing DR7 (DR3,DR7; and DR5,DR7) were also found to be 
significantly associated with protection (Larsen et ~ 1989). In the latter report, the 
authors predicted the existence of a hybrid DQ molecule (DQA1*0501 from the DR3 
or DRS haplotype combined with DQB1*0201 from the DR7 haplotype), might 
confer protection by affecting T cell selection. This is an interesting hypothesis since 
the DQB1*0201 allele from DR7 haplotypes differs from that of the DR3 haplotype 
by a substitution at position 135 in the second domain (Hall et al., 1992); they have 
predicted that a similar heterodimer might confer susceptibility to the development 
of Coeliac disease. 
Since DO specificities are in linkage disequihl>rium with several different DR 
alleles, it is instructive to review the DO alleles on "suscepbole" haplotypes and 
"protective" haplotypes. These are summarized in Table 22 and it is apparent that 
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some DO specificities, including 007 and DQ8, are found in both groups. For 
example, the DQA •oso1 and DQB1•0301 alleles, which encode 007 on the 
DRBt•t402 haplotype are positively associated with RA (Nelson et ai., 1992), while 
the same alleles on the DRll haplotypes are associated with protection. This refutes 
the notion that the 007 molecules encoded by DQA1*0501 might be protective 
(McCusker and Sing~ 1988). Furthermore, the DQ7 specificity that is encoded by 
At•ooot and Bt•oJOl is associated with susceptibility on the DRB1*0401 haplotype, 
but associated with protection on DRB1*0407 haplotype. Similarly, DQ8 is associated 
with susceptlbility (DRB1*0401 and 0404) and with protection (DRB1*0402). It has 
been proposed that DQ2 might be protective (Ronningen et al., 1990) but its 
presence on certain DRB 1*0405 haplotypes (A wad et ~ 1990) which are associated 
with RA, would argue for DR7 being the protective molecule. 
The only consistent finding in Table 2.2 regarding DQ alleles is that those 
encoding 006 specificities are almost always associated with protection. However, 
the DR alleles that are found on these haplotypes have major differences in the 
putative susceptibility sequence. Thus, DQ molecules do not appear to confer 
susceptibility or protection, but several DRBl alleles that encode aspartic acid at 
position 70 are frequently associated with RA. 
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Table 2.2 lll.-A Class II Haplotypes associated with A) Susceptibility or B) Resistance to the 
development of Rheumatoid Arthrins. 
A) Susceptibility 
DRB1* DRB1*67-74 86 DQA1* DQB1* DQ 
0401 LLEQKRAA G 0301 0301 7 
0401 LLEQKRAA G 0301 0302 8 
0404 LLEQRRAA v 0301 0302 8 
0405 LLEQRRAA G 0301 0401 4 
0405 LLEQRRAA G 0301 0201 2 
1402 LLEQRRAA G 0501 0301 7 
0101 LLEQRRAA G 0101 0501 5 
0102 LLEQRRAA v 0101 0501 5 
1001 LLERRRAA G 0101 0501 5 
B) Resistance 
0402 ll.EDERAA v 0301 0302 8 
0403 LLEQRRAE v 0301 0302 8 
0407 LLEQRRAE G 0301 0301 7 
0701 ll.EDRRGQ v 0201 0201 2 
0803 ll.EDRRAL G 0103 0601 6 
1101 FLEDRRAA G 0501 0301 6 
13 ll.EDERAA v 0102 0603 6 
0103 0604 
0605 
1501 ll.EQARAA v 0102 0601 6 
B5*01 FLEDRRAA G 
Boldface lettering indicate amino acid residues that differ from those in DRB1*0401; boldface 
and italics, indicate DQ alleles that are associated with both susceptibility and resistence. 
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2.5 SUSCEPTIBIU1Y VERSUS SEVERflY 
The vast majority of studies that have shown a significant association of DR4 
and/or DR1 with RA have been carried out on hospital-based patients. Some of the 
very early studies suggested that DR4, in particular Dw4, was associated with disease 
severity. For example, it was found that 75-80% of hospital based RA patients had 
DR4 (Stastny, 1978; Roitt et ~ 1978; Panayi et al., 1978), while DR4 was only 
marginaJJy associated with RA in those patients who were grouped together on the 
basis of ARA criteria (Stastny, 1980 IHW). In a prospective study of RA in the UK, 
it was found that DR4 was significantly increased only in those patients who 
progressed to erosive bone disease as detected by radiographic changes (Young et 
al., 1984). A community-based study in the Netherlands, showed no significant 
increase of DR4 (de Jongh et al., 1984). 
The idea that the presence of DR4 in these patients might be a marker for 
severity was strengthened by two different studies, which showed that more than 90% 
of hospital based patients who developed severe extra-articular forms of the disease 
had DR4 compared to 78% (Oilier et aL, 1984) and 63% (Westedt et al., 1986) of 
those who did not. Several studies showed that patients who were seropositive, which 
is generally an indicator of disease severity, were usually DR4 ( Stastny, 1980, 
Stastny et al., 1988; Olsen et al., 1988). However, in a comprehensive study, by Calin 
et al., (1989) in which they compared two sets of patients who were matched for age, 
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sex and bone destruction, but differed in seropositivity, they showed that DR4 was 
equally prevalent (69%) in both groups. They suggested that DR4 might be a marker 
for disease progression and severity. 
As serological methods and cumbersome cellular methods were replaced by 
DNA typing. a more accurate analysis of the HLA genes that are involved in 
susceptibility or severity has been made. Much of this has already been reviewed with 
an overall ronsensus that both DRB1*0401 and 0404 are most often associated with 
severe forms of RA (Nepom et al., 1986; Hillarby et al, 1991; Lanchbury et al., 
1991). It appears that Dw14 has a synergistic affect on Dw4; recently Nepom (1992) 
reported that the risk ratio for developing clinical RAin the white population is 1/7 
for DRB1*0401/0404, 1/35 for 0401 or 0404; 1/46 for 0401/00101 or 0404/0101 
compared to 1/580 for the general population. It is intriguing, however, that in Greek 
and Oriental populations DR4 is not associated with severity and that the DR4 
subtypes associated with RAin these populations are Dw14 and/or Dw15, but not 
Dw4. 
Recent reports have firmly supported the idea that predisposition to disease 
severity is greatest when the patient carries two copies of the susceptibility sequence, 
particularly in the DR4 context. For example Wordsworth et al, (1992) have 
calculated a hierarchy of risks in the following order: 0401/0404 > 0401/0101 > 
0404/0404 > 0401/0401 >0404/0101 >04/x - 0101/0101 >01/x > x, where xis any 
allele except 0401/0404/0101. Weyand et al (1992a, 1992b) also found that 
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homozygosity for the susceptibility sequence in the DR4 context was associated with 
extra-articular features, joint replacement and the worst prognosis. DR4 homozygosity 
was also shown to be significantly associated with severe radiological changes in RA 
patients who did not have extra-articular features (McMahon et al.41, 1993). 
2.5.1 DR4 as a Prognosis Marker? 
Retrospective studies have strongly suggested that DR4 may be useful in 
predicting patients who will progress to severe RA Thus DR4 and particularly DR4 
genotyping may be a useful prognosis marker, but it needs corroborating by doing 
prospective studies. A few prospective studies have already been done, but 
unfortunately in the majority of these studies the patients were not DR-genotyped. 
The results have been somewhat controversial and inconclusive. 
An early study (Young et al., 1984) found an association between DR4 and 
the development of bony erosions, while another (de Jong et al., 1984) found no 
association. Of four prospective studies that have been recently reported in which DR 
subtyping was not done, one suggested that DR4 is a useful predictor for disease 
progression (van Zeben et al., 1993), two showed a significant increase in DR4 in the 
RA populatio~ but one of these suggested that it was not useful for prognosis 
(Paimela, 1993); the other suggested that it was limited to predicting large joint 
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damage (Eberhardt et al., 1993) In a large community based study in Norwich, DR4 
was not significantly increased over that found in the normal population, and it was 
suggested that DR4 is only associated with long term RA (Thompson et al., 1993). 
A small fifth study was recently reported in which DR genotyping was performed 
(Salmon et al., 1993). They showed that about half of the patients who presented 
with RA-like polyarthritis developed classical or persistent RA and these patients had 
a significant increased frequency of Dw4 compared to the patients who did not 
develop classical or severe RA However, Dw14 or DRl were not increased in either 
group, which suggest that Dw4 may be associated with persistent forms of RA 
The difficulty with all of these studies is that due to the heterogeneity of RA 
it is hard to establish whether DR4 or any other marker is useful for prognosis when 
it is likely that there is no HIA association with mild forms of polyarthritis that 
happen to fit the ARA criteria for RA. Thus, it has been suggested that there may 
be two main subsets of the disease, HIA-linked and non-HlA-linked (Deighton et 
al., 1993a, 1993b ). The HI..A-linked would include poor prognosis, extra articular 
involvement, RF positivity, a significant association with the susceptibility sequence 
and inheritance. 
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CHAP'IER 3 
THESIS PROPOSAL AND RESEARCH PLAN 
When this thesis project was first proposed, the direction of much of the 
efforts in the field of HIA immunogenetics and HLA-associated diseases, was based 
on T -cell and molecular methodology (lOth International Histocompatibility 
Workshop). However, it was felt that a major contribution in this area could be made 
by making monoclonal antibodies to the DR4 subtypes; these subtypes were known 
to be important in transplantation and in conferring susceptibility to certain 
autoimmune diseases, notably Type I Diabetes and Rheumatoid Arthritis. 
The belief that monoclonal antibodies could be made, at least against some 
of the subtypes, was partly based on the identification of a cluster of alloantisera in 
the 9th International Histocompatibility Workshop which produced three different 
DR4 serological patterns. In addition biochemical variants were described that 
correlated with the T -cell defined subtypes. Most importantly, a shared determinant 
(MCl), which was found on the DR molecules that are associated with RA, was 
identified both by alloantisera and T cell clones. Coincidently, transfectants 
expressing class n genes had been described and these appeared to be a 
considerable improvement over the usual B cell lines as immunogens. 
It was anticipated that anti-DR4 mAbs would be useful for tissue typing, thus 
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contributing to the field of transplantation. In particular, it was envisioned that they 
would be valuable in the study of the ID.A-association with Rheumatoid Arthritis, 
as tools for testing the "shared epitope" hypothesis advanced by Gregerson et al., 
(1987). It had been proposed that non-DR4 individuals who develop RA have 
epitopes shared with DR4 on their DR. H this were proven to be correct, then 
antibodies that recognize such epitopes would be useful for identifying individuals at 
risk for RA and for probing the molecular structure of these disease-associated 
determinants. 
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3.0 SPECIFIC AIMS AND OBJECTIVES 
(i) to produce monoclonal annbodies that recognize epitopes on DR4 molecules and 
that differentiate the various DR4 subtypes 
(ii) to produce monoclonal antibodies that recognize shared structures on the DR 
molecules that are implicated in susceptibility to the development of rheumatoid 
arthritis. 
(iii) to use these monoclonal antibodies to search for "shared epitopes" in 
rheumatoid arthritis patients 
iv) to use these monoclonal antibodies to map the critical residues that are involved 
in the formation of the "shared epitope." 
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3.1 STRATEGY FOR THE DEVEWPMENT OF TilE MONOCLONAL 
ANTIBODIES 
To optimi:re the conditions for making the anti-DR4 mAbs, it was decided to 
forgo using human B cells for immunization in favour of mouse cell transfectants, 
which express a single type of HLA molecule. It was envisioned that mice immunized 
with these cells would make a significant response to the foreign HLA molecule with 
an amplification in the number of antigen-specific B cells available for fusion. 
It was decided to make these DR4-expressing transfectants using DNA-
mediated transfer of genomic DNA into L cells which had proven to be successful 
for the expression of lllA class I and CD molecules. This became unnecessary when 
a set of transfectants were generously donated by Dr. R Sekaly and Dr. R. Karr. 
Previously described fusion methodology (MSc thesis, Drover, 1986) was 
modified so that approximately one hybridoma per well in a 96-well microtitre tray 
was obtained, thus simplifing the interpretation of the screening results. 
A previously developed screening method, cellular enzyme-linked 
immunoassay (CEUSA) was adapted for fast differential screening of hybridoma 
supernatants using transfectants that adhered to the plastic wells of a microliter tray. 
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CHAPTER4 
TRANSFECTION OF HLA GENES USING GENO:P.fiC DNA1 
4.0 ABSTRACf 
Mouse L cells expressing HlA genes are potentially useful for producing and 
analyzing monoclonal antibodies (mAb) to HLA molecules. This paper describes the 
preparation of transfectants using uncloned human DNA and three methods to 
isolate the HI.A-expressing transfectants. Transfectant libraries were made by co-
transfecting mouse thymidine kinase (tk) deficient L cells with a calcium phosphate 
precipitate containing genomic DNA and tk plasmid DNA Transfectants expressing 
InA-genes were isolated using these methods: immunomagnetism, replicate-plating 
combined with CEUSA, and sorting using a F ACS. Two Hl.A-A2 transfectants were 
isolated using immunomagnetis~ two HIA-A24 transfectants by replicate plating 
and one Hl.A-Bw60 transfectant by FACS. However, no transfectants were isolated 
that stably expressed class II genes. The class I transfectants have been useful in 
characterizing several locally prepared mAbs- which bind to monomorphic 
determinants on class I lllA molecules. Two of the transfectant lines, one expressing 
HIA-A2 (8001) and the other lll.A-A24 (8008), have been included in the collection 
of lines distributed for use in the 11th International Histocompatibility Workshop. 
1 Published: Sbeila Drover ud William H Marshall, BII.DUUI lmmVPOIOIJ 31: 293,1991. 
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4.1 INTRODUCfiON 
Production of monoclonal antibodies (mAbs) in the mouse to HLA 
polymorphism.s has proven to be difficult largely because mice have been immunized 
with impure mixtures of antigens. The use of mouse cells expressing cloned HLA 
genes should improve the technology, since only one foreign molecule is presented 
to the mouse (Heyes et al., 1986). Using this technology to produce monoclonal 
antibodies to all the 1-ll.A polymorphism.s would require cloning and transfection of 
more than 150 InA genes. This appears to be an impractically large undertaking. 
The use of whole uncloned human DNA to make stable transfectants has been 
described by various authors; for example, Kavathas and Herzenberg, (1983) showed 
that about 1/1000 of such transfectants express lllA class L This prompted us to 
attempt to transfect class II IDA genes in the same manner. 
4.2 MATERIALS AND METIIODS 
4.2.1 Cell Lines 
Human B-cell lines were maintained in RPMI-1640, with 10% fetal bovine 
serum (FBS), and antibiotics. Two EBV -transformed cell lines, derived from patients 
with multiple sclerosis were used to prepare genomic DNA FS-6467 was HIA-typed 
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as A2,3; Cw4,w6; B14,44; DR2,4,w53; DQwl,w3 and FS-6845 typed as A3,24; 
Cw6,w7; B7,w60; DR2,4,w53; DQw1,w3. 
Two sublines of the tk negative C3H mouse fibroblast L cell line were used. 
1be H subline was given to us by H. Hamada; the K subline, was obtained from P. 
Kavathas. Both were maintained in Dulbecco 's Modification of Eagle • s Medium 
(DMEM)* containing 10% FBS, 2-mercaptoethanol and antibiotics. 
4.2.2 Co-Transfection 
Genomic DNA was isolated from the B cell lines, FS-6467 and FS-6845, as 
described (Kavathas and Herzenberg, 1986). The plasmid pHSV106 (BRL Life 
Technologies, Inc., Burlington, Ont. Can. L7P1Al) carrying the tk gene was co-
transfected with the genomic DNA into tk negative C3H L cells (Kavathas and 
Herzenberg, 1986). Briefly, the DNA (20 JJ.g genomic DNA to 200ng pHSV106) was 
calcium-phosphate precipitated and immediately added to a monolayer of L-cells, in 
a 100 mm tissue culture dish (Becton & Dickinson, Lincoln Park, NJ, USA 07035). 
Four hr later the cells were shocked for 3 min with 15% glycerol, washed with 
DMEM and returned to growth medium. In some experiments the cells, at 20 hr 
after glycerol shock, were trypsinized and plated at 5000 cells per well in 96-well flat-
bottom Linbro plates (Flow Laboratories, Inc.). Transfectants were selected by 
feeding with HAT* medium (Kavathas and Herzenberg, 1986) at 48 h and every 
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three days from then on. 
4.2.3 Antibodies 
The mAbs we used are shown in Table 4.1. They were either ascites fluid or 
supernatants from overgrown hybridoma cultures and were optimaJJy diluted in 
medium. The secondary antibody used in CEUSA was affinity purified F(ab • )2 
fragments of goat anti-mouse immunglobulin conjugated to horse radish peroxidase 
(GAM-HRP), (Jackson Immunoresearch Laboratories Inc West Grove, PA 19390). 
For cell sorting and flow cytometry the secondary antibody was either FITC-labelled 
whole molecule IgG goat anti-mouse IgG + lgM (FITC-GAM), (Coulter 
Immunology Hialeah, FL USA 33010), or dichlorotriazinyl amino-fluorescein-
labelled affinipure F(ab' )2 fragments of goat antimouse IgG + IgM (DTAF-FITC), 
(Jackson Immunoresearch Laboratories, Inc.). 
4.2.4 Immunometallic Bead Technique (lmmuaomagnetism) 
Transfectants were harvested at three weeks by trypsinizing the cells for 10 
min. The cells were then left in 10 ml HAT medium in non-tissue culture petri dishes 
(to which they do not adhere) for 24 hr before assay. 
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Table 4 .1. Monoclonal antibodies used in the isolation and selection of HLA-expressing 
transfectants. 
mAb Specificity 
NFLD.M1 anti-DR4 plus 
NFLD.M2 anti-A2 + A28 
NFLD.M6 anti-DR 
NFLD.Ml5 anti-class I 
NFLD.Ml6 anti-class II 
NFLD.M44 anti-A24 
W6/32 anti-class I 
BB7.6 anti-Bw4/w6 
L243 anti-DR 
IVD12 anti-DQ3 
GAP A3 anti-A3 
T~..! 39 anti-class II 
MB40.3 anti-B40 + B7 
B27.Ml anti-B27 + B7 
A TCC, American Type Culture Collection 
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Source/ reference 
Local/Drover et al. (1985) 
Local/1Oth IHW 2021 
Local/ Marshall et al . ( 1986) 
Local/unpublished 
Local/unpublished 
Local/unpublished 
ATCC/Barnstable et al. (1978) 
ATCC/Brodsky et al. (1982) 
ATCC/Lampson and Levy ( 1980) 
ATCC/Giles et al. (1983) 
ATCC/van Schravendijk et al. ( 1983) 
1Oth lHW, Knowles et al., 1989 
A TCC/Parham ( 1981) 
A TCC/Grumet et al. ( 1981) 
For isolating and selecting Hl.A-expressing transfectan~ 2 x Hf transfectants in 2% 
FBSfDMEM were reacted with 0.5 ml of a cocktail consisting of three m.Abs 
recognizing class-IT determinants: NFLD.Ml, NFLD.M6, & NFLD.M16, as well as 
two against HlA Class 1: NFLD.M15, and NFLD.M2 (see Table 1). The mixtures 
were rotated at room temperature for 60 min, washed 3 times and resuspended in 
FBS/DMEM. lmmunometallic beads (Lea et al., 1985) coated with goat anti-mouse 
IgG (Dynallnc., Great Neck, NY 11021) were added at a ratio of 3 beads per cell 
and rotated in the cold for 30 min. Harvesting was done by washing with 10 ml 
FBS/DMEM and trapping rosetted cells on the side of the tube using a cobalt 
magnet (Dynal Inc.). Mter four washes the trapped cells were resuspended in 1 ml 
HAT medium, counted and subcultured at 2000 cells/well in a 24-well plate (Linbro). 
This was followed by cloning by limiting dilution. An alternative method used in a 
few experiments was to directly rosette the colonies using mAbs and immunometallic 
beads. Single colonies were removed with trypsin inside a cloning ring. 
4.2.5 Replicate Plating and CELISA 
Transfectants seeded in a 96-well flat-bottom microtiter plate were allowed 
to grow to confluency and then, after trypsinization, three replicate plates were made. 
The cellular enzyme-linked immunoassay (Drover and Marshall, 1986) was used to 
identify wells containing HI.A-expressing transfectan~ by using a mAb cocktail 
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(W6/32, BB7.6, !243, IVD12 and NFID.M6) or an individual mAb (See Table 4.1). 
Positive cultures were cloned by limiting dilution from the third replicate plate and 
positive wells again identified by a CEUSA on replicate plates. 
4.2.6 Cell Sorting and Flow Cytometry 
In some of the later experiments transfectant libraries were sorted using a 
Coulter EPICS-CS F ACS. Five million cells were reacted aseptically with 0.5 ml of 
a mAb cocktail consisting of Tu39 and W6/32 for 45 min on ice. This was followed 
by three washes with 2% FBS in DMEM and staining with 500 111 of GAM-FITC 
(Coulter). After the final wash dead cells were stained with propidium iodide 
(Sigma), analyzed and sorted essentially as descnbed by Kavathas & Herzenberg 
(1983). The cells were sorted at 5000 cell/sec and collected at 100, 50 and 10 cells 
per well in 96-well Iinbro plates using the Autoclone attachment. Transfectant clones 
isolated by immunomagnetism, replicate plating and cell sorting were also analyzed 
by flow cytometiy, using various mAbs and and staining with DTAF-GAM. 
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4.3 RESULTS 
4.3.1 Isolation and Analysis of HLA-Expressing Transfectants 
4.3.1A HLA.A2 
lfl.A-expressing cells were sorted from three transfections using 
immunomagnetism. After transfection, the number of tk positive colonies surviving 
the HAT selection was approximately 500 per million cells plated. Between 1% and 
3% of cells were rosetted in the three experiments (1.6%, 2.6%, 1.0%) and the 
magnetic sorting procedure resulted in an apparent enrichment of up to forty fold 
(68%, 53%, 15%). In control experiments less than 0.5% of non-transfected L cells 
bound three or more beads. The isolated cells (a mixture of rosettes and non-
rosettes) and beads were plated at 2000 cells/well in 24 well plates. 1bc cells 
isolated from one experiment (Bl2) grew well but for unknown reasons ceDs from 
the other two failed to grow. Some days later they were recultured in limiting 
dilutions in 96 well plates, having either 100, 50, 25 or 12.5 cells per well Tbc:re was 
growth in all wells. Replicate plates were made and CEUSA tests do~ which 
showed positive results (O.D. above 0.5 after background subtraction) in aD wells 
seeded with 100/well, in 92% of wells seeded at 50/well, in 68% of wells seeded at 
25 cells/well, and in 25% of wells seeded at 12.5 cells/well. This data suggests that 
approximately one cell in eight that had been plated out after immunomagm:tic 
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TABLE 4.2. Comparison of the expression of HLA on the transfectants to HLA 
expressed on homozygous B cell lines using CELISA and a panel of monoclonal 
antibodies. 
mAb 
NFLD. NFL D. 
W6/32 BB7.6 M2 M44 GAP.A3 MB40.1 
Cell HLA~ACB 1110 1/5 1/10 1/10 1/10 111 
BL2-8G-E6 A2 0.42" 0.02 1.02 0.02 0.01 0.01 
K2B-12H-G7 A24 0.57 0.01 1.90 0.02 0.01 
WG50-F3 Bw60 0.98 1.31 0.04 0.01 0.02 1.33 
JESTHOM A2~CwlO;B27 2.4 2.4 1.82 0.01 0.04 0.35 
DKB A24;Cw10; 2.5 1.96 0.03 2.13 0.09 1.73 
B40 
SAVC A3;Cw7;B7 2.4 1.89 0.05 0.04 0.80 1.92 
• OD values after the background was subtracted. 
B27.M1 
1/1 
0.01 
0.01 
0.01 
0.78 
0.23 
0.18 
enrichment was a stable lllA expressor. 
Further cloning and testing resulted in a clone, BI2-8G-E6, whose reactions 
with a panel of antibodies {Table 42 and Figure 4.1) indicated that it was expressing 
lllA-A2, the key reaction being with NFLD.M2 an antibody characterized in the 
lOth Workshop (fable 4.1). 
In addition to the lll.A-A2 transfectant described above, a second one was 
isolated from a different experiment using the K subline of L cells. This yielded 1400 
colonies which were directly rosetted on the plate using the same mAb cocktail and 
immunometallic beads. Two rosetted colonies were removed using a cloning ring. 
One survived the cloning procedures and was shown to express A2 (data not shown). 
4.3.1B HLA.A24 
The replicate plating method together with the CEI.JSA assay was used to 
isolate an HIA-A24 transfectant called K2B-12H. Cells from a transfection done 
using genomic DNA from FS-6845 and the K subline of L cells, were seeded at 5000 
cells per well in 96 well microtiter dishes. Colonies grew in all 288 wells. Replicate 
plates showed that two wells gave high O.D. values, (1.33 and 20) with the antibody 
cocktail. Only the latter survived the subsequent cloning procedure and was shown 
to express lllA-A24, the key positive reaction being with NFLD.M44 which is 
considered specific for HLA-A24 (by extensive testing on cell lines), together with 
negative results with GAP A3 (anti-A3) and the B locus mAb BB7.6 (Table 42). 
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4.3.1C HLA.B7 /40 
A library of transfectants made from genomic DNA derived from FS-6845 was 
reacted with a mAb cocktail (W6/32 + Tu39), stained with FITC-GAM and sorted 
using the FACS. The sorted cells were plated at 10, 50 and 100 cells per well. 
Between 33o/c-63% of the wells grew cells and those were replica plated. Eight wells 
gave strong positive results with W6/32; those cells were also positive with BB7.6 (B 
locus) but negative with antibodies to A3 and A24 (data not shown). Since the DNA 
donor was HIA-B7 and 840 (subtype 60), the cells were tested to see which of these 
genes had been successfully transfected. Using the mAbs MB40.3 and B27.Ml, which 
are specific for lll.A B7 + B40 and for lllA B7 + B27, respectively, it appeared 
that these cells were expressing the gene for HIA-Bw60 (Table 4.2). 
4.3.2 Analysis of HLA Expression on the Cloned Class I Transfectants 
4.3.2A Flow cytometry 
Each of the cloned transfectants was tested with the anti-class I mAb (W6/32), 
and a mAb recognizing the appropriate lllA specificity. Culture medium served as 
a negative control. It is apparent from Figure 4.1 that the majority of cells in both 
the BI.2-8G E6 and K2B-12H G7 populations are high expressors and most likely 
clonal. The WG50-4C F3 population is more heterogenous with a large proportion 
of the cells being high expressors and a small proportion of the cells being negative. 
82 
BL2·80 ee K2B 12H 0 7 WG 50-~C FJ 
MEDIUM 
W6"32 
NFLO M44 MB40 3 
0 LOGARITHMIC FLUORESENCE 1000 0 LOG ARITHMIC FLUORESENCE 1000 0 LOGARITHMIC FLUORESENCE 1000 
Figure 4.1 Shows flow cytometry analysis of the expression of class I molecules on the 
transfectants. Each of the cloned transfectants was reacted with medium (negative 
control) shown in the top panel, and with the anti-class I mAb (W6/32), shown in the 
second panel. Each of the transfectants was also reacted with a mAb specific for the 
molecule expressed (shown in the third panel). 
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4.3.28 CELISA 
A panel of mAbs was used to compare the expression of HIA on the 
transfectants to that on B-cell lines. It can be seen from Table 42 that in each case 
the specific antibody gave a lower optical density in CEUSA with transfectants than 
it did with the appropriate B cell line; calculating the difference in terms of 
percentage of OD, shows 56% for A2, 89% for A24 and 73% for Bw60. This is a 
crude comparision and does not directly correlate with the number of molecules 
expressed per cell. In the case of W6/32, which binds to all class I molecules, the 
difference at this dilution is considerably larger; however it should be remembered 
that while B cell lines express HIA-A, HIA-B and HIA-C molecules, the 
transfectants are presumed to express only one of these. 
4.3.3 Use of HLA-Class I Transfectants for Characterizing Monoclonal Antibodies 
to Class I Monomorphic Determinants 
The three class I t:ransfectants have proved useful in characterizing some 
locally-prepared mAbs; these react with all human B cell lines tested except Daudi, 
a class I negative line, suggesting that they are antibodies against monomorphic 
determinants on class I molecules (data not shown). CEUSA was done in which four 
of our mAbs plus W6/32 and BB7.6 were tested on the three transfectants (Figure 
42). As expected W6/32 (anti-lll.A-ACB) reacted with all three transfectants 
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whereas BB7.6 (anti-B locus) was positive only with WGSO (lll.A-Bw60). NFID.M23, 
NFID.M25, and NFLD.M26 produced OD values comparable to that produced with 
W6/32, suggesting that these are directed to an epitope on the heavy chain. 
NFID.M15 reacted only with the Bw60 transfectant and not with the A2 or A24 
transfectants, and reacted in a manner similar to the BB7.6 control. This suggests that 
it is directed to an epitope on the HIA-B heavy chain 
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Figure 4.2 The specificities of anti-class I mAbs (NFLD.M15, 
NFLD.M23, NFLD.M25, NFLD.M26) were analyzed by 
CELISA using K2B-12H G7 (HLA-A24),BL2-SG E6 
(HLA-A2),and WG50-4C F3 (HLA-Bw60). WS/32 and BB7.6 
were used as controls. 
4.4 DISCUSSION 
It is well documented that L cells are good recipients for the expression of 
cloned class I and class II genes (Lemonnier et al., 1982; Germain and Malissen, 
1986). Although we were successful in making class I transfectants, our initial goal 
in these experiments, to produce mouse cells that expressed HLA class II molecules, 
was not reached. There was no stable expression of class n, although there was some 
evidence of transient expression of class II genes in a few experiments (data not 
shown). Possibly a recipient cell that expresses mouse class II molecules might be a 
more appropriate recipient, for example a mouse lymphoma or leukaemia line. The 
transfection of class I genes by this method may turn out to be the more important 
aspect since there are by now considerably more cloned class II genes available in 
expression vectors than there are for class I. 
An estimate of the frequency of transfection of class I genes can be made 
from our data. Among the cells surviving HAT selection that were tested and isolated 
using immunomagnetism, approximately 2% appeared to bind anti-lll.A antibodies 
in the initial set of experiments. When these cells were sorted from the rest and 
cloned, about one in eight developed into a stable transfectant. By calculating 
backwards and ignoring the possibility of artifacts in the sorting and rosetting 
methods, we can estimate that about one in 400 of the original cells became stably 
transfected with the HLA-A2 heavy chain gene. When immunometallic beads were 
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used to directly rosette the colonies, 2/1400 colonies were rosetted, giving a 
frequency of 1/700. The same frequency was obtained using the replicate plating 
technique, in which it was found that two out of 288 wells contained class I 
expressors, in an experiment in which there were probably 1400 transfectants (about 
five tk transfectant colonies per well); thus about 1/700 transfectants was expressing 
a class I gene. This estimate is in line with that calculated by Kavathas & Herzenberg 
(1986). 
Our experiments never showed evidence for simultaneous transfection of an 
HLA-A and an HLA-B gene; we had no reagents to see if HLA-C and lll.A-B had 
been transfected together, which would be not unlikely, given the closeness of those 
two genes. The transfection of two unlinked genes e.g. two different Hl.A-A genes 
or an HLA gene and a beta 2-microglobulin gene would be a rather rare event and 
we found nothing to suggest this might have happened; the latter was excluded by 
testing with BBMl (Brodsky et al., 1979), an anti beta 2 microglobulin antibody (data 
not shown). 
This method, which relies on simple yet effective technology brings the 
production of transfectant cells within the reach of any tissue typing laboratory that 
has cell culture capability. Expensive instruments such as a F ACS are not required. 
Two of the transfectants described here are in the collection circulated for use 
in the 11th International International Workshop; they are BI2-8G-E5 (8001) and 
K2B-12H (8008). 
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CHAPTERS 
USE OF TRANSFECTANTS AS IMMUNOGENS FOR MAKING ANTI-DR4 
MONOCWNAL ANTIBODIES 1 
5.0 ABSTRACf 
Monoclonal antibodies (mAbs) that are specific for DR serotypes and subtypes 
have been difficult to make using human B cell lines as immunogens. The work 
presented here descnbes efforts to make mAbs using mouse cell transfectants, which 
express a single DR4 specificity, as immunogens. Several different immunization 
schedules were tried including neonatal tolerance, which failed. The first eleven 
fusions produced 6500 hybrids, of which one was DR4-specific. Fifteen fusions done 
to find the the optimal immunization scheme, produced over 8000 hybrids, of which 
thirteen made antibodies to DR4 polymorphisms. The largest number of specific 
mAbs were derived from mice that had been given a single injection of cells, either 
subcutaneously in CF A or intraperitoneally, followed by an intrasplenic boost three 
days prior to fusion. Eight antibodies that were selected have the following 
preliminary specificities: NFIDDl, DR4-specific; NFID.D7, pan-DR4, DR2 and 
DR52; NFLD.D2, NFID.D3, NFID.D4, NFLD.D8, NFID.D9 and NFLDDlO all 
recognize subsets of DR4, excluding DwlO, as well as certain non-DR4 molecules 
that are usually associated with Rheumatoid Arthritis. 
1Shorter fti'Bioa puNhhed: Sheila Drover, Dianne Codner, Jane Gamber&, •d Willlalll H MarshalL 
In: TsuJI X, Ahawa M, Sas•nki T (eels): liLA 1991, Volt. (hf'onl. (hf'onl Uahtufty Press, 1992. 
89 
5.1 INTRODUCfiON 
Efforts to make murine monoclonal antibodies {mAbs) that differentiate the 
lll.A antigens have proved it to a be difficult task. This is partly due to the 
immunogen, B cells or B cell lines which express an enormous array of different 
molecules including at least six different HlA antigens. The murine immune system 
recognizes most of these molecules as foreign and even when purified lllA 
molecules are use~ the majority of the antigen-specific cells recognize the species-
specific or monomorphic determinants present on histocompatibility molecules 
(Bodmer et al., 1984). 
The availability of mouse L cell transfectants expressing lllA genes as 
immunogens is a promising alternative since, conceptually, the only foreign molecule 
expressed on the surface of the transfectant should be an HlA molecule. Therefore, 
it is expected that some of the antigen-specific B cells in a C3H mouse immunized 
with such transfectants will be directed to Hl.A molecules and that some of these 
should be against polymorphic determinants. Since only one kind of IH.A molecule 
is-expressed on an L cell transfectant, the task of differentially screening hundreds 
of hybridoma supernatants for specific antibody in a short time, is enormously 
simplified. 
The use of a transfectant by Heyes et al, (1986) to produce anti-DP mAbs, 
including one against a polymorphic epitope, was encouraging for those interested 
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in producing mAbs with the ability to differentiate between allelic variants previously 
only defined by T cells. For example, the DR4 specificity consists of several variants 
including eight T-cell defined subtypes (Bodmer et al., 1990). The work presented in 
this paper describes efforts to produce mAbs to HlA-DR4 molecules using 
transfectants expressing various DRB 1 *04 alleles. The complete characterization and 
epitope mapping of these mAbs is described elsewhere (see CHAPTERS 6 AND 7 ). 
5.2 MATERIALS AND METHODS 
5.2.1 Transfectants 
The DR4 transfectants used for the immunizations and most of the analysis 
(Table 5.1) were generously provided by Robert Karr and Raffi Sekaly and were 
later included in the transfectants distributed by the organizers of the 11th 
International Histocompatibility Workshop (ffiW) (Inoka et al., 1991). They were all 
made using mouse L cell of C3H origin. They include 1..89.2. (Dw13); L164.11 
(Dw10); L165.6 {Dw14), all of which were generously donated by Robert Karr. The 
Dw4 transfectant (DAP3-DR4) which was used for most of the immunizations was 
a kind gift from Raffick Sekaly along with three non-DR4 lines. 
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Table 5.1 HLA-DR expressing transfectants obtained from the 11th International 
Histocompatibility Workshop and used for limited specificity analysis. 
11th ffiW No. HLA Specificity Local Name Contributor 
8103 DRl DAP3 DRl R Sekaly/E Long 
8107 DR2aDw2 DAP-3DR2a D Jaraquemada/E Long 
8109 DR2bDw2 DAP-3DR2b D Jaraquemada!E Long 
8111 DR2bDw12 LARBl H Inoko 
8112 DR3 L168.2 R Karr 
8115 DR4Dw4 DAP-3DR4 R Sekaly/E Long 
8116 DR4Dw10 L164.11 R Karr 
8118 DR4Dwl4 L165.6 R Karr 
8123 DR4DwTAS L89.2 R Karr 
8125 DRw11Dw5 L91.7 R Karr 
8126 DRw14Dw9 L167.2 R Karr 
8127 DR14Dwl6 L182.1 R Karr 
8134 DRw52bDw25 DAP-3DR52b R Sekaly/E Long 
8205 DQ2aDQ~ L21. R.Karr 
8305 DP4.2 LlS.J R.Karr 
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All transfectants were grown in Dulbecco • s modified Eagles medium (DMEM) 
containing 10% fetal bovine serum (FBS), penicillin and streptomycin (aJI from Flow 
Laboratories, McLean, VA 22102) 5 x lo-s mM 2-mercaptoethanol (Sigma, St. Louis, 
MO 63178). The cells were grown in either 10 em dishes (Becton Dickinso~ lincoln 
Park, NJ 07035) or 75cm flasks (Linbro, Flow Laboratories), and were harvested in 
log phase using trypsin (Flow Laboratories,) and then left in ordinary bacteriological 
petri dishes (to which they do not stick) for one to three days before use. Expression 
was assayed with the monoclonal antibody, Tu39, which is specific for monomorphic 
determinants on class II molecules (Knowles et al., 1989), using either a cellular 
enzyme-linked immunoassay (CELISA) or indirect immunofluorescence and flow 
cytometry as previously described (see CHAPTERS 4 and 6.). 
5.2.2 Immunizations 
Mice were either procured from Charles River Canada Inc., St. Constant, 
Quebec or bred in the local animal facilities. Cells expressing high levels of DR 
molecules (optical density (OD) of at least 2.0 in CEUSA with one of the above 
anti-OR mAbs) were washed three times with phosphate-buffered saline (PBS) and 
in all immunization procedures 1 x 107 cells were injected. Essentially three strategies 
were tried (Tables 5.2 to 5.4 ). The first consisted of indiscriminate standard-type 
immunizations where young adult C3H mice were immunized two or three times 
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intraperitoneally (IP) over a period of 1 to 6 months followed by a fmal boost 
intravenously (IV) or IP three days prior to fusion (Table 52). In the second 
approach neonatal tolerization was attempted. Groups of mice (3 to 5 to a group) 
were injected with 1 x 107 non-DR4 transfectants, (a mixture of DR2, DRS and 
DR52) at less than 24 hours after birth and at various times, thereafter (Table 5.3). 
Fmally, the third group consisted of 10 wk old female mice which were primed either 
IP in saline or subcutaneously in complete Freund •s adjuvant (CFA), left for 4 to 6 
weeks and then boosted either IP or intrasplenically (IS) three days prior to fusion 
(fable 5.4 ). For all these experiments the transfectant DAP-3.DR4, which expresses 
the Dw4 subtype was chosen because 1) an antibody to Dw4 was most desirable, 2) 
its DR4Dw4 expression was excellent and 3) it tested mycoplasma free. In several 
experiments sera were collected before and /or at the time of fusion and were tested 
for specific antibody in CEUSA 
5.2.3 Fusion 
All fusions were done three days after the final boost and were carried out 
using the fusion partner SP2/0-Ag14 {Shulman et al., 1978). Hybridization was done 
according to a previously described method (Drover, 1986) and the fused cells were 
plated in 96-well flat-bottom microtiter trays (Linbro ). In two experiments cells were 
seeded at various concentrations and with different feeder cells, in order to establish 
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optimal conditions. Selection was done using standard HAT reagents in DMEM 
containing 20% FBS and supplements as previously described (Drover, 1986). 
5.2.4 Screening & Specificity Testing 
All supernatants were tested approximately 10 days after fusion using CEUSA 
as previously described (Drover, 1986; Drover and Marshall, 1986). For the first 
screen the supernatants were tested against the immunogens; all positives were then 
differentially screened on the following day against the immunizing cell and non-
transfected L cells. Those that were positive only with the immunizing cells were 
selected for further testing against a small panel of transfected cells including those 
expressing DP, DQ and informative DR. Hybridomas were then selected for freezing, 
cloning and further analysis on both transfectants and B cell lines as descnl>ed as 
previously described (Drover, 1986). 
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5.3 RESULTS 
5.3.1 Optimal Culture Conditions 
The first fusions were carried out using the culture conditions that had been 
found to be satisfactory for fusions derived from Balb/C mice, namely plating at a 
density of (3-5 x lOS cells/well) together with feeder cells consisting of 2 x 107 red 
blood cells (RBC)/ml and 2.5 x lcf splenocytes/ml (Drover, 1986). However, the 
hybrids that grew in the initial fusions were rapidly overgrown and appeared to be 
killed by cells resembling small lymphocytes. 
Two experiments were devised to check the plating density and the use of 
different feeder cells, in order to overcome this problem. The feeder cells were all 
from C3H mice and included splenocytes (S), red blood cells (R), peritoneal exudate 
cells (P) and thymocytes (T). The numbers of surviving hybrids in all wells were 
counted on days 10, 12, 15 and 17. 
The density of the fused cells per well greatly affected the number of surviving 
hybrids (Figure 5.1) Plating at a density of greater than 2 x lOS /well aeated 
conditions which led to the loss of the majority of the hybrids as early as day 10 with 
virtually none alive by day 15. Although a plating density of 2 x lOS per well yielded 
a high number of hybrids (approximately 400/lfl splenocytes), the number 
significantly decreased by day 15. 
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YJgDre 5.1 Effect of cell density on the number of hybrids per lOS spleen cells. Two 
different fusions (R6 and R 7) were plated at five different densities as shown on the 
X axis. Hybrids were evaluated by phase contrast microscopy on days 10, 12, 15 and 
17. 
97 
At a plating density of less than 2 x lOS, the actual number of hybrids per lOS 
splenocytes increased and they survived for a longer period. However, at 5 x let or 
even 1 x lOS /well, the number of wells that would have to be plated per spleen would 
be unmanageable; for example, an immunized spleen can yield as many as 4 x lOS 
cells, which would generate 4000 to 8000 wells at such a low plating density. 
The choice of feeder cells was important (Figure 5.2). Thymocytes were 
consistently poor feeders in FB-plates, but in U-bottom plates, thymocytes were 
supportive when the fused cells were plated at low density ( < 0.5 x lOS cells/well) but 
inhibitory when plated at high density(> 1 x 1cf) (data not shown). Other feeder cells 
were not significantly different from each other in their ability to promote or inhibit 
growth, although PECS seemed slightly better while RBC' s were less effective when 
the cells were seeded at a low densi-ty. 
After reviewing the data it was decided to plate the fused cells at 1.5 x tOS to 
2 x lOS cells per well in flat-bottom plates, to use RBC • s as filler cells and to test the 
supernatants by day 10. Careful monitoring of the hybrids using phase-contrast 
microscopy was done after 1 week and hybrids were usually tested on day nine or day 
ten. It is evident from the data presented in Tables 5.2 to 5.4 that these conditions 
were sufficient to generate about 350 hybrids/lOS splenocytes seeded for each fusion. 
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Figure 5.2 Effect of using different feeder cells (S, splenocytes; R, red blood cells; 
P, peritoneal exudate cells; T, thymocytes) in promoting the growth and survival of 
fused cells plated at five different densities. The number of wells with viable hybrids 
were estimated by phase contrast microscopy on days 10, 12, 15 and 17. 
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5.3.l Indiscriminate Immunizations 
In the first set of experiments, summarized in Table 5.2, five fusions were 
derived from mice that had been randomly immunized. Supernatant fluid from over 
2500 hybrid cultures were assayed on the immunizing cells. After differentially 
saeening the positive wells, seven were further analyzed for polymorphic specificity. 
As can be seen from the da~ there were no hybrids that made antibodies with a 
short specificity; two antibodies had polymorphic activity but were "broadly reactive" 
and were of low affinity. Five hybrids produced antibody to class II monomorphic 
determinants. None of these were considered worth following and were discarded. 
5.3.3 "Neonatally tolerized11 Mice 
An attempt was made to tolerize neonatal C3H mice by injecting them with 
non-DR4 transfectants, which consisted of a mixture of transfectants expressing DR2 
and DR52. Cells were given IP within 24 hours of birth and at various times 
thereafter, as shown in Table 5.3. Serum samples were collected from a group of 5 
•tolerized" mice and 3 non-tolerized littermates at about 7 weeks and titered in 
CELISA against the tolerizing cells and non-transfected L cells. 
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Table 5.2 Summary of dat2 on fusions del"ived from CJH mice gh·en indiscriminate immunizations with 
11 LA-class II expa·essing transfectants. 
lmmuni7atioll Schtdule 
Fusion Sex llllmunizations 
10 I" DRI IP 
R5 M 12 2~ DRl IP 
14 .r DRl IP 
2 1" DR4 + CFA SIC 
R12 M 16 r Dw4 lP 
32 3• Dw4 IP 
20 t• DwJO IP 
RIJ F 28 r DwiO IP 
20 t• Dw·U IP 
R14 F 28 r Dw·14 IP 
20 1" Dw14 IP 
RlS F 28 r Dwl41P 
Boost 
DRI-IP 
S wks after 
last boost 
Dw4-IP 
4 wk.~ after 
)ad boost 
DwlO-IV 
3 wk~ after 
llut boost 
Dwl4-IV 
3 wk."' after 
last boost 
Dw14-IP 
3 wks after 
last fusion 
I# H,·brids• 
(per 101 
aplenocytn)' 
75 
(214) 
860 
(478) 
101!\ 
(423) 
204 
(82) 
336 
(280) 
HLA-~pecinc• 
h~brids 
1 DR monomorph 
1 DR monomorph 
2 long polymorphs 
2 DR monomorphs 
1 DR monomorph 
NONE 
• total number of wells w·ith bylllrids; • approximate au.mber of hybrids per 101 spleen eelb; • based on limited specifidty 
analysis 
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Table 5.3 Resulh of fusion!! done using "neon.a.tally toleri1.ed" CJH mice and non-tolerizcd littermates 
lmmuni7.ation Detaih 
Fu,.ion SL•J. A~e Cell" U~L·d Cell" u~ecl Bou•t ## hybrid,." S.-1.-cc.-d 
at to to detaib (per 101 H~ ltrid!lc 
injection tolerize immunize splenocytes)~ 
R6 M <2.&hn DR52 + DR2 
2wlu 1 "lllcak 
4 wks D"ft41P 412 po~morph 
6wks rg 17 wk!l (258) 1 DR 
8wlu 0"·4 + CFA m._morph 
14 l\"ks Dw4 JP 
R7 M <24hrs DR52 + DR2 
2 Wk!l 
4wlu 
6wks 
8 wk.• D" 14 + CFA D""'4 IS 273 2111eak 
14 wk.• Dl'14 IP @ 17 wlu (273) po~morphs 
NONE 
R8 F 8 \\k!l 14 Dw4 + CFA D\\4IP 750 I ... nomorl'h 
16 wlu 2" Dw4 JP ~ 20 l\"kll (469) 1111eak 
po~morph 
NONE 
R9 M 8 l\"k.' 1" Dw4 + CFA o .... ·.a JP 750 l•ooomorpb 
16 wlu 2" Dw4 IV ·~ 20 wlu (444) 1 weak 
po~morph 
RIO M 24 hrs DwlO o,.·JJ-? 1250 
16 wlu Dw13 + CFA ~ 28 wlu (288) NONE 
20 l\"lu DwlJ IP 
NONE 
Rll M 16 wkll DwtJ + CFA DwJJ 600 1 -ti DR4 
20 wlu DwtJ JP @; 28 wlu (462) 3-rplu 
• Cotal number of wcllll nith hybrids '~ appro:d.-ale number of hybrid!! per 101 "1•1-:cn cell"; < "clcced on bam of limited 
specificity testing 
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The CEUSA data showed evidence of antibody activity in the sera of the "tolerant" 
mice, but not in the sera from control littermates, to the "tolerizing" cells and to 
non-transfected L cells, indicating that tolerance had not been achieved (data not 
shown). The sera were then adsorbed twice with L cells and once with the 
•tolerizing" cells and tested on DAP-3 DR52 and DAP-3 DR4Dw4 transfectants 
(Figure 5.3). It is apparent that there was no difference in the anbbody titer against 
DR52 (one of the "tolerizing" cells and DR4Dw4, not used for tolerizing), which 
strongly suggested that the mice were not tolerized to the DR molecules. 
It was decided to use some of these mice for fusions. Thus at age 8 to 16 
weeks, they and some of their non-tolerized litter mates were immunized with 
DR4Dw4 or Dw13-expressing transfectants. The data in Table 5.3 show that very few 
hybrids were selected for further studies despite screening over 4000 hybrids. Three 
fusions from the "tolerized" group produced 1935 hybrids, of which one reacted with 
a monomorphic determinant and 3 reacted weakly with polymorphic determinants. 
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FigUre 5.3 Adsorbed sera from mice that had received non-DR4-expressing 
transfectants, as described under methods, were titered in CEUSA using DAP-3 DR4 
and DAP-3 DR52 transfectants as targets. lines connecting symbols represent the 
mean of CEUSA data from five different sera; unconnected symbols represent one 
standard deviation above and below the mean. 
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From the non-tolerized gro19 three fusions yielded 2100 hybrids of which 5 had 
monomorphic specificity, 2 were weakly reactive with polymorphic determinants and 
1 reacted with all DR4 molealies. The reaction pattern and epitope mapping for this 
last antibody (derived from the R11 fusion and now called NFlDD1) is described 
in Reference 10 and CHAP'l'ER 6. 
5.3.4 Comparative Immunizations 
Fifteen fusions that were done to compare different immunization schedules 
were very productive. The daia summarized in Table 5.4 clearly show that the worst 
immunization strategy was an IP primary followed by an IP boost. The best result was 
obtained by immunizing subcutaneously along with CFA followed by an IP boost, 
while the other two strategies immunizing IP in saline or subcutaneously with CFA 
followed by an IS boost were equally good Titering of sera, taken at the time of 
splenectomy, was not always predictive of the number of specific hybrids. For 
example the mouse (fusion R21) that produced the highest titer against the 
immunizing cells produced a large number of hybrids, but did not yield a single 
antigen-specific hybridoma, while the mouse (fusion R16) which had the lowest titer 
produced 7 antigen-specific hybridomas. On the otherhand, the most prolific fusion 
(R19) was derived from a JDOilse with one of the highest titers; thus, titering of sera 
at this stage was not a reliable indicator of the number of specific hybrids. 
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Table 5.4 Results of fusions done to c:ompare immunization schedules. 
Immunization #I Hybrids• Number of Post-fusion 
Time (per 101 H)· brid~ &rum 
Fusion Primary lntcn·al Boost 11plcnoc~ tcs)b Selected Titer• 
(wcclu) 
R16 IP 4 IS 1128 (434) 7 <1/100 
R22 5 336 (480) 2 111600 
R27 6 238 (170) 5 11400 
R29 7 467 (275) 3 11800 
X= 542 (340) X= 4.3 
R18 IP 4 lP 864 (455) 0 11800 
R20 5 41 41 1 11800 
R26 6 546 (455) 1 11800 
X= 483 (317) X= 0.7 
Rl7 4 758 (237) 1 >111600 
R2J CFA 5 IS 38 (23) 3 >111600 
R25 SIC 6 409 (340) 4 111600 
R30 7 592 (423) 4 1/3200 
X= 449 (258) X=3 
Rl9 4 812 (427) 18 113200 
R21 CFA 5 IS 672 (354) 0 >113200 
R24 SIC 6 560 (467) 9 >11800 
R28 7 704 (440) 7 >113200 
X =687 (422) X=ll 
• total number of wells with hybrids; • appro1imate number of hybrids per 101 spleea cells 
c (OD of test serum with Immunogen) - (OD of test serum with L cells) = 0.5 
was arbitrarily chosen as the end point of titer. 
IP = Intraperitoneal; CF A = Complete Freunds Adjuvent ; 
SIC = Subcutaneous; IS = lntrasplenlc; X = Average 
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From fifteen different fusions, yielding over 8000 hybrids, sixty-four were 
selected for further analysis (Table 5.4). Thirteen produced antibody to pol~orphic 
determinants. Eight of these were selected for complete specificity analysis using 
transfectants and homozygous cell Jines. There were se~·eral patterns of reactions 
including: (i) Dw4, Dw14, DRl and DR14 (Dw16); (ii) Dw4, Dwl4, Dw13 (weak), 
DRl, DR14 (Dw16) and DR2; (iii) DR4 (except DwlO), DRl, DR2, and DR14; (iv) 
all DR4 molecules and DR2, plus DR52. A complete description and analysis of 
these antibodies is in press (see CHAPTER 6 ). 
5.4 DISCUSSION 
It was found that the conditions that had been used for previous fusions, which 
were done using Balb/c splenocytes and Balb/C-derived fusion partner, SP2/0-Ag14 
(Drover, 1986) were not suitable for fusions using spleen cells from C3H mice. Since 
these rrlice are H-2 incompatible, it is possible that allogeneic T cells from the C3H 
spleen (unfused cells from immunized spleen and feeder cells) were cytotoxic for the 
Balb/c SP2/0-Ag14 fusion partner, which express class I antigens. The failure of 
feeder T cells to support hybrid growth supports the idea that T cells were 
responsible for hybrid cell death during the early phase of the culture period 
particularly when wells were seeded at a high cell density. Ideally, feeder cells should 
be X-irradiated, but by plating at a density of less than 2 x lOS fused cells/well and 
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using red cells as feeder cells, the problem of hybrid death was almost completely 
e1iminated. In most of the subsequent fusions 80-90 % of the wells produced hybrids 
with a yield of about 350 hybrids/lOS splenocytes. In later experiments (data not 
shown), T cell depletion of the spleen cells prior to fusion combined with using 
irradiated feeder cells allowed for plating the cells at 1 x lOS cells/ well and 
increased the number of hybrids per fusion by almost two-fold. 
Although a large number of hybrids were obtained from the the set of fusions 
shown in Table 5.2, none were obtained that made DR4-specific antibody. The idea 
to tolerize mice to the monomorphic determinants on the HLA molecules expressed 
on syngeneic transfectants seemed reasonable, since the immune system of a neonatal 
mouse is immature and thus should be susceptible to tolerance induction. It was also 
anticipated that the syngeneic L cells might survive for a long period, thus increasing 
the likelihood of inducing tolerance. However, this was not the case as sera from all 
mice that were tested, made antibody that bound to transfectants expressing lllA-
DR; in addition they bound to human B cell lines that did not carry the •tolerizing" 
lllA molecules (data not shown). 
Fusions that were done using the so-called "tolerized" mice and their 
littermates were again disappointing, as despite a high yield of hybrids, most of the 
selected hybrids were making monomorphic anti-DR antibodies. However, the 
limited specificity analysis suggested that one hybrid from Rll fusion was making 
anti-DR4, which was subsequently confirmed ( 4, CHAPTER 6). At this point it was 
108 
difficult to determine the problem as a number of different immunization schedules 
and immunogens had been used and a significant number of hybrids grew from each 
fusion. Retrospectively, it was shown that some of the transfectants used for 
immuni:n~tion were infected with mycoplasma; thus some of the hybrids that gave 
polymorphic, but inconsistent patterns may have been related to mycoplasma-specific 
antibodies. 
The fusions that were done to compare immnni:n~tion schedules generally 
yielded a large number of hybrids that were specific for some subtypes of DR4 -
molecules. The best fusions came from the group that were immunized 
subcutaneously with the cells emulsified in CF A and followed by an IP boost at 4-7 
weeks. Perhaps the clearest finding was that IP immunization followed by IP boost 
was the worst of all four combinations. This helped explain the failure of the first set 
of fusions (Table 5.2), which were mostly done by this method. 
Unfortunately, the mice were not bled prior to boosting, but the results of 
post-boost sera suggest that the titers are not necessarily predictive of the number of 
liLA-specific hybrids. Intuitively, one feels that high titered sera should yield 
desirable hybrids, but due to the multiplicity of antibodies in serum, this is not 
necessarily true. One possibility is that the presence of high titered antibody at the 
time of immunization may serve to downregulate B cells if they bind antigen via Fe 
receptor and antibody-receptor. Thus, it may be more appropriate to give the booster 
after the earlier immune response has subsided. 
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CHAPTER6 
ANALYSIS OF MONOCLONAL ANTIBODIES SPECIFIC FOR 
UNIQUE AND SHARED DETERMINANTS ON HLA-DR4 MOLECULES1 
6.0 ABSTRACf 
The specificities for seven monoclonal antibodies to HLA-DR4 were 
determined using homozygous B cell lines and L-cell transfectants expressing wild-
type DR molecules. Three (NFLD.Dl, NFLD.Ml and NFLD.D7) bound all DR4 
molecules, but only one was specific for DR4. Four antibodies (NFLD.D2, NFLD.D3, 
NFLD.D8 and NFLD.DlO) reacted with some DR4 subtypes and had extra reactions, 
particularly, with DR gene products associated with susceptibility to rheumatoid 
arthritis (RA). To localize the antibody binding epitopes on DR4 molecules, the 
antibodies were analysed on transfectants expressing hybrid genes, which were 
generated by exon shuffling of DRBl *0403 and DRBl *0701. Two of the pan-DR4 
antibodies bound epitopes which require the /32 domain while the third mapped 
primarily to the HVR-1 region. One antibody to subtypes of DR4 mapped to residues 
40-97 on DR/31 *0403 chains. Comparison of reaction patterns with amino acid 
sequences suggests that the antibodies against subtypes of DR4 are specific primarily 
for a region containing sequences postulated to determine susceptibility to RA. 
1In Press: Sheila Drover, Robert W Karr, Xin-Ting Fu, and William H Marshall, Human Immunology, 
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6.1 INTRODUCTION 
The HL\-DR4 specificity currently consists of fifteen DRB1 allelic variants 
(DRB1*0401 to DRB1*0415) that have been identified using DNA based technology 
(Bodmer et al, 1992; Petersdorf et al., 1992; Stastny and Kimura, 1992; Pile et al., 
1992; Tiercy et aL, 1993; Zhang et al., 1993). Eight of these can be differentiated by 
T-cells in a mixed lymphocyte typing procedure; they are Dw4 (0401), DwlO (0402), 
Dw13.1 (0403), Dw14.1 (0404), Dw15 (0405), DwKTI (0406), Dw13.2 (0407), Dw14.2 
(0408). When the amino acid sequences for the DR4 /31 chains of the T-cell defined 
subtypes are compared, it is apparent that they differ from DRB1*0401 by only one 
to four amino acid residues (Table 6.1). Most of the variability is located in the third 
hypervariable region (HVR-ill) around residues 67-74 and at position 86. Residues 
1-66 are the same for all alleles except for DRB1*0406 which has serine substituted 
for tyrosine at position 37, DRB1*0405 which has serine substituted for aspartic acid 
at position 57 and DRB1*0415 which has glutamic acid substituted for alanine at 
position 58. The latter DR4 allele (0415), described by Tiercy et al. (1993), differs 
from the other DR4 alleles in that it has sequence homology with DRB1*1104 at 
amino acid residues 58-86. 
Four alleles DRB1*0401, 0404, 0408 and 0405 which have conservative 
substitutions in the HVR-m are associated with susceptibility to the development of 
Rheumatoid Arthritis (RA) in several ethnic groups (Wordsworth et aL, 1992). 
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Table 6.1. Comparison of amino acid differences in DR4 JH chains ofT ceU-defmed subtypes 
Amino acid positions 
DRBt• 37 57 67 70 71 74 86 
Alleles Subtype 
Bt•040t Dw4 y D L Q K A G 
Bt•0402 DwlO I D E v 
81•0403 Dwl3.1 R E v 
Bt•0407 Dw13.2 R E 
Bt•Q404 Dw14.1 R v 
Bt•0408 Dw14.2 R 
BI*0405 Dw15 s R 
BP0406 DwKT2 s R E v 
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The fact that other variants (DRB 1*0402, 0403, 0406 and 0407) have both non-
conservative and conservative substitutions in this region and are not associated with 
RA susceptibility, has led to the suggestion that a molecular structure resulting from 
the amino acid sequence 67-86 may play a key role in RA susceptibility (Gregersen 
et aL, 1987). Two non-DR4 alleles, DRB1*0101 and DRB1*1402, which have major 
differences in HVR-1 and HVR-ll from each other and from DR4, are completely 
homologous in HVR-m to each other and to DRB1*0405 and DRB1*0408 
(Wordsworth and Bell, 1992; Willkens et al., 1991; Nelson et al., 1992). That these 
molecules are also associated with RA in different ethnic groups further supports the 
idea that shared residues (67-86) found on DR4 and non-DR4 131 chains are 
somehow critical. However, the mechanism by which this susceptibility is conferred 
remains unknown. 
In the course of attempts to make monoclonal antibodies to the variants of 
DR4, seven hybridomas whose specificities are the subject of this report were 
produced; three recognize all DR4 molecules and the other four recognize some of 
the DR4 subtypes but not others (CHAPTER 5). Here we describe a detailed analysis 
of the specificities of these antibodies using a collection of homozygous B cell lines 
(BCL) which have well-defined lllA specificities (Yank et al., 1989; Kimura et al., 
1992). Mouse L cell transfectants expressing wild type DRB genes were used to 
confirm the specificity and to identify the DRp chain responsible for the mAb 
binding epitope in each case. In addition transfectants expressing 
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DR(P1*0403/~1*0701) hybrid molecules were used to locate the primary sequences 
on the DR4 molecule that are essential for binding each of these mAbs. 
MATERIALS AND METHODS 
6.2.1 Cells 
Homozygous BeL, obtained through the lOth International Histocompatibility 
Workshop (IHW) were maintained in RPMI-1640 containing 10% fetal bovine serum 
(FBS), 50units/ml penicillin and 50~g/ml streptomycin, (P /S), and 2mM sodium 
pyruvate, (Flow Laboratories). Transfectants were cells of the DAP.3 subclone of 
class II negative murine L cell fibroblasts which had been transfected with DRA and 
DRB eDNA constructs as described previously (Klohe et al., 1988). The source of the 
cDNAs and a list of the transfectants, which includes some of those distributed by 
the organizers of the 11th IHW, are shown in Table 6.2 Construction of DR4 
(B1*0403) and DR7 (B1*0701) hybrid cDNAs, by the hemidomain shuffling method 
and subsequent transfection, has been described (Alber et al.,1989; Fu et al., 1992). 
All transfectants were grown in Dulbecco • s modified Eagles medium containing 10% 
FBS, 5 x to-s mM 2-mercaptoethanol and P /S. The cells were grown on either 10 em 
dishes (Falcon) or 75cm flasks (linbro) and were harvested in log phase using 0.25% 
trypsin (Flow Laboratories) in phosphate buffered saline. 
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Table 6. 2 ID.A-DR expressing t:ransfectants used for characteri7ing the specificities of NFLD 
monoclonal antibodies. 
Cell Line 
DAP-3 DRl 
DR-BON 
L466.1 
L468.5 
IA15.2 
L168.2 
DAP-3 DR4 
1..243.6 
L164.11 
L89.2 
L165.6 
1.566 H6 
B18 
L91.7 
L167.2 
L182.1 
ID.A-DR Dw 
specificities 
DRl Dwl 
DR Bon 
DR15 Dw2b 
DR15 DwUb 
DR16 Dw21b 
DR3Dw3 
DR4Dw4 
DR4Dw4 
DR4Dw10 
DR4DwTAS 
DR4Dwl-l 
DR4Dw15 
DR4DwKT2 
DRllDwS 
DR14Dw9 
DR14 Dw16 
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11th rnw 
Allele Number Contributor 
DRB1*0101 8103 R. Sebly/ 
E. Long 
DRB1*0103 8104 R. Oaude/ 
C. Thomsen 
DRB1*1501 R.Karr 
DRB1*1502 R. Karr 
DRB1*1601 R. Karr 
DRB1*0301 8112 R.Karr 
DRB1*0401 8115 R. Sebly/ 
E.Loog 
DRB1*0401 R. Karr 
DRB1*0402 8116 R. Karr 
DRB1*0403 81.23 R. Karr 
DRB1*0404 8118 R. Karr 
DRB1*0405 R. Karr 
DRB1*0406 8122 R. Lechler 
DRB1*1101 81.25 R. Karr 
DRBt•t401 8126 R. Karr 
DRB1•1402 8127 R. Karr 
Table 6.2 Continued. 
Cell Line 
L605.1 
19.0.c:n 
IA163 
L467.1 
IA14.1 
1..575.1 
LlOS.l 
L576.5 
L17.8 
Hl.A-DR Dw 
Specificities 
DR7Dw17 
DRlO 
DR51(DR15) Dw2a 
DR51(DR15) Dw12a 
DR51(DR16) Dw21a 
DR52a Dw24 
DR52a Dw25 
DR52cDw26 
DR53 
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llthlliW 
Allele Number Contributor 
DRB1*0701 R.Karr 
DRB1*1001 8131 H. Peter 
DRB5*0101 R.Karr 
DRB5*0102 R.Karr 
DRB5*0201 R.Karr 
DRB3*0101 R.Karr 
DRB3*0102 8134 R.Karr 
DRB3*0103 R.Karr 
DRB4*0101 8138 R.Karr 
6.2.2 Antibodies 
Generation ofmAbs (NFLD.D1, NFLD.D7, NFLD.D2, NFLD.D8, NFLD.D3 
and NFLD.DlO) using transfectants as immunogens has been described elsewhere 
(9); all are IgG 1 antibodies. Other mAbs used in these studies include NFLD.M1 
which reacts preferentially with DR4 molecules (Drover et al., 1985) and 1243 which 
reacts with a monomorphic determinant on DR molecules (Lampson and Levy, 
1980). L243 was obtained as a bybridoma from the American Type Culture 
Collection. The secondary antibody for CELISA, affinity purified F(ab • )2 fragments 
of goat anti-mouse IgG + IgM (heavy and light chains) conjugated to horse radish 
peroxidase (GAM-HRP), was obtained from Jackson Immunoresearch Laboratories. 
6.2.3 Binding Assays and Data Analysis 
Optimally-diluted mAbs were tested against the various cell types using a 
cellular enzyme linked immunosorbent assay (CEUSA) essentially as described for 
human BCL (Morris et al., 1982; Drover and MarshalL 1986) with the following 
modification for transfectants. After harvesting, the transfectants were left in 
bacteriological-type petri dishes, to which they do not adhere, for up to 5 days. For 
assays, transfectant cells were washed and plated in culture medium at 5 x 1<t cells 
per well in a 96-well sterile micro titer tray (Iinbro) and left to adhere to the plastic 
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for a minimum of2 hours at 3-r'in a C02 incubator. Medium was removed from the 
wells by flicking; cells were washed once in 0.05% Tween 20 (Sigma) in phosphate 
buffered saline and assayed as previously described (Drover and Marshall, 1986). 
CEUSA binding data obtained for test mAbs were analyzed relative to the 
positive control (1243) as described previously (Drover et al., 1985). Essentially, a 
percent(%) binding value was obtained as follows: the background optical density 
(OD) was subtracted from each test and the mean OD value from replicate wells was 
expressed as a percent of the mean OD value of the reference mAb 1243. In order 
to compare binding of the test mAbs to transfectants expressing 
DRB1*0403/B1*0701 hybrid molecules, the results were double normalized by 
dividing the percent binding to the hybrid by the percent binding to the DR(P1*0403) 
wild type transfectant as follows: 
% Bindin~ to DRB1*0403/0701 Trapsfectant x 100 
% Binding to DRB1*0403 Wild Type Transfectant 
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RESULTS 
6.3.1 Specificity Analysis of DR4 mAbs 
Prior to performing specificity analysis, the mAbs were titered using the 
appropriate cells. The dilution of 1.243, the DR reference mAb, that gave an OD of 
1.5 to 2.0 was chosen as the positive controL For analysis each test mAb was diluted 
so that it gave at least 100% binding relative to 1243 binding with the immunizing 
cells. For most of the DR4 mAbs this dilution gave greater than 100% binding with 
BCL expressing the prototype DR4 gene. The reactivity patterns for the mAbs can 
be divided into two categories, those that bound all DR4 subtypes and those that 
bound some of the DR4 subtypes. With the exception of NFLD.D1 which is a pan-
DR4 with no extra reactions, each mAb also recognized at least one other DR 
specificity. 
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TABLE 6.3. Reactivity of NFLD.D monoclonal antibodies with human B cell lines. 
Converted CEl.lSA Scores For mAb Bindmge 
Cell DR DR Alleles D1 D7 D2 D8 D3 DlO 
9034 4,53 0401 0101 8 10 10 10 10 10 
cxn:7 4,53 0401 0101 10 10 10 10 10 10 
9026 4,53 0402 0101 10 10 1 1 1 1 
9030 4,53 0407 0101 10 10 6 6 6 10 
9024 4,53 0406 0101 10 10 6 8 6 10 
9098 4,53 0404 0101 10 10 10 10 10 10 
HAS15 4,53 0405 0101 10 10 10 6 8 10 
9002 1 0102 1 2 10 6 6 10 
9003 1 0101 1 4 10 10 8 10 
9010 15,51 1503 0101 1 10 6 6 10 10 
9011 15,51 1502 0102 1 10 8 6 10 10 
9009 16,51 1601 02 1 10 10 10 10 10 
9016 16,51 1602 02 1 10 10 10 10 10 
9023 17,52 0301 0101 1 10 1 1 4 2 
9021 18,52 0302 0101 1 10 1 1 1 1 
9037 11,52 1101 0202 1 10 1 1 1 1 
9038 12,52 1201 0202 1 10 1 1 1 1 
9060 13,52 1.301 0202 1 10 1 1 1 10 
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TABLE 63 Continued 
Hl.A-CLASS nt' Converted CEUSA Scores For mAb Bin~ 
Cell DR DR Alleles D1 D7 D2 D8 D3 D10 
Lines• Specificity B1* B3* B4* B5* 
9059 13,52 1302 0301 1 4 1 1 1 1 
9055 13,52 1302 0301 1 6 1 1 1 1 
9057 14,52 1401 0201 1 10 1 2 1 8 
9064 14,52 1402 0101 1 10 10 10 10 10 
9049 7,53 (r7 0101 1 1 1 1 2 1 
9047 7,53 (r7 0101 1 1 1 1 1 2 
9096 7,53 0002 0101 1 1 1 1 1 4 
9068 8 0801 0 1 0 2 1 1 
9071 8 0802 1 1 1 1 1 1 
9070 8 0803 1 1 1 1 1 1 
9076 9,53 0901 0101 1 1 1 1 1 6 
• refers to the 10th International Histocompatibility numbers designated for the homOZ)'gOUS B cell lines 
(reference 10) 
b the HLA class ll types and splits were obtained from references 10-11 
c the CEUSA data converted to serology scores: 1, 0-10% binding; 2, 11-20%; 4, 21-40%; 6, 41-80%; 
8, 81-100%; 10, > 100%; 0, not done. 
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6.3.1A mAbs that react with all DR4 molecules 
NFLD.D1 was derived from a fusion in which the mouse was immunized with 
transfectants expressing DRB1*0403 (CHAPTER 5). It reacted positively with DR4 
positive BCL (Table 6.3) as well as with DR4 positive peripheral blood B cells (data 
not shown), but it did not bind any DR4 negative B cells. This pan-DR4 specificity 
was confirmed using transfectant/s expressing individual wild type DRB genes. (Fig. 
6.1a). It is apparent that NFI.D.D1 bound all six transfectants expressing individual 
DR4 variants and did not bind any transfectant expressing other DRp 1 chains, nor 
any chains derived from DRB3, DRB4 or ORBS genes. NFI.D.D1 is thus specific for 
a determinant found only on DR4 molecules. 
NFLD.M1 was previously shown to bind strongly to DR4 positive BCL and 
weakly to DR3, DRS, DR6, and DR8 positive BCL (Drover et al., 1985). With 
transfectants (Fig. 6.1b) this antibody recognized an epitope on all DRB1*04 variants 
as predicted. NFI.D.M1 reacted also with transfectants expressing DRB3 genes 
(DR52 variants), but failed to react with those expressing other DRB1 genes (0301, 
1101, 1401, 1402) which explains its ~xtra reactions with B cell lines; transfectants 
expressing DRB1*08 genes were not available for testing. There was also weak 
reactivity with transfectants expressing DRB5*0201.The major reactions of 
NFI.D.Ml were thus with all DR4 molecules and with molecules containing DRp3 
chains. 
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Figure 6.1 Binding of NFLD.Dl (A), NFLD.Ml (B), and NFLD.D7 (C) to mouse cell 
transfectants expressing DR molecules. The DR specificities and DRB genes expressed by the 
transfectants are shown to the left of each panel. Binding of each mAb is expressed as a 
percent of L243 as described under methods. Error bars show the standard error of the mean. 
NFIDD1 was derived from a fusion in which the mouse was immunized with 
DAP.3 DR4 transfectants expressing DRB1*0401 (CHAPTERS). As can be seen 
from Table 6.3, NFID.D7 bound strongly to all DR4, DR15 and DR16 positive BCL 
It also bound strongly to most DR52 positive BCL with the exception of two cells, 
9055 and 9059, which expresses DRB3*0301. This complex pattern of reactivity was 
elucidated further by analysis with transfectants. The results presented in Fig. 6.1c 
clearly show that binding to DR4 positive cells was due to DR4 fJ t• chains. Binding 
to DR15 and DR16 cells was due to molecules encoded by DRB1 (150L 1502,1601) 
and not by DRB5 genes. The data presented in Table 6.3 showing positive NFLD.D7 
binding to most DR52 positive BCL and negative binding to DR8 positive cells 
(B1*0801, 0802, and 0803), which carry DR52-like determinants, but do not carry 
DRB3* genes (Table 6.3), suggested that NFill.D7 might bind molerules encoded 
by DRB3 genes. As can be seen from the reactivity pattern with transfectants (Fig. 
6.1c) this was confirmed; NFID.D7 only bound DRB3 gene products (DR52) and did 
not bind the associated DRBl gene products (DRB1*0301, 1101, 1401 and 1402) . 
. NFlD.D1 is therefore reactive with all DR4, DR15 and DR16 and most DR52 
molecules. 
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6.3.18 mAbs that react with a subset of DR4 specificities 
NFID.D2 and NFID.D8 were derived from the same mouse spleen, while 
NFIDD3 and NFIDDlO were derived from two different mice. In all cases the 
immunizing cells were DAP 3 DR4 (B1*0401) transfectants (CHAPTER 5). The 
reactivity patterns for all four mAbs with BCL (Table 63) were similar, since they 
reacted strongly with cells expressing some DR4 subtypes DR(B1*0401, 0404, 0405) 
but did not bind cells expressing ORB 1*0402; they differed in the degree to which 
they bound cells expressing the DR4 subtypes, B1*0407* and B1*0406. It is also 
apparent from Table 63 that these antibodies boun~ with varying degrees, to cells 
expressing variants of DRl, DR15, DR16, and DR14; NFID.D10 additionally bound 
to DR9. Since B cells express at least three class ll molecules, the precise target of 
each antibody could not be proven from those data. Transfectants expressing single 
species of p-chains were useful for this purpose. 
Studies using the transfectants confirmed that all four antibodies react 
strongly with DRB1*0401, 0404, and 0405 and not with DRB1*0402. However, 
NFIDD2 and NFIDD3 (Fig 6.2a and 6.2c) were essentially negative with 
transfectants expressing DRB 1*0403 and 0406 genes, NFID.D8 (Fig 6.2b) bound 
weakly, while NFID.DlO (Fig 6.2d) was strongly reactive with the same transfectants. 
Binding patterns with products of the relevant non-DR4 genes showed that the 
majority of the positive reactions of these four antibodies could be attributed to 
DRBl chains (Fig. 6.2). 
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Figure 2. Binding of NFLD.D2 (A), NFLD.D8 (B), NFLD.D3 
(C) and NFLD.DlO (D) to transfectants, as described in Figure 
1. 
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One notable exception is that the DR51 transfectant (DRB5*0201) bound all four 
mAbs, thus identifying DR,85* as the source of the epitope for all four mAbs in 
DR16 positive B cells. Transfectants expressing other relevant ORB genes such as 
DRB4, DRB5*01 and DRB3 did not bind any of these mAbs. It is interesting that 
the binding patterns of these four antibodies with DRl, DR15, and DR14 
transfectants were somewhat different from each other (Fig. 6.2) and that these 
binding patterns did not always correlate with those obtained with BCL expressing 
the relevant genes (Fig. 6.4). The possibility that chains from other loci e.g. DQ or 
DP could bind these mAbs seemed unlikely from an examination of the rest of the 
BCL data; furthermore, testing on the 11th IHW panel of transfectants expressing 
DQ and DP was negative (data not shown). ThUSy these four antibodies recognize a 
subset of DR4 molecules and in addition a varying constellation of other DR 
molecules particularly in the sets coded on DRl, DR14 and DR15 and DR16 
haplotypes. 
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6.3.2 Epitope Mapping Using DRP1*0403/Pl*0701 Hybrid Molecules 
Transfectants expressing hybrid DRp chaim have proven useful for locating 
the critical sequences that determine certain antibody binding epitopes (Alber et al., 
1989; Fu et al., 1992). The eight DRB1*0403/DRB1*0701 hybrid cDNAs and the 
wild type cDNAs used in these mapping experiments are shown in Fig. 6.3. Each 
hybrid is referred to by four numbers; the first segment represents the leader 
sequence and is not included in the numbering. The first number refers to amino acid 
residues -6 to 21, the second to residues 22-40, the third to residues 41-97, and the 
fourth number refers to the p2 domain. Antibody binding to the hybrid molecules was 
measured by CEUSA; each antibody was tested in duplicate on two different 
occasions and the results were double-norma1ized as described under methods. 
NFLD.M1, previously shown to bind an epitope in the second domain of 
DRp*0403 molecules, was included as a control; the previous results (Alber et al., 
1989) with this antibody were confirmed. NFID.Dl which is monospecific for DR4 
produced a binding pattern remarkably similar to that of NFLD.Ml, binding only 
those hybrids (4474, 7444,7744,4744, m4) that contained the DR4 /12 domain (Fig. 
6.3b). However, NFLD.Dl binding to 4474 and 7774 hybrid molecules was somewhat 
less than that of NFLD.Ml binding, while its binding to 7444 was increased relative 
to that of NFLD.Ml. Significantly, there was no binding of either antibody to hybrid 
molecules where DR7 sequences formed the second domain 
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Wildtype and Hybrid DRBl•0403/0701 eDNA NFLD mAt- Reactivity with Transfectants 
Constructs Expressed by DAP-3 Transfectants Exrressing eDNA Constructs 
M1 01 D7 DID 
L 11.1 IJ.1 TMIC 
I I j I 4444 .1.QQ 100 lQQ 100 
-6 :!1 40 97 
Sad Taql Bsu361 
7777 1:/1 ~~~~~~~~ 0 0 0 0 
4474 I I I ~~ I ll2 59 110 0 
4477 t:-1 I v~~~~~~~ 0 0 125 0 
7444 ~ I I I 2J.. lli 0 34 
7744 I V/1/1 I I .l.U ill 8 130 
7747 ~~ v~~~~~ 2 0 9 llQ 
4777 t/i ~~~~~~~~ 0 0 0 0 
4744 I I l/1 I I 111 120 ll ~ 
4447 I I I I ~~~~~ 2 0 .1QQ ill 
7774 ~~~~ 145 87 0 0 
F'JgUre 6.3 Tbe panel on the left shows a schematic diagram of the wild type DR(pt•0403) (open bars), 
DR(P1*0701) (hatched bars) and the recombinant hybrid DR(Pl-o403/0701) (open and hatched bars) 
chains. Each wild type or hybrid P chain is referred by four numbcts to indicate the origin of the four 
segments: first number, amino acid residues -6-21; second number, residues 22-40; third number, 
residues 41-97; fourth number, P2 domain. 4 = DR(P1*0403); 7 = DR(P1*0701); L, leader sequence; 
P1, first cbnain; PlJ second domain; TM, transmembrane region; I~ intracytoplasmic region. Sac I, 
Taq I and Bsu36I in the first drawing refers to the restriction enzyme sites used in the construction of 
some of the hybrids. The panel on the right shows the degree of mAb binding to the hybrid molecules. 
Binding has been double-oonnalized to that obtained for the transfcdants expressing DR(P 1*0403) wild 
type moleades, as described under methods. 
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Because the reaction patterns for NFIDD1 and NFID.M1 were different, these data 
suggest that residues in the second domain form two distinct antibody binding 
epitopes. 
NFID.D7, which binds an epitope conferred by DRp1 chains of all DR4, 
DR15, and DR16 molealies and by DRp3 chains of DR52 molecules (Fig. 6.1c), 
showed a complex binding pattern with the hybrid molecules (Fig. 6.3b ). It reacted 
strongly with 4474, 44n, and 4447 molecules, and less but significantly with 4744 
hybrid molecules. There was no binding with the 7444, 7744 or 7747 hybrid 
molecules. This suggests that residues 1-21 on the pl strand play a major role in the 
formation of the NFI.D.D7 epitope. However, since binding to 4744 hybrid molecules 
was considerably reduced and there was no binding to 4777, it is likely that residues 
in other regions of the molecule, particularly HVR-ll, also contribute to the integrity 
of this epitope. 
Of the DR4 mAbs that bind a subset of DR4 molecules, only NFLD.D10 was 
shown to bind strongly to DRp 1*0403 molecules (Fig. 6.2d), and was therefore the 
only one available for epitope mapping using these particular hybrid molecules. Only 
transfectants expressing the hybrid molecules that contained the DRB1*0403 
sequence 41-97 (7444, n44, n47 and 4744) bound this antibody (Fig 6.3b). All other 
transfectants expressing hybrid molecules (4474, 4477,4777 and 7n4) were negative 
for NFID.D10. This indicates that one or more residues near the carboxyl end of the 
P1 domain are required for NFI.D.D10 binding. 
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6.4 DISCUSSION 
The use of three different types of target cell (B cell lines, transfectants 
expressing wild-type DR molecules and transfectants expressing hybrid DR4/DR7 
molecules) to study these antibodies has allowed considerable progress towards 
identifying their epitopes. A summary of the specificity analysis resulting from 
reactions with BCL and transfectants is given in Fig. 6.4. Immunofluorescence and 
flow cytometry have shown that the antibodies also bind to peripheral blood B cells 
(unpublished data). All are lgG 1 and could not be studied by complement dependent 
cytotoxicity. 
The reactions on B cell lines and on L<ell transfectants expressing the same 
genes were not always comparable (see Fig. 6.4), despite careful normalization of the 
assay results to those for the reference antibody, l243. There are many differences 
between EBV transformed B cell lines and mouse fibroblasts, as hosts for DR genes, 
that might explain these differences; glycosylation patterns, the amount of invariant 
chain available in DAP.3 transfectants, peptide processing pathways and the range 
of available peptides for insertion into the groove may differ. The importance of 
chaperone-like molecules, such as the invariant chain, and the requirement for 
peptide to produce the correct folding of class II molecules has been document 
(Anderson and Miller, 1992; Sette et al., 1992; Germain and Hendrix, 1991). 
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Figure 4. Summarizes anti-DR4 mAb reactivity with BCL and transfectants expressing 
different HLA-DR specificities. +, positive (>40% reactivity); -, negative ( < 20% reactivity); 
+, weakly reactive (21-40% reactivity); NT = not tested. 
It is notable that neither of the antibodies which bound to second domain epitopes 
showed any reduction of binding to transfectants while the mAbs which recognized 
subtypic determinants on DR4 molecules did. NFLD.D2 was most affected by the 
nature of the host cell, which suggests that its binding epitope is more influenced by 
peptide-in-the-groove than are the binding epitopes of the other antibodies. An 
extreme example of such an antibody is one we have recently produced (CHAPTER 
8) that behaves like an alloreactive T cell, recognising the DRJ:H *0401 molecule and 
no other; this antibody completely fails to bind to transfectants expressing ORB 1 
*0401. H alloreactive T cell recognition involves co-recognition of residues on the 
alpha helix plus self peptide, as is currently believed (Lechler and Lombardi, 1991) 
then it follows that an antibody which can discriminate the same T cell-defined 
subtypic variant will also be peptide dependent. Such an antibody was also described 
by Murphy et al (1989). 
Considering the paucity of mAbs such as NFLD.D1 which define the DR~' 
serotype, it is informative to examine the DR4 P1 chains for the presence of unique 
sequences. The first possibility is residues 9-13:EQVKH which are located on the 
floor of the peptide binding groove (Brown et aL, 1993 ). Two other possibilities are 
single residues located in the p2 domain, tyrosine (Y) at position 96, which was 
earlier suggested as the polymorphism defining DR4, (Gorski, 1989) and leucine (L) 
at position 180 which is near the transmembrane portion of the molecule (Bell et al., 
1987). Although the serological pattern for NFID.D1 (Table 6.3 and Fig. 6.1a) 
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appears identical to that reported for GS359-13F10 (Alber et al., 1989), analysis with 
the hybrid molecules indicate that these mAbs bind two disparate epitopes. The 
GS359-13F10 epitope was initially localized to the region 41-97 (Alber et ~ 1989), 
and was later more definitively mapped to 96Y (Maurer and Gorski, 1991). The 
possibility that NFLD.D1 might also map to 96Y was examined in relation to the 
binding patterns obtained with the hybrid molecules (Fig. 63). Since it did not bind 
any transfectants that expressed the DR4 sequence 41-97 unless the DR4 p2 domain 
was also present, 96Y is unlikely to be important for NFLD.D1 binding. Even if 
binding is partly dependent on the sequence YPE (96-98), which is normally found 
only on wild type DR4 molecules, then NFLD.Dl would be expected to bind the 
hybrid molecules 7747 and 4447 because DR7 carries E98 and DR4 carries YP (96-
97). Thus lack of binding of NFLD.Dl to hybrid molecules carrying YPE in the 
absence of the DR4 P2 dom~ suggests that other residues in the P2 domain are 
critical for NFLD.D1 binding. A possible candidate for the NFLD.D1 epitope is 
180L Experiments are in progress to test this hypothesis. 
Attempts to map antibody epitopes on DR hybrid molecules without first 
identifying the DRP chain that confers the binding epitope, can lead to errors. For 
example, our earlier studies using BCL and DR hybrid molecules suggested that the 
epitope for NFLD.M1 is located in the second domain of DRP1 chains expressed by 
DR4, DR3, DRS, DR6 and DRS positive cells (Alber et al., 1989; Drover et aL, 
1985). Based on these findings we predicted that the critical residue was Threonine 
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(T) at position 140 on DR fj 1 chains. When the analysis was extended, in the present 
studies, to include transfectants which express individual fj 1, fj3, {:J4 and {:J5 chains 
(Fig 6.1b), NFLD.M1 was found to bind transfectants expressing DRB3*0101, 0201 
and 0301 genes, but not to those transfectants expressing DRB1*0301, 1101, 1401 and 
1402. Furthermore, comparison of the sequences of DR{:J3 chains shows that they do 
not have 140T; neither do they have any residue in the first or second domain that 
is unique to DR52 and DR4 molecules. Thus, although we have confirmed that 
NFLD.M1 binding is critically influenced by residues in the {:J2 domain of DR4 
molecules, the epitope appears more complex than we had earlier anticipated. 
A further example of the complexity of antibody binding epitopes is 
illustrated by NFLD.D7. Its specificity is similar to NFID.Ml in that it binds DR4 
and DR52 molecules; unlike NFLD.Ml, it also binds DR15 and DR16 {:Jl chains. 
Analysis with the hydrid molecules shows that NFID.D7 binding is mainly influenced 
by residues near the amino terminus of the /11 domain, notably residues 1-21. 
Comparison of DR sequences does not reveal any residues unique to DR4, DR15, 
DR16 and DR52 molecules. Furthermore, residues 1-21 which are important for 
NFLD.D7 are unlikely to be available for antibody binding (Brown et al., 1993). It 
seems likely then, that NFLD.D7 recognizes a conformational determinant that is 
dependent on the interaction of residues in HVR-1 and HVR-11 regions of DR4 
molecules. Formation of this epitope may depend on different regions in DR15, 
DR16, and DR52 molecules. 
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Epitope mapping with NFI.D.D10 showed that the sequence 41-97 in 
DRB1*0403 is essential for preservation of its epitope (Fig. 63b); unfortunately, 
mapping experiments with the hybrid molecules were not feasible for NFID.D2, 
NFID.D3, and NFIDD8 since they either do not bind (or bind poorly} to 
transfectants expressing DRB1*0403. However, the similarities in specificity between 
these four antibodies when exposed to other DR4 subtypes, both in transfectant and 
BCL forms, suggest that they too probably bind to an epitope involving the sequence 
41-97. 
The four antibodies to DR4 subtypes show reaction patterns that parallel, to 
varying degrees, the presence of a "shared sequence" that is associated with 
susceptibility to development of RA (Gregersen et al., 1987; Duquesnoy et al., 1984). 
This sequence at positions 70-74 on the beta chain is QKRAA on DRB1*0401 and 
QRRAA on the other DR4 alleles that are associated with RA (DRB1* 0404, *0408) 
and on the DR1 and DR14 alleles that are similarly associated (DRB1*0101, *1402). 
An analysis using site-directed mutagenesis of relevant ORB genes to map these 
epitopes at the level of single amino-acid substitutio~ is underway. 
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CHAPTER? 
AMINO ACIDS IN THE PEPTIDE-BINDING GROOVE INFLUENCE 
AN ANTIBODY-DEFI1'tf£D, DISEASE-ASSOCIATED HLA-DR EPITOPE1 
7.0 ABSTRACT 
A shared amino acid sequence on the alpha helix of certain DRpl chains is 
predicted to generate a "shared epitope" that is implicated in susceptibility to the 
development of rheumatoid arthritis (RA). Different relative risks (RR) for disease 
susceptibility and severity conferred by these DR.B 1 chains suggest that their "shared 
epitopes" are not equivalent. A set of monoclonal antibodies that map to the critical 
regio~ and for which optimal binding depends on DR context and cell lineage, was 
used to test this idea. Mapping experiments using mutated DRpt• molecules showed 
that the antibody-binding epitopes are overlapping; residue 700 is pivotal for each, 
but neighbouring residues on the alpha helix and on the floor of the groove are also 
involved. Importantly, these epitopes are profoundly modified by peptide loading of 
DR.Bl*0401 molecules. These data suggest that "shared epitopes" on DR molecules 
that are associated with RA are influenced by their context; such structural 
modifications may be the basis for the varying susceptibilities conferred by these DR 
molecules for the development of RA. 
1In Press:-Sheila Drover, WllliaJII H Mars~ William W Kwok, Gerald T Nepo~ Robert W KarT, 
Scandinavian J Immunology, 1994 
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7.1 INTRODUCfiON 
HLA molecules, which are encoded by the major histocompatibility complex 
(MHC), are important for binding and presentation of antigenic peptides to T 
lymphocytes. These HLA molecules show extensive polymorphism and in some cases 
are associated with susceptibility to autoimmune diseases (Nepom and Erlich, 1991). 
HLA-DR4 was found to confer risk (Stastny, 1978) for the development of 
Rheumatoid Arthritis (RA). However, this risk was not ~lute and in some studies 
in which the prevalence of DR4 was low, DR1 was shown to confer susceptibility 
(Stastny, 1980). Finer definition of the HlA alleles using T cell typing and molecular 
methods showed that the DR4 specificity was composed of a family of alleles (DR4-
Dw variants) whose risk for RA varied considerably (Zoschke and Segall, 1986; 
Nepom et al., 1986). 
A unifying hypothesis that became known as "the shared epitope 
hypothesis" (Gregersen et al., 1987) emerged from the discovery of a shared 
sequence 70-74:0KRAA/ORRAA on the DRp1 chains ofDR4 and DR1 molecules 
and a similar sequence (RRRAA) on DR10 molerules (Gregersen et al., 1986; Bell 
et al., 1985; Winchester and Gregersen, 1988; Merryman et al., 1988). Importantly, 
DRp1 chains which have one or more non-conservative substitutions in this region, 
including those contained in the same DR4 context (eg. DRp1*0402 and 0403), are 
associated with resistance to the disease (W"mchester and Gregersen, 1988; Amar et 
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al., 1982; Wordsworth et al., 1989). Further evidence for this hypothesis came from 
the finding that a rare DR6 allele (DRB1*1402), which carries the same shared 
sequence, is strongly associated with RAin two North American Indian populations 
(Willkens et al., 1991; Nelson et al., 1992). 
The presence of a "susceptibility sequence • in approximately 90% of RA 
patients of Caucasoid origin (Nepom and Erlich, 1991; Wordsworth et al., 1989; 
Wallin et al.,1991), implies that the resulting structures on the expressed DR 
molecules play an influential role in the development of RA. It has been proposed 
that structures formed by these shared sequences might be conformationally 
equivalent (Winchester and Gregersen, 1988); yet the relative risk (RR) for 
developing severe RA is significantly higher when the shared sequence is present on 
DR4 molecules than when it is present on other DR molecules (Wordsworth et al., 
1992; Weyand et al., 1992). Analysis of the published sequences (Gregersen et al., 
1986; Bell et al., 1985; Merryman et al., 1988; Marsh and Bodmer, 1992) shows that 
amino acid residues on the beta strands that make up the floor of the grooves of 
DR4, DR1, DR14 and DR10 molecules are quite dissimilar. Thus, the varying 
degrees of risk and severity conferred by these molecules may be related to 
differences in DR context, peptide binding or orientation, and/ or subsequent 
conformational alterations to their "shared epitopes". By increasing our 
understanding of the topography of these structures, some insight into their role in 
RA and other autoimmune diseases may be gained. 
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We have previously shown that four m.Abs (NFLD.D2, NFLD.D3, NFID.D8 
and NFLDD10) have simi1ar specificities and that they bind specifically to those DR 
molecules associated with RA (CHAPTER 6). In the present study, we have extended 
previous work which suggested that the integrity of these epitopes on the relevant 
DR molecules is affected by their DR context and by the cells on which they are 
expressed. Epitope mapping studies for each of the antibodies were performed using 
a series of DRP 1 mutants produced by site-directed mutagenesis of the relevant 
DRB 1 eDNA Finally, the contribution of bound peptide in the formation of these 
epitopes was addressed using an antigen-processing mutant that had been transfected 
with DRA and DRB1*0401 genes. The combined results from these studies indicate 
that amino acid substitutions at positions predicted to be involved in peptide binding, 
and/ or changes in peptide processing and presentation, alter the structure of the 
"shared epitope" that is associated with the development of RA 
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7.2 MATERIALS AND METI-IODS 
7.2.1 Cells 
Homozygous human B cell lines (BCL) obtained through the lOth 
International Workshop (IHW) and the DRB genes that they express are as follows: 
Wf51, DRB1*0401 and B4*0101 MT14, DRB1*0404 and B4*0101; KAS116, 
DRB1*0101; AMArA DRB1*1402 and B3*0101; SCHU, DRB1*1501 and B5*0101; 
MGAR, DRB1*1501 and B5*0101; E4181324, DRB1*1502 and B5*0102; KASOll, 
DRB1*1601 and B5*0201 (CHAPTER 6). The cell line HAS15 (DRB1*0405 and 
B4*0101) was kindly provided by H. Mervart through the 9th IHW (Gross-Wilde et 
al., 1984). Mouse cell transfectants were cells of the DAP.3 subclone of class ll-
negative murine L cell fibroblasts, which had been transfected with DRa and DRp 
cDN~ and have been described elsewhere (CHAPTER 6, Inoka et al., 1992). They 
include l243.6, DRB1*0401; L165.6, DRB1*0404; L566.H6, DRB1*0405; DAP3-
DR1, DRB1*0101; L182.1, DRB1*1402; L466.1, DRB1*1501; lA68.5, DRB1*1502; 
IA14.1, DRB5*0201; L164.11, DRB1*0402; L168.2, DRB1*0301 and L91.7, 
DRB1*1101. The T2 mutant (Rtberdy and Cresswell, 1992) expressing DRB1*0401 
(T2-Dw4) was made in GT Nepom •s laboratory (unpublished data). Human BCL 
were maintained in RPMI-1640 containing 10% heat inactivated fetal bovine serum, 
2mM sodium pyruvate, 50units/ml penicillin and 501-'g/ml streptomycin (all obtained 
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from Gibro, Grand Island, NY). Mouse cell transfectants were maintained in DMEM 
(Gibco) containing the same supplements plus 5 x 10SM 2-mercaptoethanol (Sigma, 
St. Louis, MO). 
7 :l:Z Generation of DRBl* Mutants 
The DRB 1*0401 mutants used for epitope mapping were derived by site-
directed mutagenesis of DRp eDNA as previously descnbed (Karr et al., 1990). In 
each mutant, a single amino acid residue found in the wild type DRp1 *0401 chain 
was replaced by the residue found at the same position of another DRB1 allele. 
Thus, positions 37, 57, 67, 70, 71, 74 and 86 were substituted using residues from 
other DR4 subtypes; another DRB 1*0401 mutant was made with residue 70R 
substituted from DRB1*1001. Positions 9, 11, 13, 28, and 30, which are conserved 
among the DR4 subtypes, were substituted with residues from DRB1 *0701. In a 
reverse approach several wild type genes, whose products do not bind the antibodies, 
were mutated at critical points in attempts to create epitopes for these antibodies. 
Thus, mutants with the following substitutions were genetated: DRB1*0402 (70D+Q); 
DRB1*1101 (70D-+Q); DRB1*1101 (70D-+R) and DRB1*0301 (73G-A). 
Transfectants expressing class ll molecules were isolated and maintained as 
previously descnbed (Kiohe et aL, 1988). 
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7 .2.3 Antibodies 
The mAbs NFLD.D2, NFLD.D3, NFLD.D8 and NFLD.D10 are murine 
monoclonal antibodies made using L cell transfectants as imrnunogens, and were 
previously shown to have similar binding patterns with DR4 variants: pt•040l, 0404 
or 0405 (Drover et al., 1992). Control mAbs used to show that the overall integrity 
of the mutated DRp 1*0401 molecules was not drastically altered, included the 
following: SG520 (obtained from Sanna Goyer-4 North Shore University Hospital, 
Manhasset, NY) and GSP 4.1 (obtained through the 10th IHW) which bind 
monomorphic determinants on DR molecules (Goyert and Silver, 1981; Knowles et 
al., 1989); 50D6 and 21r5 (obtained from Michelle Letarte, Hospital for Sick 
Childre~ Toronto, Canada), which bind all DR molecules except DR7 (Letarte et 
al., 1985; Addis et al., 1982), and map to regions 1-40 and 41-97, respectively, on the 
Pl chains (Addis et al., 1982; Alber et al., 1989); 35913F10 (obtained from Susan 
Radka, Oncogen, Seattle, WA) and NFLD.Dl, which bind all DR4 molecules (Alber 
et al., 1989; Drover et al., 1992) and map to different regions of the P2 domain 
(Maurer and Gorski, 1991;CHAPTER 6). 1243, obtained from ATCC, binds a 
monomorphic determinant on all DR molecules that is dependent on DR a chain 
sequences (Lampson and levy, 1980; Fu and Karr, 1994) and was used as a reference 
control for DR expression in all these experiments. Affinity purified F(ab ')2 
fragments of goat anti-mouse lgG + IgM (heavy and light chains), which were 
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conjugated to horse radish peroxidase (Jackson Immnnoresearch Laboratories, Inc., 
West Grove, PA), were used as the secondary antibody for CEUSA The secondary 
antibody used for immunofluorescence and flow cytometry was fluoresceinated goat 
anti-mouse lgG (Organon Technika-Cappel, Malve~ PA). 
7 .2.4 Binding Assays and Data Analysis 
Antibodies were tested in duplicate, usually on two to three different occasions 
using either a live cell enzyme-linked immunoassay (CEUSA) or 
immunofluorescence and flow cytometry as previously described (Klohe et al., 1988; 
Drover and Marshall, 1986). Various concentrations of mAbs, culture medium or 
irrelevant mouse IgG (negative control), and optimaJJy-diluted 1243 (anti-OR 
positive control), were tested on BCL and on transfectants expressing either wild type 
or mutated DR molecules. To reduce any artifacts that might result from differences 
in the level of DR expression on these cells, CEI.lSA data on the test mAbs were 
analyzed relative to the positive control, 1.243. Essentially, a percent (%)binding 
value was obtained as follows: the background optical density (OD) was subtracted 
from each test OD and the mean OD value from replicate samples was expressed as 
a percent of the mean OD value for 1.243. 
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For some of the experiments the data were double-normalized as follows: 
OD test mAb on non-DRp1*0401 or mutant - background OD/ 
OD reference mAb on non-DRp1*0401 or mutant- background 
OD test mAb on DRp1*0401 - background OD/ 
OD reference mAb on DRpl*0401 - background 
Binding assays done using immunofluorescence were analyzed on a Coulter Epics 753 
flow cytometer (Coulter Cytometry, Hialeah, FL) to determine the mean channel 
fluorescence (MCF) of each sample. The mean fluorescence (MF) was calculated 
from the MCF by the formula MF = t()MCL/8S.33. The data were double normalized 
using the same formula as shown above, but with MF substituted for OD values. 
7 .2.5 Statistical Analysis 
The significance of differences in mAb binding to relevant DR molecules 
expressed on BCL and mouse cell transfectants was determined by non parametric 
(Wilcoxan) analysis of the paired data. To determine if mAb binding to transfectaots 
expressing mutated DRp1*0401 molecules was significantly different from that 
obtained for the traosfectant expressing wild type DRp1*0401 molecules, a one way 
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analysis of variance (ANOV A) was performed; corrected Bonferroni p values (Bailar 
and Mosteller, 1992) were obtained. Both statistical methods were performed using 
a computer program called INSTAT (Graphpad Intuitive Software for Science, San 
Diego, CA). 
7.3 RESULTS 
7.3.1 The Topography or Shared Epitopes on DR Molecules Differs with Cell 
Lineage 
Previous work, which is summarised in Table 7 .1, suggested that the antibody 
binding epitopes for NFID.D2, NFLD.D3, NFLD.D8 and NFlD.D10 were 
determined primarily by the amino acid sequence 7~ 74:0KRAA/ORRAA on the 
HLA-D~l chains that are predicted to carry the putative RA shared epitope. There 
were also extra reactions including binding to BCL expressing DR15 and DR16 
haplotypes which are not associated with RA (Nelson et al., 1992; Oilier and 
Thompson, 1992). It was subsequently shown, using mouse cell transfectants 
expressing a single DR specificity, that these mAbs bind molecules carrying D~ 1*15 
or DRp5*02 chains that contain the sequence 7~ 74:QARAA; they did not, however, 
bind transfectants expressing DR.B1*16 or 0~5*01 chains that contain the sequence 
7~74:DRRAA (Table 7.1 and CHAPTER 6). 
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An interesting observation was that the antibody binding patterns differed according 
to whether the DR molecules were expressed on BCL or mouse cell transfectants. 
To further analyze the phenomenon of differential binding to BCL and 
transfectants expressing the relevant DR genes, parallel studies (CEUSA) were 
performed using three of the mAbs, NFIDD2, NFID.D3 and NFID.D10. Statistical 
analysis of the paired data for each mAb (Table 7 2) revealed highly significant 
differences in NFID.D2 binding to BCL and transfectants. The greatest contrast 
occurred for paired cells expressing DRB1*0101, 1402, 1501, and 1502. Differences 
in NFLDD3 binding to BCL and transfectants were marginaJJy significant due mainly 
to dissimilar binding to paired cells expressing DRB*0101 and 1501. NFLD.D10 
bound similarly to both cell types. The most conspicuous differences between mAb 
binding to BCL and to transfectants were revealed when binding obtained for each 
on-DRB1*0401 cell was double normalized to binding obtained for DRB1*0401. 
Paired data for each mAb are shown in Fig. 7.1. The salient feature is that NFIDD2 
reacted strongly with DRp1*1402 expressing-BeL, but not with the relevant 
transfectant, while NFLD.D3 and NFIDDlO reacted equally well or better with this 
transfectant than with the BCL In addition, weak NFID.D2 reactivity with 
DRp1*1501 molecules on BCL vanished on the transfectants. 
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Table 7J. Comparison ofmAb binding- to DR mokades expressfd on B «<lliMs (BCL) and mouse tdl 
transfectants (TFS). 
NFLD.Dl NFLD.D3 NFLD.D10 
HLA-DR' 
BCL TFS BCL TFS BCL TFS 
81*0401 126 :t: S. S' 101 :t 1.8 113:!: 3.4 96:!: 2.7 125:!: 4.8 122:!: 1.8 
B1*0404 121:!: 7.S 82 :t: 0.95 111 ± 7.4 93:!: 3.1 126 ± 9.5 132:!: 4.3 
81*040! 88 :t S.4 94 ± 3.6 86 ± 2.3 98 ± 2.4 91 ± 1.9 126 ± 7.4 
81*0101 lOS :t S.4 !1 :t 1.3 76:!: 3.8 47:!: 1.9 124 :1:: 1.5 119 :1:: 2.~ 
81*1402 136:!: 6.4 14:1:4.8 112:!: 0.9 91 :t 5.5 139 :1: 9.0 163 :1:: 5.4 
~ 85*0201 117 :1: 6.6 111 :t 1.4 111 :!: 7.3 114 :t 3.7 120 ± 7.3 119 ± 6.3 
... 
\D 81*1!01 30:!: 0.9 2.2:!: 2.2 85 :1::1.7 55± 3.4 116 ± 5.1 88:!: 6.2 
Bl*lS02 86 :t 6.4 21 :1: 1.9 103 :1: 4.1 98:!: 0.96 133::1:0 126:!: 4.3 
Wlleosan p11 • O.OtS6 p. 0.0~47 p- 0.6406 
Teat 
• mA.b bkdtg ......red a CElJSA lftd nol"lllllr.ed to lhe drmce DR control, L243, u dmcrlbed m mdhod11. 
11 DRB aDelel expre.d by taaawfedantland BCL c mean of replicate samples ::1: standard error of Cbe mean. 
.. two tailed p values. 
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Figure 7.1. Comparison of mAb binding to DR molecules expressed on BCL with 
that obtained for mouse cell transfectants expr~ng the prototype genes. The mean 
relative binding of each mAb to non-DRp1*0401 expressing cells was double 
normalized to the mean relative binding to DRJJ1*0401 positive cells for both BCL 
and transfectants, as described under methods. 
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Other points to note are: i) all mAbs bind more avidly to DR~ 1*0405 and 
DR~5*0201 when the genes are expressed in transfectants, while aU mAbs bind 
DR~ 1*1501 molecules more avidly when they are expressed in BCL; ii) NFLD.D2 
and NFLD.D3 binding to DR~1*0101 molecules, which were somewhat reduced on 
BCL, was significantly reduced on transfectants; ill) all three mAbs bind differently 
to cells expressing DR~ 1*1502 molecules: NFLD.D2 binds poorly, but more avidly, 
to BCL than to transfectants; NFLD.D3 binds better to transfectants, while 
NFLD.D10 binds equally well to both. Taken together these data show that epitopes 
generated by shared sequences vary according to both the structure of the rest of the 
DR molecule and to the cell type on which the molecule is expressed. 
7 .3.2 Contribution or Residues on the Alpha Helix and on the Floor or the Peptide 
Binding Site to "Shared Epitopes" on the Alpha Helix or DR81*0401 
Molecules 
Comparison of the reactivity patterns for these mAbs with the available 
sequence da~ suggested that the putative RA susceptibility sequence (70-74) is 
influential in forming these epitopes, and that 700 may be critical (Table 7.1). 
However, since these mAbs do not bind all DR molecules carrying 700 and since 
they show a gradient of reactivity with DR molecules containing the putative RA 
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susceptibility epitope, it was predicted that other amino acids, including peptide 
binding residues might be involved in formation of these epitopes. To test this 
hypothesis binding was analyzed on a panel of DRp 1*0401 mutants, each containing 
a single amino acid substitution (Fig. 7 .2A), including non-conservative substitutions 
(70Q-+D, 71K~E, 74A~E, S~S, 37Y~F JOY~~ 13H~Y and 9E~W) and 
conservative substitutions (860-+V, 67L~I, 71K~R, 28~E and llV-+G). 
To ensure that the structural integrity of the DRap 1*0401 mutated molecules 
had been maintained, the mutants were analyzed with several well-characterized 
mAbs. Binding of the two monomorphic mAbs, GSP 4.1 and SG520, to the mutant 
molecules were identical to that obtained for wild type molecules (data not shown). 
The DR4-specific mAbs (359 13F10 and NFID.D1), which map to different regions 
of P2 domain and two mAbs (5006 and 21r5), which map to different regions of the 
P1 domain showed no significant variation in binding to mutant molecules from that 
observed for wild type molecules (Fig. 7 .2B). These data suggested that the overall 
structural integrity of the mutated D~ 1*0401 molerules had been maintained, thus 
permitting confident analysis of the following data on antibody binding epitopes. 
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Figure 7 .2. A) Schematic representation of the class ll peptide binding site. The 
coordinates for the structure of HI.A-DRl (Brown et al., 1993) were provided by 
Jerry Brown, Harvard University, and the structure was viewed on an 
IRIS4D/310GTX workstation (Silicon Graphics, Mountain View, CA) using Insight 
ll software (Biosym Technologies, San Diego, CA). The location of the amino acid 
substitutions created in the mutants of DRB1*0401 are shown as circles. B) Analysis 
of the conformational integrity of the mutated DRB1*0401 with a panel of control 
mAbs for which mapping data were available. 
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~ys were carried out on four dilutions of NFID.D2, NFI.DD3, NFID.D8 
and NF1D.D10. Relative binding of mAb at each concentration to the various 
transfectants was cumulated (Fig. 7 .3) and relevant statistical analysis of the 
cumulative binding scores is shown in Table 7 .3. The most striking effect is 
abrogation of binding of all four mAbs by the substitution 700 for 700 (corrected 
p value,< 0.001). These data are consistent with the previously observed negative 
binding of all four mAbs to DRp*0402 and to all other molecules containing 
DRp1*:70D {CHAPTER 6). In a separate experiment (shown in Table 7.4) the 
substitution 70Q-+R resulted in significant loss of NFID.D10 binding and total loss 
of NFI.DD8, NFLD.D3 and NFI.D.D2 binding, thus confirming previous findings 
with 70R positive wild type molecules (Table 7.1 and unpublished data). No other 
substitutions on the alpha helix of DRp1*0401 molecules altered NFI.D.D10 binding. 
However, the substitution 570-+S resulted in increased binding of NFID.D8, 
NFI.DD2 and NFLD.D3, while the substitutions 61L-+L 71K-+R, 71K-+E, 74A-+E, and 
86G-+ V decreased the binding of one or more of the antibodies (Fig. 7 .3). 
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Figure 7.3 Epitope mapping for NFLD.D2, diluted 1/10-1/80; NFLD.D3, diluted 
1/2-1/16; NFLD.D8, diluted 1/100-1/800; NFLDD10, diluted 1/100-1/800 with 
DR,el*0401 mutants shown in Fig 7.2. The relative binding of each mAb to each 
DRB1*0401 mutant is shown on a cumulative scale, with each division in a histogram 
representing the %binding of each respective dilution of mAb to the various cells. 
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Significant alterations in m.Ab binding to mutants were ascertained by Bonferroni 
corrected p values (Table 7 .3); they include NFID.D2 binding to 671 (p< 0.01), 74E 
(p<0.001) and 86V {p<0.05); NFIDD3 binding to 74E (p< 0.001); NFLD.D8 
binding to 671 {p<0.05) and 74E (p<0.01). Alterations in binding caused by 
replacements 570-+S, 71K-+R and 71K-+E were insignificant (corrected p value, 
>0.05). 
Three substitutions on the floor of the groove (9E-+W, 11V-+G, 13H-+Y) had 
only trivial effects on binding (Fig. 7 3); for example, increased NFLD.DlO binding 
to the 11G mutant was insignificant (corrected p > 0.05). However, the binding of 
NFID.D2, NFLD.D3 and NFLD.D8, but not of NFLD.D10 was modified 
considerably by at least one of the other substitutions (280-+E, 30Y-+L and 37Y-+F). 
The statistical analysis {Table 7 .3) shows that reductions in NFLD.D2 and NFLDD3 
binding to the 28E mutant were significant (p < 0.001 and < 0.01, respectively), while 
NFID.D8 binding was unaffected. Increased NFIDD3 binding to the 30L mutant 
was also significant (p < 0.01), while increased NFID.D2 and NFLD.D8 binding to 
the same mutant and reduced binding by all three mAbs to the 37Y mutant did not 
reach significance when the Bonferroni correction was applied. 
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Table 7.3 Monoclonal antibody binding to wildtype and mutated DRP•0401 molecules, expressed as mean cumulative scores• and analyzed 
by ANOVAb. 
Amino NFLD.Dl NFLD.D3 NFLD.D8 
Ac:ld 
Change xc SEMd p' X SEM p X SEM p X 
Wild Type 366 6.8 277 10.7 347 10.6 385 
28: D--+E 20~ 16.8 <0.0001* .. 170 13.0 0.0002•• 352 14.4 0.074 404 
30: Y.....L 440 7.9 0.007 37~ 8.1 0.0004** 384 11.2 0.038 406 
37: Y-F 291 9.0 0.0061 218 5.9 0.01 313 13.7 0.057 415 
67: L~ 253 27.3 0.0004** 296 19.3 0.34 283 5.6 0.0024* 401 
70: Q-tD 12.2 8.8 <0.0001*** 8.8 2.5 <0.0001 ••• 8.2 2.2 <0.0001*** 10.8 
74: A-tE 171 12.~ <0.0001*** 131 9.3 o.ooo1• .. 258 15.3 0.002** 372 
86: C-.V 275 2~.8 0.002* 214 17.3 0.007 299 11.0 0.012 389 
0/o binding of each mAb sample was cumulated as shown in Fig. 7.3 
ANOVA • analysis of variance; c X, mean Ofo of replicate samples; d SEM, standard error of the mean 
p, unc:orreeted probability values; Bonferroni corrected p values: * = p<0.05; .. = p<0.01; ... = p<O.OOl 
NFLD.D10 
SEM p 
1.7 
7.8 0.37 
6.9 0.32 
4.7 0.16 
22.1 0.45 
2.8 <0.0001 ... 
15.2 0.49 
1.7 >0.8 
7.3.3 Reconstitution of Antibody Binding Epitopes in non-DR.Sl*0401 Context 
The above studies showed that 700 was critical to these antibody binding 
epitopes, and that other residues contributed to epitope formation. It was, therefore, 
pertinent to see whether these epitopes could be reconstituted by making a simple 
70D-+Q replacement in otherwise non-reactive molecules. For example, DRp1*0402 
has the same framework as the prototype DR.p1*0401 with the exception of 
substitutions 671, 700, 71E and 86V, while DRp 1*1101 carries substitutions 67F, 700 
and 86V, but differs contextually. The data presented in Table 7.4 show either full 
or partial reconstitution of all four epitopes on the DRp 1 *0402:700..0 mutants. 
Similarly, the other epitopes, except for NFIDD2, were reconstituted on 
DR.p1*1101:70D-+Q. 
Since NFID.DlO was previously shown to bind to certain wild type DR 
molerules containing DRP1:70R (Table 7.1, unpublished observations), an attempt 
was made to recreate this and the other epitopes by substituting 70R for 700 or 700. 
It can be seen from Table 7.4 that DRp1*1101:70D-+R resulted in positive 
NFI.D.DlO bindin8,whereas DRp1*0401:70Q-+R resulted in a profound loss of 
binding. Aside from trivial binding of NFID.D8 to DRp1*1101:70D-+R molecules, 
none of the other antibodies reacted with these mutants. The absence of these 
antibody binding epitopes, particularly that of NFLD.DlO, on DR3 molecules was 
curious since DRpl*03 chains carry 700. 
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Table 7 .4. mAb bindin( to mouse cell transfedants expressing wild type (W1) 
and mutated DRBI * genes. 
NFLD. 0401: 0401: 0402: 0402: 1101: 1101: 1101: 0301: 0301: 
mAb WT 70 WT 70 WT 70 70 WT 73 
~R D...() D...() D ... R G ... A 
DlO +++ ::i: +++ +++ +++ +++ 
08 +++ +++ ++ ± + 
.... 
Ul D3 +++ +++ ++ ± \D 
Dl +++ ++ ± 
• mAb binding was measured by immunoftuoresence and double normalized as 
deaibed m medlods; -, <100/o; ±, 11-25°/o; +, 26-S}o/o; ++, 51-75°/o; +++, >7So/o, 
However, it differs from DRp 1•04 chains at amino acid positions 73, 74 and T1 on 
the alpha helix, and at several positions on the beta strands. Based on the finding 
that NFID.DlO binding is unaffected by position 74 (Fig 7 .3) and the knowledge that 
position 73 is important for an anubody binding epitope on DR3 molecules (Nelson 
et al., 1992), it was predicted that 73G on DR3 molecules might prevent the 
formation of the NFID.DlO binding epitope. To test this hypothesis, the anubodies 
were analyzed on transfectants expressing wild type and mutated DRP t•OJOt 
molecules in which 73A (DRP t•040t context) was substituted for 73G. As predicted 
and shown in Table 7.4, there was substantial reconstitution (80%) of NFID.DlO 
binding; there was also partial reconstitution ( 45%) of NFID.D8 binding. However, 
the binding epitopes for NFID.D2 and NFID.D3, which were shown to be the most 
sensitive to DR context, were not reconstituted. 
7 .3.4 Peptide Loading of the Groove In.ftuences the Topography of Shared Epitopes 
on the Alpha Helix 
The above data indicated that optimal expression of some of these epitopes 
required a contribution from residues in the lll.A groove that are predicted to bind 
peptide. This, together with altered binding to DR molecules expressed on mouse 
cells (Fig. 7.1), suggested that peptide in the groove might also be involved. To further 
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investigate this idea, an antigen processing mutant, T2, was employed; this cell line 
was previously shown to express transfected DR3 molecules that were 
conformationally unstable and associated with a large invariant chain peptide 
(Riberdy and Cresswell, 1992; Sette et al., 1992). Thus, T2 cells, which were 
transfected with DRA and DRB1*0401 genes (T2-Dw4), were used as targets in 
CEUSA in which several different concentrations of antibody were used. 
The expression of DR4 molecules on T2-Dw4, as detected by the DR4-
specific mAb (NFLD.Dl), was approximately 80% of that found on a normal BCL 
(Wf51) which expresses wild type 0~1*0401 (data not shown). Binding of 
NFLDD2 and NFLD.D8 to the T2-Dw4 mutant was profoundly reduced even when 
the antibodies were used at saturating concentrations (Fig. 7.4). 
NFI.DD3 binding was also conspicuously decreased, requiring 100x more antibody 
to give 50% binding. NFLD.D10 binding, which was earlier shown to be the least 
affected by DR context, was the least modified with about a 5-fold reduction in 
binding to T2-Dw4 as compared to the normal BCL Thus, the data support the 
hypothesis of peptide involvement since those same mAbs whose binding patterns 
were most affected by cell lineage and/or DR context, also had significantly altered 
binding to T2-Dw4. 
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Figure 7.4. Comparison of mAb binding to a homozygous ~ Wf51 (solid line) 
expressing endogenous DRB1*0401 and mAb binding to an antigen processing 
mutant, T2-Dw4 (broken line) expressing transfected DRB1*0401. Several 
concentrations of mAbs (displayed in inset) were tested in CEUSA and the results 
are shown as relative binding, which was calculated as described under methods. 
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7.4 DISCUSSION 
The critical amino acids in the shared sequences (67-86) on those DR.81 
chains that are implicated in RA are oriented so that their side chains are involved 
in peptide binding and/or T cell recognition (Brown et al., 1993). The importance 
of positions 67, 70, 71 and 74 was implied from the discovery that DR4 variants 
which are neutral or confer protection against the development of RA have major 
substitutions at one or more of these positions. Thus, DRp1*0402 carries a 
conservative substitution at position 67 (isoleucine for leucine) and non-conservative 
substitutions at positions 70 (aspartic acid for glutamine) and 71 (glutamic acid for 
lysine or arginine), while p 1*0403 carries a non-conservative substitution at position 
74 (glutamic acid for alanine). In both varian~ the non-conservative replacements 
impart a negative charge on this region (Watanabe et al., 1989). Further support for 
the importance of this region in immune responsiveness comes from a mouse model 
in which the equivalent positions 67,70 and 71 on the 1-A/3 chain were shown to be 
critical in determining susceptibility or resistance to the development of an 
experimentally-induced autoimmune response in H-r and H-:zt-12 niice (Mengle-Gaw 
et al., 1984; Hochman and Huber, 1984). The concept that a shared structure 
containing these critical residues is somehow implicated in the development and 
pathogenesis of RA is tenable, but the mechanism by which it does this has remained 
an enigma It seems likely that the framework of the different DR molecules that 
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cany the RA "susceptibility sequence" and the capacity of these molecules to bind 
and orient various peptides are important in determining the topography of the 
shared structure. Thus, a structure formed by a certain sequence on DR4 molecules 
may have a different conformation from that formed by the same sequence on DRl 
molecules. The experimental evidence from this study in which m.Abs were used as 
probes to map the topography of these shared regions, supports this idea. 
The epitopes for the four antibodies in this study are formed by residues in 
a sequence on DR molecules that are implicated in susceptibility to the development 
of RA and possibly other diseases with an autoimmune component. Subtle variations 
in these epitopes, which were perceived from differential antibody binding with 
relevant DR molecules expressed on mouse and human cells, were further clarified 
by epitope mapping. From these studies, emerged a picture of overlapping structures 
with 700 forming the core, but with other residues making a significant contribution 
to the formation of each epitope (Fig. 7 5). These residues are at positions 86, 74, 67 
and 28 for NFID.D2; positions 74, 28 and 30 for NFID.D3; positions 74 and 67 for 
NFI.D.D8. Evidence was also provided that 73A is required for at least some of these 
epitopes. For example, the NFIDDlO binding epitope, and to a lesser extent that 
of NFID.D8, were created on DRp1*0301 by the substitution 7oo-A, thereby, 
generating the sequence 70-74:QKRAG. Thus, the footprint of the NFIDDlO 
epitope may only involve residues 70-73, while that of NFID.D8 also requires 74A 
and 67L for optimal expression. 
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NFLD. 02 NFLD.D3 
NFLD.D8 NFLD.DlO 
F1gure 7.5 Location of amino acid residues in DRp 1•0401 molecules that contributed 
. . 
to antibody binding.epitopes. Alterations are indicated by: open ~cles, amino acid 
substitutions that caused a .signfficant ~teration ·to the epitope; closed circles, an 
insignificant modification to the epltope; shaded Circles, no effect on the epitope. 
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The epitopes for NFIDD2 and NFID.D3 appear to be further influenced by 
more remote parts of the alpha helix and spread onto a region on the peptide 
binding site that is normally occupied by peptide. The clearest evidence for peptide 
involvement in these epitopes was the profoundly altered antibody binding to 
DRp1*0401 molecules when they were expressed by the antigen-processing mutant, 
T2. This cell line expresses conformationally unstable class ll molecules due to 
defective loading of the MHC groove (Riberdy and Cresswell, 1992; Sette et al., 
1992). As might be expected, NFill.DlO was the least affected by the absence of 
normal peptide insertion into the groove, while the binding of NFLD.D2, NFID.D3 
and NFID.D8 were markedly diminished. 
Interpretation of these data and delineation of these epitopes were aided 
immensely by the recent publication of the 3-D structure of a DR1 molecule (Brown 
et al., 1993). Amino acid positions 70 and 73 are critical residues for NFIDDlO 
which is essentially unmodified by either DR context or by peptide in the grOOYe. In 
the DR1 crystal structure the side chains of position 70 have ambigous electron 
density (Brown et al., 1993); these data suggest that the side chains of this position, 
like those of position 73, point up and away from the peptide binding site; thus. they 
are able to make direct contact with either antibody or T cell receptors. In contrast, 
are the composition of shared epitopes, such as NFLD.D2 and NFLDD3, which vary 
considerably with DR context and peptide occupancy. For example, two substitutions 
28E and 74E which significantly altered the structure of these epitopes are within a 
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polymorphic cluster (P 13, 26, 28, 71, 74, 78) which is important for peptide binding 
and orientation (Brown et al., 1992; Racioppi et al.,1993; Coppin et al., 1993). 
Position 86, which is at the entrance to the groove and appears to be involved in 
peptide anchoring (Demotz et al., 1993), also contributed to the NFID.D2 binding 
epitope. Thus, the locations of the amino acids that shape these epitopes are 
consistent with the idea that peptide occupancy of different lllA grooves can induce 
epitope variation; whether or not peptide directly contributes to some epitopes or 
acts indirectly by conformational induced alterations cannot be deduced from these 
studies. 
Other studies have identified shared structures, that form antibody or 
alloreactive T cell epitopes on the alpha helix of DR molecules, that correlate with 
the presence of an RA "susceptibility sequence• (Winchester and Gregersen, 1988; 
Duquesnoy et al., 1984; Hiraiwa et al., 1990). One of the first, designated MC1, was 
defined by Duquesnoy et al, (1984) using alloantibodies whose binding correlated 
significantly with the presence of DR4 and DRl; however, MC1 was occasionally 
found on non-DR4 molecules, a finding that is similar to these antibody epitopes. 
Particularly relevant to this work is a study done by Hiraiwa et al (1990), in which 
another mAb with MC1-Iike specificity, CCCI.20, was mapped to residues 700, 71R 
and 67L on DR.p1*0404 molecules. Its epitope is similar to those of NFID.D2 and 
NFID.D8, since all three are affected by positions 67 and 70, whose side chains face 
solvent, but it differs at positions 71 and 86. Position 71 had little impact on 
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NFID.D2 or NFIDD8, while the position 86 had no effect on CCCUO. Whether 
or not residues on the floor of the groove contribute to CCC120 was not tested, but 
the fact that the authors were able to reconstitute this epitope on a 
DRB1*1101:70D-+Q mutant, suggests that DR context may not be that important. 
The failure of NFlD.D2 to be reconstituted by similar mutations in DRB 1*1101, and 
its overall dependence on DR context and peptide binding for optimal expression, 
suggest that its binding epitope more closely resembles that of an alloreactive T cell 
epitope. 
The idea that a consensus sequence on the alpha helix of some lll.A-DR 
molecules (OKRAA/QRRAA in DR4 and DR1 or RRRAA in DR10} generates a 
conformationally equivalent determinant, that predisposes to RA, was partly based 
on the identification of another serological epitope (109d6) found on the cells of 
most RA patients (Winchester and Gregersen, 1988; Merryman et al., 1988). 
Subsequently, it was shown that the high correlation of this epitope with RA was due 
to its presence on DR53 molecules, whose gene is in linkage disequilibrium with 
DR4, but which is not associated with RA. However, 109d6 positive molecules also 
include DR10 which is associated with RA (Nelson et aL, 1992; Oilier and 
Thompson, 1992; Sanchez et al., 1990) and DR9 which was recently shown to be 
associated with RA in Chile (GomAlez et al., 1992). Interestingly, 109d6 positive 
molecules contain 70-73:RRRA, which was shown in this study to form a cross 
reactive epitope for NFID.D10. Surprisingly, the NFIDD10 epitope was recreated 
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on 0~ 1•1101 carrying the substitution 70Q-+ R, but not on DRP 1•0401 by the same 
substitution. Thus, it seems that the consensus sequence OKRAA/ ORRAA/ 
RRRAA has the potential to generate a similar configuration but which may be 
dependent on DR context and peptide in the groove. 
The finding that these four antibodies bind to cells that express certain lll.A-
DR2 (DR15 or/and OR51) is intriguing since OR2 is not associated with RA 
(Nelson et al., 1992; Oilier and Thompson, 1992). Examination of the amino-acid 
sequence data however shows that a slight modification of the key sequence QKRAA 
or QRRAA is found on some DR.B chains from DR2 haplotypes. A possible key to 
understanding this apparent paradox of epitope presence but little or no RA 
association, is that each DR2 cell expresses both D~1· and DR,BS• chains. The fact 
that QARAA seems not to predispose to RA may be because the closely linked gene 
in each case encodes a similar "protective" sequence, the same as that of 
DRB1•0402. Thus the potentially susceptible DRJJ1•t5 molecules may be 
counterbalanced by 700 in the sequence (7~ 74:0RRAA) on DRP5•01; conversely, 
the potentially susceptible ORPS•02 on DR16 positive cells may be counterbalanced 
by the protective 700 in DRP1*16 molecules. Alternatively, the fact th~t DRpt•ts 
and DRPS•02 chains carry 671 and 71A, while the RA-associated molecules carry 
67L and 71K/R may also explain the lack of OR2 association with RA 
It is tanta1izing to note that the floors of DR15 molerules are more like those 
of DR4 molecules than are the other non-DR4 molerules (DRl, DR14 and DRlO) 
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that are implicated in RA Furthermore, both DR 15 and DR4 are associated with 
several rheumatic diseases that have an autoimmune component. For example, a 
shared sequence consisting of residues 26-33:FLDR YFY on the beta strands, together 
with 70Q and 73~ on both DR15 and DR4 f3 chains have been predicted to form 
a "shared epitope" that is associated with the production of Ul-70kd autoantibodies 
in mixed connective tissue disease (K.aneoka et al., 1992). In addition, the 
development of chronic arthritis in Lyme disease is associated with DR2 and the 
same DR4 alleles that predispose to RA (Steere et al., 1990). Recently, Goronzy et 
al (Weyand et a1., 1992) also showed giant cell arteritis is highly associated with 
DR/31 *0401 and 0404/8 as well as with other DR/3 chains that carry a shared 
sequence on the floor of the groove. 
The work presented in this study provides direct experimental evidence that 
the topography of shared structures, which map to the fJ chain alpha helix of the 
peptide binding site is influenced by spatially-related residues that are located on the 
floor of the groove. The information gained about the NFLD.D2 binding epitope, 
which most closely resembles the putative RA"shared epitope", suggests that the 
conformation of the RA "susceptibility epitope" will also vary on the implicated DR 
molecules. For example, both epitopes share the· pivotal glutamine at position 70 and 
require a contribution from leucine at 67, alanine at 74 and glycine at 86; however, 
they may differ regarding the involvement of position 71, at which a basic amino acid 
is considered important for the RA "susceptibility epitope." That the substitution of 
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glutamic acid (found in DR1, DR10 and DR14) for aspartic acid (DR4) at position 
28 significantly altered the NFID.D2 epitope, both in natural variants (DR1 & 
DR14) and the 0~1*0401 mutant, suggests that this position contributes to the RA 
susceptibility epitope. Because p28 is spatially proximate to p70-74:QKfRRAA, and 
because of its importance, along with p71 and fJ74 in a peptide-binding pocket 
(Racioppi et al., 1991; Coppin et al., 1993), a substitution at this position could have 
serious implications for the binding and/or orientation of an arthritogenic peptide(s) 
by these molecules; we envisage that either the substitution, itself, and/ or peptide 
binding could conformationally-alter this epitope. The fact, that non-DR4 RA-
associated molecules (28E positive) do not carry the same risk for susceptibility and 
disease severity in RA, supports this idea Furthermore, the aitical dependence of 
the NFLD.D2 epitope on peptide in the groove reinforces the straightforward idea 
that the RA susceptibility sequence may cause its effects by determining T cell 
reactions. Whether this is achieved by affecting the T cell repertoire through an 
influence on T cell selection in the thymus, or by a peripheral mechanism, is not yet 
clear. 
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CHAPTERS 
DIFFERENTIATION OF THE T-CELL DEFINED DR4Dw4 SPECIFICITY 
FROM OTHER DR4 SPECIFICITIES WITH MONOCWNAL ANTIBODIES1 
8.0 ABSTRACI' 
The T-cell defined DR4 subtypes, Dw4 and Dwl4, have not previously been 
discemable by annbodies. It is expected that this is due to the conservative nature 
of the substitutions (lysine to arginine at position 71 and glycine to valine at position 
86) and their involvement in peptide binding. Here we describe two mAbs, 
NFLD.Dll and NFLD.Dl2, having the precise specificities of alloreactive T cell 
clones in discriminating Dw4 from other DR4 and non-DR4 subtypes. NFID.Dll 
binds only to Dw4-positive cells while NFID.D12 cross-reacts with 25% of Dw14-
positive B cell lines. The data suggest that these antibodies are peptide-dependent 
as they exhibit both tissue and species specificity and do not bind to Dw4 molecules 
that are expressed on antigen processing mutants such as T2. Furthermore, binding 
of NFLD.Dll, but not of NFID.D12 could be partially reconstituted on mouse cell 
transfectants if they were first pulsed with a human cell extract. Although these 
antibodies have similar attributes to alloreactive T cell clones, it has not yet been 
resolved if their epitopes are the same. 
1 Manuscript Ia prepantioa 
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8.1 INTRODUCTION 
Nucleotide sequencing has revealed that the serologically-defined HIA-DR4 
specificity comprises several DRB 1 allelic variants (Stastny et al., 1992; Bodmer et 
al., 1992); eight of these have previously been defined by T -cell recognition methods. 
From analysis of the inferred amino acid sequence data (Barbetti et al., 1992; Marsh 
et al., 1992) and epitope mapping studies with anti-DR4 monoclonal antibodies 
(Alber et al, 1989; Maurer and Gorski, 1991; CHAPTER 6), it appears that structures 
which determine common serological epitopes depend on a combination of amino 
acid sequences in the first and second hypervariable regions of the p 1 domain and/ or 
limited polymorphism in the fJ2 domain. 
The T -cell defined subtypic determinants on DR4 molecules map to the alpha 
helix of the p chains and vary from each other by only one to four amino acids. For 
example, Dw4 differs from Dw14 by only two conservative amino acids, lysine (K) for 
arginine (R) at position 71 and glycine (G) for valine (V) at position 86. These 
positions are located on the alpha helix in such a way that their side chains are 
involved in peptide binding (Brown et al., 1993). Since these residues are also found 
on certain non-DR4 p chains such as those of DRI and DR14, to which a Dw4- or 
Dw14-specific T cell clone does not bind, it has been predicted that these 
determinants depend on critical residues on the alpha helix, the DR framework and 
probably peptides in the MHC grooves (Lechler et al., 1991; Benoist and Mathis, 
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1991; Obato et al., 1992; Sherman and Chattopadhyay, 1993). 
In view of these findings, it is perhaps not surprising that despite extensive 
searches during several HLA workshops, no reliable allo-antisera were identified that 
correlated precisely with the T-cell defined subtypes. However, serological splits of 
DR4 were proposed based on weak reactivity patterns that correlated with DR4 1J 
chains conwining either alanine (Dw4, Dw14, Dw15) or glutamic acid (Dw13 and 
DwKT) at position 74 (Williamson et al., 1984, 1992). It is of interest that position 
74 is also involved in peptide binding. 
The data presented in this paper demonstrate that two subtypic differences 
(Dw4 and Dw14) of DR4, previously only amenable toT-cell typing, were clearly 
identifiable by two monoclonal antibodies. Furthermore, evidence is presented that 
their binding is remarkably similar to that of T cells, since peptide in the MHC 
groove is required for formation and integrity of the epitopes. 
METHODS 
8.2.1 Cells 
Human B cell lines were obtained mainly through the 9th and lOth 
International Histocompatibility Workshop (lliW) and maintained in RPMI-1640 
supplemented with 10% fetal bovine serum (FBS), 1mM sodium pyruvate, penicillin 
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and streptomycin (all from Flow Laboratories, McLean, VA). The B cell line, SA VC 
(lOth lliW number, 9034), which is homozygous for DR4Dw4, DQ8, DP10, was used 
for immunization of mice. Peripheral blood B cells (B-PBL) were prepared from 
normal blood donors in a two-step procedure; Lymphoprep (Cedar lane Laboratories, 
Hornby, ON1) was first used to isolate the mononuclear cells, which were then 
depleted ofT cells using sheep red blood cells (Qualicum Scientific limited, Nepean, 
ONT) that had been treated with neuraminidase (Sigma, St. Louis, MO) as described 
previously (Boyum 1966; Weiner et al., 1973). Different types of transfectants were 
also used for some of these studies. Mouse L cell transfectants (DAP-3 DR4 and 
l243.8) which express Dw4 have been described previously (Inoko et al., 1992; 
Chapter 6). The mutant B-celllines, T2, an antigen processing mutant (Riberty and 
Cresswell, 1992) and BLS-1, an EBV -transformed B-cellline derived from a patient 
with Bare Lymphocyte Syndrome (Hume et al., 1989), were transfected with DRA 
and DRB*0401 genes; these two mutant cell lines were kindly donated by Dr. G. 
Nepom. 
8.2.2 Monodoaal Antibodies 
Two monoclonal antibodies NFLD.Dll and NFLD.D12 (lgM kappa isotypes) 
were derived from a Balb / c mouse that had been primed with affinity purified InA 
molecules, which were isolated from a cell lysate of SA VC using immunometallic 
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beads (Dynal Inc, Great Neck, NY). The complete methodology for the preparation 
of HIA-loaded beads has been described by Qi, 1993. Essentially a mAb 
(NFLD.M67) which detects a monomorphic determinant on HIA-DP molecules 
(Marshall et al., 1992) was coated on Dyna1 beads bearing goat anti-mouse IgG. 
These beads were then mixed with the cell lysate and the lll.A-loaded beads were 
removed with a magnet. The beads were injected subcutaneously in complete 
Freunds adjuvant ( CF A) in four sites of a Balb / c mouse and left for 3 months. Three 
days prior to splenectomy and fusion the mouse was boosted intravenously with 1 x 
107 SAVC cells. Fusion was carried out using SP2/0-Ag14 cells as previously 
described (Drover, 1986). Control mAbs included NFID.D1, which binds to an 
epitope on the /12 domain of all DR4 molecules {CHAPTER 6), 1243, which binds 
a monomorphic epitope on all DR molecules (Lampson and Levy, 1980), and isotype-
matched controls: IgM, D161-X711; IgG1, K040-L631; and IgG2a, A161-L64~ which 
were obtained from Southern Biotechnology Associates, Inc, Birmingham, AL 
8.2.3 Binding Assays 
A cellular enzyme-linked immunosorbent assay (CEUSA) was used for 
screening hybridoma supernatants and for specificity analysis as previously described 
(Drover and Marsha.ll, 1986). Indirect immunofluorescence with flow cytometry was 
used for some of the analyses using a standard method Briefly, cells were washed in 
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phosphate buffered saline cont;lining 0.1% FBS and 0.01% sodium azide; 
approximately, 2 x lOS cells were reacted with 25~-£1 primary antibody or irrelevant 
lg. washed and stained with either goat anti-mouse (GAM)-IgG or GAM-IgM, which 
were labelled with fluorescein isothiocyanate (FITC) or phycoerythin (PE). In some 
assays double staining was carried out using FITC-CD19 (Jackson lmmunoresearch 
Laboratories) to stain the B cells. Log fluorescence was read using a Becton 
Dickinson F ACS Star Plus. 
8.3 RESULTS 
8.3.1 Specificity Analysis of NFLD.Dll and NFLD.DU 
8.3.1A B Cell lines as targets 
Two antibodies, obtained from the same mouse, were selected in preliminary 
screening as they were reactive with the immunogen (SA VC) but were negative with 
several other B cell lines. Comparison of lllA antigens expressed on SA VC to those 
expressed on the negative BCL suggested that both mAbs recognized the DR4Dw4 
subtype. After cloning the hybridomas, the mAbs were further analyzed in CEUSA 
on a large panel ofnon-DR4 and DR4 positive BCL, which included the majority of 
those shown in Table 6.1, CHAPTER 6. Aside from one or two minor reactions (less 
than 20% binding), they were completely non-reactive with all non-DR4 expressing 
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BCL (data not shown). 
The reactivity pattern for the DR4, DRl and DR14 positive cells are shown 
in Figure 8.1. NFLD.Dll bound strongly to all six BCL that express the Dw4 subtype 
(DRB1*0401) of DR4. NFLD.D12 gave an almost identical reactivity pattern to 
NFLD.Dll, but it also reacted significantly with one of the four lines expressing the 
Dw14 (DRB1*0404) subtype of DR4. 
Minor reactions were also noted with the remaining two Dwl4 positive cells 
as well as with a DwlO positive cell. Neither NFLD.Dll nor NFLD.D12 bound to 
cells expressing DRB1*0101, 0102, and 1402, which have previously been shown to 
encode epitopes shared with DRJ'l* 0401, 0404, and 0405 chains ( CHAPTER 7). 
These data strongly suggested that NFLD.Dll could differentiate Dw4 from all other 
DR4 specificities, whereas NFLD.D12 cross reacted with some of the Dw14 positive 
cells. These specificities were subsequently confirmed by complement-dependent 
cytotoxicity testing on a panel of 133 BCL including the following DR4 positive 
variants: nine Dw4 (B1*0401) lines, five DwlO {Bl*0402) lines, four Dw13 
{Bl*0403/7) lines, seven Dw14 (B1*0404} lines, five Dw15 (B1*0405} lines, and three 
DwKT2 {Bl*0406) lines by S. Marsh at the ICRF in London (personal 
communication). 
178 
BCL DRHI • 
' 
9034 0401 
9029 0401 
9031 0401 
9025 0401 
I -- I I 
- I I I 
- f- I I I 
- -
! I I ! 
9027 0401 -r-- I I 
9032 0401 - f- I .... ....... ·I . . . - .... 
9028 0404 - r--
.. . . 
:I .. . . . . 
---:"' 
9098 0404 - >--
,..:....:.. 
LS40 0404 - - l 
BIN40 0404 - -
HAS15 0405 
9026 0402 -r-- [] 
TS10 0402 -I- I 1 
-- I 
: 
9030 0403 
KT17 0406 
-- b j --
--
9003 0101 -I- [ I 
9002 0102 - r--
9064 1402 -r-- I I I I I I 
I I I I I I 
200 150 100 50 0 50 100 150 200 
% NFLD. D11 Binding % NFLD.D12 Binding 
Figure 8.1 NFLD.Dll (left panel) and NFLD.D12 (right panel) binding to BCL 
expressing either DR4, DRl or DR14 alleles. Binding was measured in CEUSA and 
the % binding was determined by: 
[Optical density (OD) of test] - [OD of background] 
X 100% 
[OD of 1243 positive control]- [OD of background] 
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FJaure 8.l FACS analysis of double-stained peripheral blood B cells. Cells were stained with FITC-
labelled anti-CD-19 (X axis) and anti-Dw4 mAbs (NFI.D.Dll and NFLD.D12) or irrelevant mouse IgM, 
which were detected with PE-labelled GAM-IgM (Y uis). The panels on the left show Dw4-positive 
cells [ID: DR4 (DRBt•040t), 7]; the panel on the rigbt show Dw4-negative c:ells [JG:DR13,7]. 
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8.3.18 Peripheral blood B cells and mouse cell transfectants as targets 
NFID.Dll and NFlDD12 were also analyzed by flow cytometry on a panel 
of 34 peripheral blood B cells (B-PBL). The pattern shown for NFlD.Dll and 
NFlD.D12 binding in Figure 8.2 is representative of the data for all Dw4-positive 
and Dw4-negative B-PBL Neither mAb reacted with any of the 14 non-DR4 positive 
cells, while NFI.D.Dll reacted with all U Dw4-positive ce~ but not with the 8 
samples that expressed the DR4 subtypes, Dw13, Dw14 and DwKT2; no cell with 
DwlO was available for testing. 
NFLD.Dll binding to Dw4-positive cells was between 21% to 60% of the OR-
specific positive control {1243) or the B-cell marker CD19. However, NFID.D12 
binding was usually less than 5% of the positive control. 
Flow cytometry profiles of NFlD.Dll binding to normal B-PBL and B cells 
from a chronic lymphatic leukaemic patient (B-CIL) revealed a heterogenous pattern 
compared to the relatively homogeneous and strong reactivity observed with SA VC 
(Figure 8.3). It also showed that NFlD.D12 binds slightly better to B-ClL than to 
the normal B-PBL, but its reactivity is very weak and heterogeneous compared to 
that with SA VC. 
The mAbs were also analyzed on mouse cell transfectants (Figure 8.3). It can 
be seen that the Dw4-positive transfectant (Dap-3 DR4) strongly bound the DR4-
specific mAb (NFIDDl), but was completely negative with NFlD.Dll and 
NFlDD12. 
181 
U3:279292B140,FL2-H,MSigM PE Rgn 
A SAUC D Dw4 TRANSFECTANT 
IgG Control IgG Control 
U3:300992883B,FL2-H,FL2-Height U3:228592Ae09,FL2-H,MSigM PE 
8 8-PBL DR4 1 DR7 c 8-CLL DR4 1 DR15 
IgG Control IgG Control 
Figure 8.3 mAb binding to Dw4 molecules expressed on different cell lineages. 
Binding to (A) SA VC, a B<1; (B) B-PBL; (C) B-CIL; (D) Dw4-positive mouse cell 
transfectant was detected using PE-labelled GAM-IgG + lgM., 
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The same results were obtained for 1243.4, which is another Dw4-expressing 
transfectant (data not shown). This failure of both mAbs to bind transfectants and 
of NFLDD12 to bind B-PBL is intriguing since the Dw4 genes in both cases are the 
same. Possible causes for these epitope differences are that these cell types include 
the presence of different peptides in the peptide binding grooves, differing assembly 
of the molecules in each case or differing glycosylation. 
8.3.2 Contribution of Peptide to NFLD.Dll and NFLD.D12 Binding Epitopes 
T-cell discrimination of the Dw4 and Dw14 subtypes is believed to be due to 
recognition of determinants in which the critical amino acids are peptide-binding 
residues at positions 71 and 86. It was therefore hypothesized that the negative 
NFLD.Dll and NFLD.D12 binding to mouse cells expressing Dw4 molecules might 
be due to differences between mouse and human peptide bound to the Dw4 grooves. 
To test this idea experiments were done to see if NFLD.Dll and NFLDD12 binding 
to Dw4-expressing transfectants could be reconstituted by pulsing them with a crude 
lysate from either Dw4 positive cells (SA VC) or DR4 negative cells (KAS116, DRl 
and PLH, DR7). These cells were disrupted by freeze-thawing, centrifuged and the 
supernatant collected. 
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Figure 8.4 Reconstjtution of NFLD.Dll binding epitope on mouse cell transfectants. 
Three different mouse cell transfectants, expressing DRB1*0401 (Dw4), 0101 (Dw1) 
and 0701 (Dw7) were tested for binding NFLD.Dll after exposure either to culture 
medi~ or to lysates from homozygous BCL: SAVC, DR4Dw4; KAS116, DRlDwl; 
PLH, DR7Dw7. The NFLD.Dll binding epitope was partially restored on the 
DRB1*0401-expressing transfectant with each of the lysates,. but the other non-Dw4 
transfectants were not affected by exposure to these Iysates. 
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Supernatants, containing crude membranes or the plain culture medi~ were used 
to pulse Dw4-positive and Dw4-negative transfectants for 18 hr, after which time they 
were tested for their capacity to bind NFID.Dll and NFID.Dl2. Data from one 
experiment, presented in Fig. 8.4, show that binding of NFID.Dll was partially 
restored by this procedure. This phenomenon was not observed for another 
transfectant (1243.4) which apresses the same DRB gene (data not shown). This is 
difficult to interpret since both transfectants are derived from the same L-cell 
fibroblast line (DAP.3) and bind DR4 mAbs similarly; however, morphologically, the 
two cells appear quite different. 
This experiment was repeated sometime later with a different batch of cell 
lysate; although there was a definite increase in binding to DAP .3 DR4 (P1*0401) 
pulsed with the lysate, reconstitution was not as marked as in the first experiment. 
It is notable that NFID.DU binding was not reconstituted in either experiment. 
8.3.3 DR4Dw4-specific mAbs do not Bind DR4Dw4 Molecules Expressed on 
Mutant B Cell lines 
To further explore the idea that these antibody-binding epitopes are 
dependent on MHC-peptide romplexes, binding studies (FACS and CEUSA) were 
performed using two mutant human B cell transfectants expressing Dw4, namely, T2-
Dw4 and BI..S-Dw4 (Figure 8.5). The T2 mutant has been shown previously to be 
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defective in peptide loading of lllA molecules and to express conformationally-
altered class ll molecules (Sette et al., 1992). It was therefore hypothesized that if 
these m.Abs were peptide-dependent, they would not bind to T2-Dw4 but that they 
might bind to BLS-Dw4 transfectant. This latter cell line does not express its 
endogenous class ll genes due to a defect in the transcription of its structural genes 
(Glimcher and Kara, 1992). 
Data from a representative experiment using CEUSA to measure binding is 
shown in Figure 8.5. As predicte~ neither NFLD.D11 nor NFLD.D12 reacted with 
T2-Dw4, while both reacted strongly with the normal Dw4-expressing BCL (Wf51). 
Surprisingly neither mAb reacted with Bl.S-Dw4. 
Since the relative binding of the DR4-specific mAb (NFLD.D1) to both these 
mutants was greater than to wrs1, negative binding to the mutants cannot be 
attributed to inadequate expression of Dw4 molecules. The negative binding of 
NFLDD11 and NFLD.D12 to BI..S-Dw4 transfectants was at that time puzzling since 
it suggested that Dw4 molecules expressed on the BLS transfectants might also be 
defective in peptide loading. This has subsequently been shown to be the case as 
BLS transfectants are unable to stimulate antigen-specific T-cell clones using intact 
antigen, but like T2, they can stimulate effectively when exposed to the appropriate 
peptide (S Kovats, personal communication). Thus, these data further support the 
concept that Dw4-specific antibodies recognize structures that are similar to the 
determinants that are recognized by alloreactive T-cells. 
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Figure 8.5 mAb binding to Dw4-positive BCL mutants (f2-Dw4 and Bl..S-Dw4) and 
on a normal BCL (WT51). Binding was measured in CEI.JSA and is expressed as 
a percent of the DR posjtive control, 1..243. as descnbed for Figure 8.1. 
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8.4 DISCUSSION 
The data presented in this paper clearly demonstrate for the first time, that 
antibody can differentiate Dw4 from all other DR4 subtypes, including the highly 
related Dw14 subtype, with the same exquisite specificity as an alloreactive T cell. 
The rareness of this finding can be attributed to the conservative nature and location 
of the two amino acids that distinguish Dw4 from Dw14. For example, the key 
polymorphic difference between the two subtypes is an arginine substitution for lysine 
at position 71 in both dimorphic variants of Dw14 (Bl*0404 and 0408); the latter 
variant of Dw14 (B1*0408) is more like Dw4 in that it also has glycine instead of 
valine at position 86. Furthermore, there is substantial evidence implicating both 
positions 71 and 86 in peptide binding pockets (Coppin et al., 1993; Demotz et al., 
1993; Brown et al., 1993 ). Thus, not only are the critical amino acids conservative 
and equally charged, but their side chains are buried in peptide binding pockets so 
that they are inaccessible for TCR or antibody binding. 
What then is the nature of the allo-determinant that distinguishes Dw4 and 
is it similar to the antibody-binding epitope (s) that have been identified in this 
study? The phenomenon of alloreactivity and the nature of the allo-detenninants 
have been extensively studied and debated. It is now generally accepted that 
alloreactive T cells bind complexes of allo-MHC plus a peptide, which may be 
cellular- or serum-derived This theory is based on considerable experimental 
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evidence demonstrating peptide-dependency of alloreactive T cell clones, while there 
is no clear evidence that empty HLA molecules stimulate alloreactive T -cells 
(reviewed in Sherman and Chattopadhyay, 1993). Whether or not the bound peptide 
is part of the allo-determinant or whether it induces a conformational change in the 
critical part of the alpha helix to which the TCR binds, has not been completely 
elucidated. For example, some alloreactive T cell clones do not exhibit peptide 
specificity, since they have been shown to respond to otherwise empty MHC 
molecules that have been filled with different synthetic peptides. 
It is beyond the scope of the data presented in this study to answer the 
question regarding the composition of the antibody binding epitopes. Unfortunately, 
an informative cell expressing B1*0408 (86G) was unavailable to test the importance 
of 86G to the integrity of these epitopes. However, since 86G or 86V is found on all 
DR molecules and since 71K is also found on the 1J chains of DR3 and some DR52 
molecules, none of which bind either NFLDDll or NFLDD12, it is likely that other 
residues and/ or peptide contribute to the formation of these allele specific epitopes. 
The reactivities of the two antibodies are analogous to the type of reactivity 
reported for alloreactive T cells. The best example of this is the restoration of 
NFLD.D11 binding, but not of NFLD.D12 binding to Dw4-expressing mouse cells 
when these cells are pulsed with crude membranes. This finding is reminiscent of an 
experiment by Heath et al., (1991) in which a cyanogen-bromide, cleaved murine-
derived peptide was used to restore the cytolytic activity of an alloreactive T -cell 
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clone for H-~ molecules that were expressed on a human cell. Furthermore, the 
failure of both mAbs to bind Dw4 molecules expressed on antigen processing mutants 
is similar to the failure of alloreactive T cells to bind empty HLA molecules. For 
example, it is well-known that transfected class n molecules on T2 are 
conformationally unstable and are largely occupied by a peptide derived from the 
Invariant chain (Sette et al., 1993); however, they can efficiently present exogenously 
added peptide to the appropriate antigen-specific T cells. It will therefore be 
informative to pulse T2-Dw4 and BLS-Dw4 with B-cell derived and other peptides 
to see if the antibody binding epitopes can be restored 
It is interesting to speculate on the derivation of the peptide that purportedly 
contributes to these antibody binding epitopes. The fact that the NFID.Dll binding 
epitope was restored by the human cell lysate and not by the culture medium that 
was used for growing the cells suggest that the involved peptide( s) is endogenously-
derived. The failure of NFID.D12 to be restored by this lysate could be due to 
inadequate processing of the human proteins by the mouse fibroblast. It is also of 
interest that the NFID.DU epitope was inadequately expressed on peripheral B 
cells, which suggests that the appropriate peptide may be supplied by EBV or 
possibly by a blast-related antigen. Experiments are planned to test these ideas. 
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CHAPTER9 
GENERAL SUMMARY AND DISCUSSION 
9.0 PREFACE 
The work described in this thesis was essentially done in four phases: i) an 
attempt to make transfectants expressing DR4 molecules using genomic DNA; ii) 
preparation, selection and cloning of hybridomas secreting mAbs that are specific for 
DR4 molecules; iii) complete specificity analysis of the anti-DR4 mAbs using various 
types of cells; iv) epitope mapping studies using transfectants that express mutated 
DR molecules. Most of the experimental details and results have been summarized 
and discussed in each of five manuscripts (Chapters 4-8) that correlate approximately 
with the different phases mentioned above. In the ensuing sections I will focus on the 
background under which certain aspects of the research were carried out and 
highlight some unanticipated and intriguing findings that have emerged from this 
work. I will also discuss the significance of the information gained from the epitope 
mapping studies to furthering our knowledge about a putative "shared epitope" that 
is carried by the various DR molecules that are associated with Rheumatoid 
Arthritis. 
191 
9.1 CHOICE OF IMMUNOGEN FOR MAKING DR4 MONOCWNAL 
ANTIBODIES 
When this work was initiated there were no known monoclonal antibodies 
(mAbs) that exclusively recognized either the serologically-defined DR4 specificity, 
the putative serological splits (DR4.1, 4.2, and 4.3), or any of the biochemical or T-
cell defined subtypes. One antibody, NFID.M1, which was shown to be strongly 
reactive with DR4 molecules, also reacted weakly with some DR52 positive cells 
(Drover et al., 1986). In addition a few mAbs were described that recognize some of 
the DR4 subtypes, but crossreacted with DRl and/or DR9 (reviewed in Bodmer et 
al., 1984; Nispersos et al., 1987). These partially resembled the MCl specificity, which 
is associated with DRl and the DR4 subtypes (Dw4, Dw14 and Dw15) and which was 
shown to confer a higher degree of risk for the development of RA than either DR4 
or DR1 alone (Duquesnoy, 1984) 
It was clear from previous experience and various reports that the vast 
majority of m.Abs generated using B cells as immunogens were against non-lll.A 
molecules or monomorphic lll..A determinants (reviewed in Drover, MSc thesis, 
1986). Thus, while the probability of making mAbs to the "shared epitope" 
associated with RA was viewed optimistically, the challenge in producing allele-
specific monoclonal antibodies was fully recognized. The fact that Heyes et al. (1986) 
had successfully used DP-expressing transfectants to make a mAb to a polymorphic 
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determinant on DP molecules, which were normally typed by primed-T lymphocytes, 
was particularly encouraging. It was therefore anticipated that the likelihood of 
making DR4 allele-specific mAbs would be enormously increased, if DR4-expressing 
transfectants were available for immunization. 
9.2 EFFORTS TO CREATE DR4-EXPRESSING TRANSFECTANTS 
Since no DR4-expressing transfectants or cloned DR4 genes were immediately 
available, an attempt was made to create transfectants using genomic DNA The 
impetus to cany out these experiments came from the work of Kavathas and 
Herzenberg (1983, 1986), who had successfully obtained HlA class 1-expressing 
transfectants by co-transfecting thymidine kinase (tk) negative L cells with undoned 
genomic DNA and the chicken tk gene. Based on their calculation that each 
transformant contained about 1500 Kb of DNA, which is larger than the entire class 
ll region, it was predicted that a class ll-expressing transfectant could be made in a 
similar manner. 
Subsequent experiments produced transfectants that expressed either IDA-A 
or lll.A-B genes, but failed to yield stable transfectants that expressed DR4 or any 
other class ll genes. However, the simplicity of the methods that were developed for 
selecting and isolating these transfectants (immunomagnetism and replicate plating 
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combined with CEUSA, described in CHAPTER 4) were considered a notable 
contribution to this field In retrospect, it is perhaps not surprising that stable 
expression of class n genes was not achieved. Most of the DNA that is taken up 
during transfection is likely degraded and the amount of DNA that encompasses the 
region encoding a DR molerule is significantly larger than that which encodes a class 
I heavy chain Furthermore, class ll expression requires that both DRA and DRB 
genes be properly integrated into the mouse chromatin structure, while class I 
expression requires the integration of a single class I gene. This is because the 
resulting heavy chain is able to pair with the endogenous mouse /32 microglobulin. 
Experiments that were planned to use cloned genes and to investigate whether 
a mouse B cell lymphoma {A20), which constitutively expresses class II, would make 
a better recipient for class n expression, were terminated because a set of relevant 
DR -expressing transfectants became available through the generosity of Raffi Sekaly 
and Robert Karr. 
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9.3 TRANSFECI'ANTS VERSUS B CELLS AS IMMUNOGENS FOR MAKING 
ALLELE-SPECIFIC MONOCLONAL ANTIBODIES 
Early in the second phase of this study it became apparent that immunization 
with DR4-expressing mouse cells was not a panacea for obtaining allele-specific 
mAbs. The work described in CHAPTER S underscores some of the difficulties that 
were encountered. For example, it was found that most of the antibodies that were 
produced to the transfectants were either irrelevant or L-cell specific, which 
suggested that the L-cells carried tumour-associated antigens and probably bound 
proteins or peptides that were derived from the culture medium. In the final analysis 
twenty-nine fusions yielded 15,000 hybrids, of which approximately seventy hybrids, 
or one in every 200, secreted an antibody to a polymorphic determinant on InA-DR 
molecules. Although most of these mAbs bound to polymorphic determinants that 
were found on a large variety of different DR molecules, several proved to have 
interesting and/ or novel specificities. 
To recapitulate, NFID.D1 recognized a common epitope on all DR4 
molecules and no others; NFIDD7 bound an epitope that is present on all DR4, 
DR2 and DR52 molecules; several (NFID.D2, NFLD.D3, NFID.D4, NFLD.D8, 
NFLD.D9 and NF1D.D10) bound some of the DR4 subtypes as well as some DR 
molecules that carried homologous sequences at positions 67-86 on the alpha helix 
of the DR fJ chains. One of these (NFLD.D2) was especially exciting because its 
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binding epitope correlated with that of the "shared epitope" that had been predicted 
to be implicated in the development of Rheumatoid arthritis (Gregersen et al., 1987). 
Paradoxically, after having made such a huge effort to obtain anti-DR4Dw4 
mAbs from fusions in which transfectants were used as immunogens, the most 
interesting mAbs came from a fusion in which the mouse was immunized with B 
cells. These two mAbs (NFLDD11 and NFLDD12, described in CHAFfER 8), 
which have the ability to differentiate the Dw4 subtype from all other subtypes, were 
created through serendipity. The mouse from which they were derived had first been 
immunized with DP molecules, but was boosted with a Dw4-positive human BCL 
prior to fusion. Dw4 molecules could potentially have been present in the primary 
immunization. if the DP monomorphic mAb (NFID.M67), which was used to isolate 
the DP molecules, binds an epitope on the DP a chain; in this way mixed molecules 
(eg. DPa DR.p1*0401) as well as normal DP molecules may have been isolated. 
However, it is more likely that these Dw4-specific mAbs mAbs, which are IgM, 
resulted from the IV boost that acted as a primary immunization for the mouse with 
respect to Dw4 molecules. This idea is supported by recent experiments, in which 
fusions done after primary immunizations, produced an array of interesting anti-IDA 
mAbs (unpublished data). Thus, the work has come full circle as experiments are 
now in progress to produce anti-Dw14 mAbs using a similar immunization scheme. 
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9.4 NFW.D MABS: COMPARISON TO 01HER MONOCWNAL ANTIBODIES 
As previously mentioned, the number of mAbs available that identified 
polymorphic determinants, particularly those restricted to a particular serotype or 
subtype, were disappointingly small. It was therefore of some interest to see if mAbs 
produced during the course of this wor~ particularly those made using transfectants, 
had novel specificities. Since this work coincided with the 11th rnw, the opportunity 
was provided to compare these specificities with consensus specificities for other 
DR4-specific mAbs and alloantisera (Juji et al., 1992; Marsh et al; 1992) or 
antibodies that have been otherwise described. 
The DR4-specific mAb, NFIDD1, was found to have an identical reactivity 
pattern to another mAb, GS359-13F10 (Alber et al., 1989); however, it was found to 
map to a different region of the second domain of DRp*04 chains (Maurer and 
Gorski, 1990 and CHAPTER 6). A similar mAb (AMO 801, 5G616E10) was 
analyzed in the serology component of the 1991 rnw, but it was found to have extra 
reactivity with DR16-positive B cells. The pan-DR4 specific mAb, NFID.D7, which 
also binds DR52 and DR2 molecules is somewhat similar to OU 823. A subtle 
difference, however, is that OU 823 but not NFID.D7, reacts with DRS positive cells 
(Juji et aL, 1992). Whether or not they map to the same region of DR4 is not known 
as there is no mapping data available for OU 823 .. 
Several mAbs including N1 (BRS 801), PLM 14 (MAZ 801), AC1.59 andJSI 
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appear similar to NFLD.DlO, since they all bind DR4 molecules with the exception 
of the DwlO subtype and also various non-DR4 subtypes. For example, N1, a human 
mAb originally described by Yendle et al., (1990), appeared to be identical to 
NFLD.DlO, since both bind to B cell lines that express DR1, DR2, DR14, DR9 and 
DR10. However, analysis of Nl in the 11th lliW showed that it was essentially 
negative with DR2-positive peripheral blood B cells; in contrast NFID.DlO binds 
strongly to DR2-positive cells BCL, B-PBL and transfectants. The other mAbs also 
had fine differences in their specificities; for example, MAE 801 (PLM14) does not 
bind DR2-positive ce11s (Juji et al., 1992); AC1.59 does not bind DR2, but crossreacts 
with some DR8 and DRS-positive cells (Richardi et al., 1984); JSI does not bind 
DR9, DR10 or DR2, but binds DR3 and DR52 (Sachs et al., 1986). 
Each of the other mAbs (NFLD.D27 NFLD.D3, and NFLD.D8) has subtle 
differences from each other, but clearer differences from NFLD.D10 or any of the 
mAbs described above. In particular, they react either weakly or negatively with the 
DR4 subtypes Dw13 and DwKT2. NFLD.D2 closely resembles the MC1 specificity 
(Duquesnoy, et al., 1984) and the mAb, CCCL 20 (Dejelo et al., 1986), but again 
each has a somewhat different reactivity pattern_ For example, NFLD.D2 additionally 
reacts with a DR51 subset of molecules encoded by DRB5*02 genes, while CC CL 
20 binds poorly to Dw4 subtypes. 
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The singularity of NFLDD11 and NFLDD1~ which were made using BCL 
as immunogens, has previously been addressed (CHAPTER 8). As far as can be 
ascertained from a review of the literature, NFIDD11 is the only known antibody 
which can differentiate Dw4 from closely related DR4 and all non-DR4 molecules, 
while NFLDD12 is similar, but crossreacts with Dw14. The only other mAb reported 
to recognize subtypic differences in the DR4 specificity is 6ED, which was made 
using a Dw13 synthetic peptide (DRB1:66-81) (Muller et aL, 1992). This mAb 
preferentially binds Dw13 and DwKT subtypes but was found to give inconsistent 
reactions with Dw4 and DR2 positive cells. 
9.5 LOCATION AND CO:MPOSffiON OF POLYMORPIDC ANTIBODY-
BINDING EPITOPES ON DR4 MOLECULES 
The availability of completely HLA-genotyped BCL (Yang et al, 1989; Kimura 
et al., 1992) and transfectants expressing single InA specificities (Inoko et aL, 1992) 
combined with sequence data for all the known class ll genes (Marsh and Bodmer, 
1992) have made it possible to assign exact specificities to mAbs. Although the 
epitopes for some mAbs can be correctly predicted from such information, precise 
epitope mapping is ideally done using cells that express appropriately-mutated genes. 
Through the generosity of Robert Karr, a set of transfectants that expressed mutated 
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DR genes was made available for detailed mapping studies. Thus, mAb binding 
epitopes were identified on the second domain, the alpha helix of the peptide binding 
site and to the first and second hypervariable regions of the DR4 fJ chain. For some 
of these epitopes, peptide-binding residues in the groove were involved (see section 
9.6). 
9.5.1 Epitopes on the Second Domain 
The epitope for NFLD.D1, which is exclusively found on DR4 molecules did 
not map to the DR4-specific residue {DRB1:96:Y), which was previously shown to 
be critical for the DR4-exclusive mAb, GS359-13F10 (Maurer and Gorski, 1991). 
However, it did map to the {J2 domain, which appears to contain another allele-
specific residue, B1:180:L (Andersson et al., 1987; Gorski, 1990; Marsh and Bodmer, 
1992). Studies are currently being done in Robert Karr • s laboratory to test whether 
this position is critical to the formation of the NFLD.Dl epitope. 
It is interesting that the only DR4-exclusive mAbs, NFLD.Dl and GS59-
13F10, thus far identified, map to different regions of the second domain Moreover, 
a third mAb, NFLD.M1, which is essentially DR4-specific with B-PBL (unpublished 
data), but is weakly reactive with DR52 positive BCL and transfectants, also binds 
an epitope in the {J2 domain {Alber et al., 1989). We previously suggested that 
DRB:140T is critical for this epitope (Alber et al., 1989), but during this study, it was 
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shown that NFID.Ml bound all three different DR52 subtypes (FigUre 6.1), of which 
only one subtype carries 140:T. Thus, although the location of the NFID.M1 epitope 
is known, the residues which contribute to its formation are not immediately 
apparent and will require further studies. 
It may be of some significance that so few amino acids dispersed over the 
second domain constitute several different epitopes. There is some evidence to 
suggest that these amino acid differences can also induce structural alterations in T-
cell defined determinants, which are clustered around the peptide binding site. For 
example, the only difference between the two T-cell defined subtypes of DR7 (Dw7 
and DB1) is an arginine replacement for a glutamine at position 107. Furthermore, 
in the murine class I system, it has been shown that mutations in the a 3 domain of 
a class I molecule (equivalent to /3J altered the binding of alloreactive T cells and 
antibody (Potter et al., 1987; Maziarz et al., 1988). Since the accessory molerules, 
CDS and CD4, interact with the class I a 3 domain and class ll 132 respectively, one 
might speculate that the polymorphisms in these domains may somehow affect the 
interaction of MHC and these accessory molecules. 
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9.5.2 Epitopes that Map to Sequences on the Floor or the Peptide Binding Site 
There was no evidence from these mapping experiments to suggest that the 
DR4 allele-exclusive residues 13H and 33H, which are located on the floor of the 
peptide binding groove (Brown et al, 1993), were involved in the DR4-exclusive mAb 
epitopes described above. The side chains of these residues are buried by bound 
peptide so that they are not available for direct interaction with antibody. However, 
sequences on the floor were shown to be important for the NFLD.D7 binding 
epitope, which was lost when the first and second hypervariable regions of DRB1*04 
were replaced with those from DRB1*07 (FigUre 6.3). Subsequent analysis of 
NFLD.D7 using DRB 1*0401 mutants, which expressed single amino acid substitutions 
in these regions (9E-W, llV-G, 13H-Y, 280-E and 30Y-L), showed no altered 
binding to any of these mutants (data not shown). It is suggested that polymorphic 
residues on the floor of the groove may induce conformational changes· in remote 
structural determinants or perhaps, they induce conformational changes through the 
family of peptides that they bind (see section 9.6). 
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9.5.3 Epitopes on the Alpha Helix of the Peptide Binding Site 
Most antibodies that bind all DR4 subtypes with the exclusion of Dw10, 
usnaJJy bind other DR molecules that have glutamine (Q) at position fJ70. As 
predicted this residue was shown to be critical for NFIDD2, NFLD.D3, NFID.D8 
and NFIDD10 binding (CHAPTER 7); it has also been shown to be critical for the 
binding of similar antibodies, CCCL 20 (Hiriawa et al. 1991) and N1 (Barber et al, 
1991 ). However, none of these mAbs bind all DRB:700 positive molecules, which 
suggests that many diverse epitopes are generated from a common sequence in which 
position 70 is pivotal. Furthermore subtle epitope variations result from differences 
in peptide binding residues in these MHC grooves. The information gained from 
epitope mapping with the DR mutants and natural variants indicate that the 
footprints of these mAb-binding epitopes on DRB*0401 are composed as follows: 
NFLD.D2, DRB1*67-74:LLEQKRRAA/86:G/28:D; NFLD.D3,B1:70-
74:0KRAA/28:D/30Y; NFLD.D8, B1: 67-74:LLEQKRAA; NFLD.D10, B1:70-
73:QKRA It is important to note that these residues may not be all inclusive; for 
example, the pattern of binding to non-DR4 wild type molecules {Table 7.1) suggest 
that other residues on the floor, (for example, those at positions 26, 31, 32 and 33) 
may modify the epitopes of NFLD.D2, NFIDD3 and NFLDD8. However, the 
appropriate mutants were not available to test this hypothesis. 
The epitopes for NFLDD11 and NFLD.D12 are predicted to involve 
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ORB 1:71K and 86G, since these are the only two residues that differentiate the Dw4 
subtype from Dw14. However, as previously noted, it is unlikely that these antibodies 
directly contact these residues since their side chains are not solvent exposed (Brown 
et al., 1993). Furthermore, these residues are also found on other DR molecules, to 
which NFID.Dll and NFID.Dl2 do not bind As discussed below, it is predicted 
that the Dw4-specific mAbs bind either a composite of residues and peptide or a 
conformational determinant that is extremely sensitive to peptide in the grOOYe. 
9.6 PEPTIDE-DEPENDENT, ANTIBODY-BINDING EPITOPES ON DR 
MOLECULES 
The fact that the reactivity patterns for several mAbs differed according to the 
cell type on which the DR molecules were expressed was intriguing. Two mAbs 
(NFIDDl and NFID.D7) that were made using transfectants as immunogens 
generally bound well to transfectants, but unexpectedly, most of the other mAbs, 
reacted better with BCL than with the relevant transfectants. Antibodies which 
mapped to the putative RA susceptibility sequence were particularly sensitive to 
whether the DR molecules were expressed on mouse or human cells. The most 
conspicuous example was NFID.D2, which consistently reacted strongly with Dw16-
positive BCL, but negatively with Dw16-positive transfectants; (Figure 7.1 and 
unpublished data). NFID.D2 also reacted weakly with Dw13, KT, and DR15-
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positive ~ but not with the relevant transfectants or normal B-PBL Similarly, 
NFID.D3 and NFID.D8 also showed some differential binding to human and mouse 
cells expressing these DR moleailes., but importantly, they bound Dw16-positive BCL 
and transfectants equivalently. 
In considering the reasons for this phenomenon, it was duly noted that other 
In..A antibodies were reported to have a broader reactivity pattern with :sa.. than 
they do with normal peripheral blood B cells or mouse cell transfectants that express 
the same specificities (Stinchcombe et al., 1985; Yendle et al., 1990). It is possible 
that the higher density of lllA molecules on BCL (Trucco et al., 1980) or low 
antibody affinity for a partirular DR specificity may explain some, but not all 
examples of differential binding. As previously discussed in CHAPTERS 6 AND 7, 
the creation of artifacts due to differences in antibody affinity or expression of DR 
molecules should have been eliminated or reduced by expressing binding of the test 
mAbs relative to a DR positive control mAb. 
The explanation that is favoured and for which there is supporting evidence, 
is that differences in peptides that bind to the grooves of these DR molecule affect 
the conformation of the antibody-binding epitopes. For example, the epitopes for 
these mAbs require a contribution from amino acids (p28, 74 and 86) that are 
involved in different peptide binding pockets in the MHC groove (Brown et al., 
1993). Importantly, the same epitopes were profoundly altered on Dw4 molecules 
expressed on antigen processing mutants. The MHC-grooves of molecules expressed 
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on these cells are either empty or obscured by a large invariant chain fragment that 
has not disassociated (Riberty and Cresswell, 1992; Sette et al., 1993). Such molecules 
have previously been shown to be non-reactive with certain antibodies to polymorphic 
determinants (Mellins et al., 1991). Interestingly, one of the first antigen-processing 
mutants identified was produced by immunoselection with a peptide-sensitive DR3-
specific mAb (Mellins et al., 1990, 1991; Sette et aL,1993). 
Sequencing of peptides eluted from class ll grooves has revealed that the 
majority of these peptides are endogenously derived (Rudensky et al., 1991; Chicz et 
al, 1993). Therefore it is likely that the array of peptides that bind to the MHC 
grooves of molecules expressed on EBV -transformed B cells, normal B cells and 
mouse cell transfectants will be different in composition, size and orientation. Such 
differences have the potential to alter conformational determinants on the alpha 
helix, as was observed for the antibody-binding epitopes for which DRB1:70:Q was 
critical. Such antibodies are often referred to as "peptide-sensitive". 
At the extreme end of this spectrum of peptide-sensitive antibodies are the 
Dw4-specific mAbs (NFLD.Dll and NFLD.D12) which absolutely require particular 
peptides or subsets of peptides in the groove for binding. Since they both exhibit no 
binding to Dw4-positive mouse cells but differ in their binding to B-PB4 it seems 
unlikely that the required peptides are derived from culture medium. The data 
presented in (CHAPTER 8) suggests that the peptides are endogenously-derived; 
furthermore, the lack of NFLDD12 binding to normal B-PBL suggests that the 
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peptide involved in this epitope may be EBV ~erived. Further investigation is 
required and experiments are planned to elucidate the nature of the peptides 
involved in these epitopes (See section 9.9) 
9.7 SIMILAIUTIES BE'IWEEN THE SPECIFICITIES OF ALLOREACTIVE T 
CELLS AND ALLELE-SPECIFIC ANTIBODIES 
The generally accepted paradigm for antibody recognition of allo-MHC is that 
an antibody binds to conformational determinants and that its affinity is such that it 
is relatively unaffected by subtle changes to the conformation that may be brought 
about by the array of different peptides that bind to the groove. In contrast, 
alloreactive T cells are believed to bind either a composite of peptide and MHC or 
are exquisitely sensitive to peptide-induced alteration of critical determinants on the 
alpha helix (Sherman et al., 1993; Ramansee et al., 1993). Thus, to suggest that 
certain antibodies potentially recognize all~eterminants in the same way as T cells 
may seem at first like a renunciation of the current dogma of T -cell and antibody-
recognition of antigen. However, it has been clearly shown in the murine system that 
the binding of certain allo-antibodies to H-2 is peptide~ependent. 
Substantial evidence for peptide involvement in antibody-recognition of allo-
epitopes has come from two recent reports regarding several allo-antibodies to H-
2Kb. Both studies utilized the availability of mutant cell transfectants which do not 
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normally express class I molecules due to deletion of the TAP1 genes; hmRVer by 
utilizing temperature shifts, such cells can be induced to express empty class I 
molecules. Such molecules are useful for identifying the composition of peptides that 
affect T cell or antibody all~recognition. Thus, some all~antibodies to H-:zxt' were 
shown to differentially bind to different peptide/H-2Kb complexes (Hogqui.R et ~ 
1993; Sherman et aL, 1993). Furthermore, these mAbs varied in their ability to 
immunoprecipitate H-~ molerules that were loaded with known peptides (self or 
foreign). Using different variants of a peptide that had been shown to affect the 
binding of some but not all antibodies, Hogquist further showed that the sensitivity 
of certain antibodies to peptides was due to steric hinderance induced by solvent-
exposed residues on the peptide. Importantly, a few antibodies were sensitive to 
peptide variants in which the residues were not exposed but buried in the MHC 
groove. It was further shown by Sherman et al (1993) that acid-eluted peptides from 
IC' molecules immunoprecipitated with these anbbodies, varied in their ability to 
reconstitute the activity of a panel of T cell clones. 
It is intriguing that the reaction patterns of the peptide-sensitive or peptide-
dependent anti-DR4 antibodies that are descnbed here, have similar or identical 
reaction patterns to some of the specificities of alloreactive T cells ( Goronzy and 
Weyand, 1989, Flomenberg et ai, 1989; Obata et aL, 1992). These can be divided into 
two groups: allele-exclusive m.Abs such as the anti-Dw4 (NFLD.D11) which. like an 
alloreactive T cell has the power to differentiate Dw4 from Dw14. The second group 
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is crossreactive and recognizes determinants that are formed by homologous 
sequences on the alpha helix. It is thus interesting that, like antibodies, more 
alloreative T cell clones belong in this category than in the former category. For 
example, several T cell clones recognize different but overlapping epitopes on DR4 
and certain non-DR4 molecules. One such T cell clone (6052) from the lOth lliW 
recognizes Dw4, Dwl4, Owl, Dwl6 molecules; similar clones have also been 
described by others (Goronzy and Weyand, 1989). Interestingly, this pattern is almost 
identical to that of NFLD.D2 except that the latter also binds DRB5*02-encoded 
molecules on DR16 haplotypes. Again it is interesting to note that another clone 
(6047) from the same workshop recognized a determinant on cells expressing DRl, 
DR16, Dwl4 and Dwl6, which is similar to the NFLD.D3 specificity. It has been 
clearly demonstrated, using site-directed mutagenesis of the relevant DR genes, that 
the CC CL 20 antibody-binding epitope is remarkably similar to a T cell determinant 
on DRl, Dwl6 and Dwl4 molecules (Hiriawa et al., 1991). 
Altogether these observations and results suggest that alloreactive T cell 
clones and certain antibodies bind a similar set of alia-determinants. It is also 
noteworthy that some investigators have shown that some murine allo-antibodies 
showed a total dependence on a particular subset of peptides in the groove. For 
example, Murphy et al (1990) reported on a mAb that recognized a subset of l-Ab 
molecules, which were later shown to contain peptides from the I-E a chain 
(Rudensky et al., 1991). 
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9.8 SIGNIFICANCE OF NFLD MABS FOR FUTURE STUDIES OF THE HLA-
DR ASSOCIATION WITII RHEUMATOID ARTHRITIS 
The HIA-DR association with Rheumatoid Arthritis was extensively reviewed 
in CHAPTER 2. In summary a homologous sequence DRB1:70-
74:0KRAA/ORRAA/RRRAA is found in approximately 90% of hospital-based 
patients. These sequences are predicted to form similar epitopes, usually referred to 
as "shared epitopes" that somehow confer susceptibility to the development of RA 
However RA is heterogenous with symptoms ranging from mild polyarthritis to 
debilitating destruction of the joints and even to showing extraarticular features. An 
accumulating body of evidence suggests that the severe forms of this disease are 
more likely to occur in DR4-positive individuals. In particular, the genotype, 
Dw14Dw4 confers the highest degree of risk for severe forms of the disease 
(Wordsworth et al., 1992; Weyand et al., 1992). It has therefore been suggested that 
these DR subtypes may serve as useful prognostic markers, but more studies of a 
prospective nature are required to confirm this hypothesis. Possible roles for NFLD 
antibodies in such studies are discussed below. 
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9.8.1 Application or anti-DR4 mAbs for Diagnosis and Prognosis 
At least three of the mAbs that are described here may be useful in aiding 
the diagnosis and treatment of RA Firstly NFLDDl can identify all DR4 
individuals; NFLD.D2 can identify those that carry the putative suscepubility 
sequence; NFLD.Dll can identify individuals who have Dw4, which is the subtype 
most commonly associated with severe forms of RA Other mAbs which map to this 
region may also be useful for identifying susceptible individuals. In fact one of the 
objectives of this work was to study the binding of mAbs such as these so as to 
compare results on a panel of cells from RA patients with those on cells from normal 
controls. 
Pre1iminary studies have been carried out on a panel of EBV -transformed 
cells and B-PBL from patients and controls. Essentially, the mAbs gave the same 
binding pattern on RA cells as they do on cells from healthy people, that is the 
binding correlated with the same DR specificities. Studies are in progress to test the 
usefulness of NFLD.D2 and NFIDDll for identifying RA patients who carry the 
susceptibility sequence and those who may be at an increased risk for the 
development of severe RA 
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9.8.2 Relevance or Antibody and Epitope Mapping Studies to Understanding the 
Nature or the 11Shared Epitope11 in the Development or RA 
The epitope mapping studies descnOed here provide direct experimental 
evidence for the existence of several overlapping structural determinants on the 
alpha helix of the DR molecules that are associated with RA This concurs with what 
was found for T cell recognition of determinants that map to this region ( Goronzy 
and Weyand, 1989; Hiraiwa et al., 1991). A significant finding from these studies was 
that the NFID.D2 binding epitope, which most closely resembles the putative 
RA"shared epitope", was profoundly modified by the DR framework and peptide 
in the groove. By implication the conformation of the RA "susceptibility epitope" 
will vary also on the different DR molecules that are associated with RA, and may 
explain why non-DR4 molecules confer lower relative risks for the development of 
RA, despite carrying an identical susceptibility sequence. 
9.8.3 Putative Role for DRB1:28D in the RA Susceptibility Sequence 
An in-depth analysis of these data suggest that position 28 may be intimately 
involved in conferring susceptibility to the development of RA. The evidence for this 
is derived from several observations. First, all non-DR4 molecules that carry the RA 
susceptibility sequence, but confer low relative risk for the disease, have glutamic 
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acid at position 28. In contrast the DR4 molecules that carry the same susceptibility 
sequence and confer the highest degree of risk have aspartic acid at this position. 
Secondly and importantly, the DRB1:28:D-+E substitution in the DRB1*0401 mutant 
and in natural variants (DRl & DR14) profoundly altered the NFID.D2 epitope. 
Thirdly, because p28 is spatially proximate to the consensus sequence P70-
74:QK/RRAA, and because of its importance, along with P71 and P74 in a peptide-
binding pocket, a substitution at this position could have serious implications for the 
binding and/or orientation of an arthritogenic peptide(s) by these molecules. In these 
experiments peptide in the groove clearly altered the structure of the NFLD.D2 
binding epitope. 
It is therefore predicted that either the substitution at position 28, itself, 
and/ or peptide binding modifies the "shared epitope" such that the epitope on 
DR4 molecules is conformationally different from that which is present on DRI 
molecules. Whether it is an alteration of the conformation of the shared epitope or 
the ability to bind different peptides in the groove that is responsible for the different 
degrees of risk conferred by these different molecules is open to speculation. 
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9.9 FUTURE PLANS 
The potential of these mAbs as markers for RA susceptibility and severity 
have already been addressed in section 9.8. Since a Dw14-specific mAb would 
increase the potential of their value as prognostic markers, efforts will be made over 
the next few months to accomplish this. It is further anticipated that these mAbs may 
be useful for probing the nature of the peptides that bind to the RA-associated MHC 
grooves and those peptides that are involved in the composition of allodeterminants 
on the Dw4 molecules. 
9.9.1 Purification of MHC-Peptide Complexes from Rheumatoid Synovium 
If one operates on the premise that RA is initiated or persists due to T cell 
recognition of an "arthritogeneic" peptide bound to the groove of a "susceptible" 
DR molecule, then it is conceivable that, by using these mAbs for the purification of 
MHC-peptide complexes, information may be gained about the nature of the 
"arthritogeneic" peptide. The advantage of this collection of mAbs over 
monomorphic mAbs is that they are specific for the molecules that are implicated in 
RA and that they include antibodies whose epitopes are either sensitive to or 
dependent on the peptides that are present in the grooves. For example, NFID.D2 
preferentially binds DR molecules which are implicated in susceptibility to RA and 
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is peptide senstive; NFI.D.D11 is Dw4-specific and peptide-dependent; NFI.D.D1 is 
DR4-specific and appears to be unaffected by peptides that are bound to the grooves. 
Thus, the application of these mAbs to the purification of MHC-peptide complexes 
from RA synovium and microsequencing of the peptides, might provide insight into 
the nature of the peptide that triggers RA. Such findings might have implications for 
the design of therapeutics. 
9.9.2 Mapping of Dw4-specific Epitopes 
The composition of the epitopes for the two Dw4-specific mAbs is particularly 
intriguing and requires further characterization. Preliminary work using crude 
membranes from EBV-transformed cells indicated that at least the NFI.D.D11 
binding epitope could be reconstituted on Dw4-positive mouse L cells. The 
experiment needs to be repeated using peptides from cyanogen-bromide cleaved 
membranes (Heath et al., 1991). These peptides could be fractionated by HPLC and 
each fraction tested to see if one or more can reconstitute the epitopes on Dw4-
positive L cells and/or Dw4 positive T2 cells. This is analogous to similar work 
described by Sherman et al., (1993) on reconstitution of alloantibody epitopes and 
alloreactive T cell determinants on the empty H-2Kb molecules expressed by the T2 
antigen processing mutant cell line. Restoration of these epitopes on Dw4-positive 
L cells would be of particular interest, since the panel of DRB1*0401 mutants 
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(described in CHAPTER 7), in which each carries a single amino acid substitution, 
could be used to investigate the importance of residues on the floor and the alpha 
helix to the formation of these determinants. 
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